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RA-Illudin 5 retinoic acid illudinyl M ester 
rb molar ratio of platinum bound to nucleotides 
ri molar ratio of input drug/DNA 
sc(DNA) super helical covalently closed plasmid DNA 
SDS sodium dodecyl sulphate 
TEA tetra-ethyl-ammonium 
TRIS tris(hydroxymethyl)aminomethane(2-Amino-2-hydroxymethyl-
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Introduction 
 The history of empirical preparation changed when the first isolation of active 
drugs (alkaloids such as morphine) arrived in the hospitals during the early 19th 
century. Soon, the first derivatives were synthesized (e.g. heroine from morphine) and 
natural products became preferable lead structures for synthetic drugs. Major 
pharmaceutical companies have been eagerly searching for naturally designed drugs 
worldwide possessing potentially interesting pharmaceutical effects. A small series of 
these fascinating compounds is mentioned below. 
1.1 Novel chemotherapeutic drugs based on scaffolds designed by nature 
 Fruits of Schisandra chinensis (Turcz.) Baill (Schisandraceae) belong to the 
most widely used plants in traditional Chinese, Japanese and Russian herbal medicine 
due to their hepatoprotective, antiasthmatic, antidiabetic, sedative and tonic properties 
(Chang et al., 2005). Monoester derivatives of schisandrol A (Figure 1- 1) inhibited 
the P-gp drug transporters of multidrug-resistant human KBv1+Vbl cervix carcinoma 
cells better than the natural benzoate and comparable to the clinical sensitizer 
verapamil (Schobert et al., 2008). A novel schisandroxy(methyl)titanocene complex 
reached single-digit micromolar IC50 values against cells of leukemia HL-60, 
melanoma 518A2, multi-drug resistant cervix carcinoma KBv1+Vbl and breast 
carcinoma MCF-7+Top (Gmeiner et al., 2010). 
Simple terpenes ((+)-menthol Figure 1- 1, thymol, perillyl alcohol, limonene, linalyl 
acetate) can affect the permeability of cell membranes as well as membrane-anchored 
and down-stream proteins crucial for proliferation-related signalling (Hardcastle et al., 
1999; Trombetta et al., 2005; Yuri et al., 2004). Antiproliferative effects of various 
terpene alcohols esterified with [6-(aminomethyl)nicotinate]dichlorideplatinum(II) 
complex (nic-Pt) were demonstrated on different cancer cell lines (Bernhardt et al., 
2008; Schobert et al., 2007). 
The combretastatins are natural compounds extracted from the tree Combretum 
caffrum (Pettit et al., 1989) and were the first microtubule depolymerizing agents 
identified to have tumor vascular disrupting activity at well tolerated doses (Chaplin 
et al., 1996; Dark et al., 1997). Combretastatin A-4 phosphate (CA-4-P or Zybrestat) 
(http://www.oxigene.com), a soluble pro-drug of the natural parent CA-4 molecule in 
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Figure 1- 1 (Pettit et al., 1995), is by far the most widely studied VDA of the 
microtubule depolymerizing family and was the first such agent to enter clinical trial 
(Dowlati et al., 2002). It specifically binds to the colchicine binding site of tubulin 
and exhibits distinct anticancer activity in vitro and in vivo (Hinnen and Eskens, 
2007). 
 
Figure 1- 1 Structures of schisandrol A, (+)-menthol and combretastatin A-4. 
1.1.1 Combretastatin A-4 analogue – chalcone (1) 
 Trimethoxyphenyl chalcones like 1 are structurally related to combretastatin 
(Lawrence et al., 2006). Chalcones, which are classified under polyphenolic 
compounds, are basically flavonoids, ubiquitously presented in plants, especially in 
fruits and vegetables (Calliste et al., 2001). A cursory look at the recent literature 
cited in relation to chalcones indicates that there is a growing interest in evaluating 
the pharmaceutically important biological activities of chalcones, presuming their role 
in the prevention of various degenerative diseases and other human ailments 
(Batovska and Todorova, 2010). Some chalcones were reported with significant 
anticancer activities originating from other modes of action such as the inhibition of 
resistance-relevant ABC-transporters (Hirschmann-Jax et al., 2004; Liu et al., 2008). 
Recently, fluorinated 2’-hydroxychalcones of the garcinol type were shown to owe 
their increased anticancer activity in a pancreas tumor to an up-regulated COX-2 
expression (Padhye et al., 2010), and a chlorambucil conjugate of combretastatin A-4 
was found far more efficacious against neuroblastoma cells than combretastatin A-4 
alone (Coggiola et al., 2005).  
Recently, chalcone (1) and its dichloridoplatinum(II)(6-aminomethylnicotinate) 
complex (Figure 1- 2) inhibited the polymerization of tubulin when applied in vitro 
(Schobert et al., 2009). Morphologically, both test compounds led to a rounding and 
detachment of 518A2 cells and an enhancement of their motility and cell shrinking 
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dynamic. This behaviour is in line with the generally accepted mechanisms of tubulin 
binding agents (TBAs) (Lippert, 2007) involving activation of RhoA/RhoA kinase, an 
intracellular coordinator of cytoskeletal rearrangement of microtubules and actin 
(Zoldakova et al., 2010).  
 
Figure 1- 2 Structure of studied chalcone (1) and dichloridoplatinum(II)(6-aminomethylnicotinate; nic-Pt).  
  The tumoral vascular network is characterized by peculiar irregularities and 
thus has been identified early on as a promising drug target. Vascular disrupting 
agents (VDAs) have been intensively investigated and some already went on clinical 
trials, mostly as combination with DNA-targeting drugs (Kanthou and Tozer, 2009; 
Lippert, 2007). The majority of VDAs shows a pronounced affinity for tubulin and 
interferes with the delicate mitotic machinery of dynamic microtubule formation and 
destruction. The microtubule cytoskeleton fibers are crucial to mitosis and cell 
division, for the maintenance of cell shape and for the transport of vesicles (Vantard 
et al., 2000). Moreover, they are essential structural components of dendrites. In the 
brain, the formation of dendrites is dependent on neural activity and is mediated in 
part by the modulation of mictrotubule stability (Vaillant et al., 2002).  
1.1.2 Natural alkylation agent - illudin M (4) 
Illudin M and its close congener illudin S are natural sesquiterpenes of the 
bioluminescent Jack o’Lantern mushroom (Omphalotus olearius, formerly Clitocybe 
illudens) growing in the east of North America, which were discovered by Anchel et 
al. in the course of their search for fungal antibiotics in 1950 (Anchel et al., 1950). 
The unique chemical structures of these sesquiterpenes displaying a tricyclic 
spirocyclopropylindane core were determined by McMorris and Anchel in 1963 
(McMorris and M., 1963). Their mode of action was soon discovered to be a special 
sort of triggered alkylation. Initially attacked at their enone moiety by naturally 
occurring sulfur nucleophiles, both compounds alkylate nucleic acid and protein 
targets by ring opening of the spirocyclopropane (Figure 1- 3). Alkylation of the DNA 
leads to apoptotic cell death (McMorris et al., 1990).  
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Figure 1- 3 Proposed mechanism of the illudin M action. After a pre-activating reduction of its enone by 
NADPH-dependent oxido-reductases or glutathione (Nu1), illudin M can alkylate DNA, RNA and proteins 
(Nu2) via opening of the spirocyclopropane and so induce apoptotic cell death.  
Although both illudin M and illudin S showed high cytotoxic activity in various 
cancers they turned out to be too toxic for any clinical application (Kelner et al., 
1987). However, due to their unique mechanisms of action many efforts to synthesize 
novel and improved illudin derivatives have been carried out (Schobert et al., 2011). 
Indeed, less reactive semi-synthetic illudin derivatives were discovered with 
diminished toxicity and improved therapeutic indices.  
1.1.3 Activity of all trans retinoic acid  
 Retinoids are naturally occurring or synthetic compounds related to vitamin A 
(retinol). They have significant effect on many cell functions including differentiation 
and apoptosis (Aebi et al., 1997; Tavares et al., 2008). Retinoic acid (RA, Figure 1- 4) 
induces differentiation of various types of stem cells, including cancer stem cells and 
neural stem cells, making it a useful tool for the treatment of cancer (Matthay et al., 
2009; Schlett and Madarasz, 1997; Tang and Gudas, 2011). RA is mainly involved in 
the induction of neural differentiation, motor axon outgrowth and neural patterning. 
These effects are mediated by nuclear retinoic acid receptors, usually heterodimers of 
RAR and RXR proteins (Chambon, 1996; Mey, 2006). Thus, RA could be used as a 
therapeutic molecule for the induction of axon regeneration and the treatment of 
neurodegeneration (Maden, 2007).  
 
Figure 1- 4 Structure of all-trans retinoic acid (RA). 
In addition, interactions with other signaling pathways like estrogen signaling were 
discovered (Hua et al., 2009). Retinoids induce differentiation and stop proliferation 
combination with classical anticancer drugs like cisplatin (Aebi et al., 1997). 
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 Mechanisms of all trans retinoic acid (RA)-induced differentiation are also 
covered but not fully understood. RA is a potent inducer of HL60 cell differentiation 
and when used as a single agent it can induce complete remission in patients with 
acute promyelocytic leukemia (APL). While one mechanism of the effect of RA 
involves RA nuclear receptors, retinoylation (a posttranslational modification of 
proteins by RA) may be a new non-genomic mechanism by which RA acts on cells 
(Takahashi, 2002).  
 Cell differentiation is essential for normal growth and homeostasis, and drug-
induced differentiation of tumor cells into benign or normal cells is an important 
approach for anticancer chemotherapy. Studies of induction mechanisms for cell 
differentiation and discovery of differentiation-inducing factors are thus critical 
components of drug development. 
1.2 Drugs uptake and efflux 
 The cell membrane is often overlooked in drug development. However, the 
membrane is not a passive or necessarily benign solvent and directly impacts on the 
protein molecules and complexes it contains. Various membrane transporters and 
carriers mediate cellular uptake and efflux of drugs Figure 1- 5. The uptake may 
involve the carriers or channels as well as various endocytotic routes.  
 
Figure 1- 5 Scheme of drug transport through cell membranes. Passive transport is represented by simple 
diffusion (as well as channel-mediated or carrier mediated diffusion). Endocytosis plays a specific role in 
drug uptake and here the clathrine-dependent endocytosis is shown. Positively charged drugs are actively 
transported via organic cation transporters (OCT = SLC22A1/2), which pump the compounds against the 
concentration gradient. The copper-related transporter (Ctr1) was found to transport platinum complexes 
(Safaei and Howell, 2005).  
 The existence of different endocytotic mechanisms is interesting; for instance 
in relation to growth and differentiation, cell adhesion, regulation of the activity of 
signalling receptors and drug delivery. There are several endocytotic mechanisms. 
The clathrin-dependent one and mechanisms, which operate without clathrin, are 
based on different requirements (dynamin, small GTP-binding proteins of the Rho-
family and specific lipids). One of the most studied examples of a clathrin-
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independent endocytic mechanism that is based on actin polymerization is 
macropinocytosis, a major fluid-phase uptake pathway (Sandvig et al., 2008). 
Macropinocytosis differs from other types of endocytosis by its unique susceptibility 
to inhibitors of Na+/H+ exchange. However, the functional relationship between 
Na+/H+ exchange and macropinosome formation remains obscure. Recently, 
submembranous acidification was found to play a crucial role in the elimination of 
macropinosomes formation (Koivusalo et al., 2010).  
The Na+/K+-ATPase, sometimes called Na+/K+ pump, is a transmembrane enzyme 
acting as an electrogenic ion transporter in the plasma membrane of all mammalian 
cells. Each cycle of Na+/K+-ATPase activity extrudes three Na+ ions from a cell, 
moves two K+ ions into the cell and utilizes the energy from the hydrolysis of one 
ATP molecule (Rakowski et al., 1989). The primary role of the Na+/K+-ATPase is 
therefore to maintain high intracellular K+ and low intracellular Na+ (Robinson and 
Flashner, 1979).  
Like other P-type ATPases, proteins utilize the energy of ATP hydrolysis to transport 
Cu2+ across the vesicular membrane via a process that involves the formation of a 
transient acylphosphate intermediate (Solioz and Vulpe, 1996). The major Cu2+ 
uptake transporter is the copper transporter receptor 1 (Ctr1) (Culotta et al., 1999). 
Recent data indicate that the Cu2+ homeostasis system also regulates the uptake, 
intracellular compartmentalization and efflux of cisplatin (Katano et al., 2003; Safaei 
and Howell, 2005).  
The majority of drugs for therapeutic use including many antihistaminics, antacids, 
antiarrhythmics, antihypertensives and anticholinergics are organic cations or weak 
bases, i.e. molecules with a transient or permanent positive net charge (Muller et al., 
2005). The main membrane transporters for cationic drugs are the organic cation 
transporters (OCT) of the SLC22 family (Cetinkaya et al., 2003; Koepsell et al., 
2007). The OCTs play a pivotal role in the distribution and excretion of cationic 
drugs. They mediate electrogenic translocation of cations in both directions. OCTs are 
poly-specific transporters (Koepsell, 2011; Koepsell et al., 2007). They mediate 
intracellular uptake of a broad range of structurally diverse organic cations with 
molecular masses generally < 400 Da (Wright, 2005; Zhang et al., 2006). 
There are many genes encoding major human transporters such as:  
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• Solute-linked carrier organic anion transporter family: SLCO1B1 (OATP1B1, 
OATP-C, OATP2), SLCO1B3 (OATP1B3, OATP8), SLCO2B1, SLC21A9 
(OATP-B).  
• Solute-linked carrier transporter family: SLC10A1 (NTCP - sodium 
taurocholate co-transporting polypeptide), SLC10A2 (ASBT- apical sodium-
dependent bile salt transporter), SLC15A1 (PEPT1); SLC15A2 (PEPT2), 
SLC22A1 (OCT-1 - organic cation transporter), SLC22A2 (OCT2), SLC22A3 
(OCT3), SLC22A4 (OCTN1), SLC22A5 (OCTN2), SLC22A6 (OAT1 - organic 
anion transporter), SLC22A7 (OAT2), SLC22A8 (OAT3). 
  
Interactions between exogenous, amphiphilic compounds and the membrane can be 
critically damaging to the cell and affecting its structural integrity. This may produce 
a desirable outcome concerning tumor treatment. Resistance of cancer cells is a main 
problem for a successful treatment. ATP-binding cassette (ABC) transporters 
represent a family of proteins that mediate multi-drug resistance (MDR) (Figure 1- 6). 
The ABC superfamily is probably the largest and most diverse family of proteins that 
mediate the selective movement of solutes across biological membranes (Higgins, 
1995, 2007).  
 
Figure 1- 6 Relevant ABC-transporters responsible for drug efflux and multi-drug resistance.   
Cells may become drug-resistant by several different mechanisms. One major type of 
MDR is linked to the over-expression of a 170 kDa plasma membrane glycoprotein 
known as the P-glycoprotein (P-gp) (Sharom, 1997). This protein functions as an 
ATP-dependent efflux pump for hydrophobic drugs, including the Vinca alkaloids, 
anthracyclines, epipodophyllotoxins, and taxanes. P-gp expression in tumors in vivo is 
often associated with poor overall prognosis and response to chemotherapy 
(Goldstein, 1996). 
Over-expression of the member G (white) subfamily of ABC transporters was found 
in MCF-7 human breast carcinoma cells, and this transporter was termed breast 
cancer resistance protein (BCRP) (Doyle and Ross, 2003). Unlike P-glycoprotein and 
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MRP1, which are arranged in 2 repeated halves, BCRP (ABCG2) is a half-transporter 
consisting of just one nucleotide binding domain connected to a single membrane-
spanning domain (Rocchi et al., 2000). The strategic and substantial localization of 
BCRP in the placenta, in the small intestine, and in the liver suggests that BCRP 
functions as a protective efflux pump in the placenta and has the potential to limit oral 
absorption and increase biliary elimination of toxic xenobiotics that are BCRP 
substrates (Mao, 2008; Mao and Unadkat, 2005). 
The multidrug resistance-associated protein (MRP) is a 190-kDa membrane-bound 
glycoprotein. Similar to P-gp, the MRP gene product contains two nucleotide-binding 
motifs localized in the intracellular domains and thus appears to be another member 
of the ATP-binding cassette transporter superfamily (ABC-C) (Wada et al., 1999). P-
glycoprotein transports unmodified drugs, whereas MRP1 can transport drugs either 
conjugated to anionic ligands such as glutathione (GSH), glucuronide, or sulfate, or in 
an unmodified form, possibly together with GSH. Concerning all MRP family 
members, MRP3 is closest to MRP1 (58% amino acid identity) and able to confer 
resistance to many anti-cancer drugs (as methotrexate, etoposide, and teniposide) 
(Kool et al., 1999).  
The main transporters associated with mammalian drug resistance in the ABC 
superfamily are once more listed below: 
• ABCB1 (P-gp- P-glycoprotein, MDR1 - multi-drug resistance). 
• ABCB4 (MDR3). 
• ABCB11 (BSEP - bile salt export pump). 
• ABCC1 (MRP1: multi-drug resistance related protein). 
• ABCC2 (MRP2, CMOAT). 
• ABCC3 (MRP3, CMOAT2); ABCC4 (MRP4); ABCC5 (MRP5); ABCC6 
(MRP6). 
• ABCG2 (BCRP: breast cancer resistance protein).  
1.3  Cisplatin and chemoresistance 
Cisplatin has a central role in cancer chemotherapy, especially for testicular cancer, 
for which the overall cure rate exceeds 90%, and reaches nearly 100% for early stage 
cancers (Bach et al., 2001). The treatment is limited, however, by side effects 
including nephrotoxicity, emetogenesis and neurotoxicity (Wang and Lippard, 2005). 
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A profound understanding of the mechanism by which cells process cisplatin (CDDP) 
provides important insights for the design of more efficient platinum-based drugs.  
The mechanism of cellular uptake and efflux of cisplatin is still not fully understood. 
Early studies suggested that cisplatin enters the cell mainly by passive diffusion but 
recently grooving body of evidence revealed a direct link with the cooper related 
protein (Ctr1) (Binks and Dobrota, 1990; Ishida et al., 2002). Several reports already 
suggested that Na+/K+-ATPase mediates the uptake of CDDP (Andrews et al., 1991; 
Kishimoto et al., 2006). Recent data indicate that the Cu2+ homeostasis system 
likewise regulates the efflux of CDDP (Ahmed et al., 2009; Katano et al., 2003; 
Safaei and Howell, 2005). 
Cisplatin is usually administered in chloride-containing solution as short intravenous 
infusion. In the bloodstream cisplatin encounters a relatively high concentration of 
chloride ions (100 mM) that suppresses hydrolysis (Figure 1- 7).  
 
Figure 1- 7 Hydrolysis of cisplatin in aqueous solution. The chloride ligands are hydrolysed, which results in 
reactive compounds.  
After entering the cell, the diminished chloride concentration (~20mM) facilitates the 
hydrolysis of cisplatin resulting in activated positively charged mono- and di-aqua 
species (Jennerwein and Andrews, 1995). The hydrolysis reaction is the rate-limiting 
step for DNA-binding (Carte et al., 2000). 
 There is convincing evidence that the cytotoxic properties of cisplatin are a 
consequence of DNA-adduct formation, which affects DNA-dependent cellular 
functions. Cisplatin reacts with DNA preferentially by coordination to the N-7 atoms 
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of purines, which are exposed in the major groove of the double helix and are not 
involved in base-pair hydrogen bonding (Balcarova et al., 1992; Brabec and 
Kasparkova, 2002; Zoldakova et al., 2011). Up to 90% of platinum-DNA adducts 
comprise of 1,2-intrastrand CLs (Figure 1- 8) involving adjacent bases, and 1,2-
d(GpG) CL involving two adjacent guanine is two to three times more frequent than 
1,2-d(ApG) CL involving adenine adjacent to guanine (Poirier et al., 1992). 
 
Figure 1- 8 Cisplatin-DNA adducts comprise of 1,2d(GdG)-intrastrand (90%) or interstrand cross-links 
(6%).  
 The Schobert’s group synthesized large number of platinum- or ruthenium 
based conjugates (Bernhardt et al., 2008; Biersack et al., 2010; Schobert and Biersack, 
2005). Several of them displayed cytotoxicity at nanomolar concentrations and were 
specific against various cancer cells. Recently, chalcone (1) and its Pt(II)-dichlorido-
(6-aminomethyl)-nicotinate ester presented remarkable combinatorial effects on DNA 
and tubulin and inhibited the growth of certain cisplatin-resistant tumor cell lines 
(Schobert et al., 2009). Conjugate (2) is accumulated in cancer cells mainly via cell-
controlled transporters and induces apoptosis by triggering multiple targets 
(Zoldakova et al., 2010).  
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1.4 The aim of this study 
 The molecular mechanism of chalcone (1) deals with microtubules. However, 
its vascular disrupting effects are yet not fully understood. Moreover, the breach of 
cisplatin resistance is crucial for future oncological research.  
 In the presented study of complexes based on m-hydroxychalcone (1) and 
cisplatin a focus was set on mechanisms of action and effects in living cells and in 
vitro. Novel conjugates 2 and 3 of the combretastatin A-4 analogous chalcone (1) 
were tested for antitumor activity, altered cell shapes and sub-cellular compartments, 
apoptotic signals, DNA-binding and glutathione-binding properties. 
 Furthermore, the selective impact of illudin M and its new retinoate (5) on 
glioma and stem cell rich astrocytoma cells was tested and compared with that on 
normal neurons, astrocytes and cancer cells.  
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Material and Methods  
2.1 Material  
 Flasks 75 cm2 (Nunc, Wiesbaden, Germany), 96-well filtration plates HTS 
(Millipore), 50 mL falcon type tubes (Greiner bio-one), 10 mL falcon type tubes 
(VWR), glass slides (round) AL; Ø 1.5 cm, microscope slides AL; ca. 76 × 26 mm, 
petri dishes Ø 13.5 cm (Roth), sterile filter pore size: 0.25 – 0.45 μm (NALGENE), 
FACS tubes (Becton Dickinson), 18×18 mm Aclar-folia (Ted Pella), slot grids 
(Plano), Maco EM-Film EMS, 8.3×10.2 cm (Maco), imaging plate BAS-IP MS 2040 
– 20x40 cm (Cat. No: 08000097-Fujifilm). 
2.1.1 Instruments  
 Microplate reader (MWG-BIOTECH/BioRad), TECAN Infinite F200 plate 
reader, autoclave H+P (Varioklav), centrifuge (Eppendorf), miniSpin Centrifuge 
(UNIEQUIP), UNIVAPO 150 H Centrifuge (Heraeus); Varifuge 20 RS -Rotor: 5148, 
fluorescence spectrometer Inc. LS 50 B (Perkin Elmer), gel-documentation apparatus 
(LTF Labortechnik), heater (Eppendorf), thermomixer 5436, hemocytometer - 
Neubauer improved (Brand), horizontal gel electrophoresis apparatus C.B.S Model 
#SGU-020T-02, Incubator (Heraeus), Laminar-Flow-Box aura Vertical S.D. 4 
(Nunc), Optical Microscope Axiovert 135 and AxioCam MRc5 (Zeiss), UV-
Transilluminator (Vilber Lourmat), Vacuum centrifuge - Vacuum Concentrator BA-
VC-300H (Saur), Mini 900rate meter (Thermo), FPLC was carried out on a Waters 
FPLC system consisting of Waters 262 Pump, Waters 2487 UV detector and Waters 
600S Controller with MonoQ HR 5/5 column. Autoradiograph reader and Eraser –
Raytest (Fujifilm BSA-2500).  
2.1.2 Chemicals 
 Antibiotics antimycotics from Gibco, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT; ABCR), acetic acid (Fluka), agarose (Roth, 
Serva), BSA – bovine serum albumin (Roth), cimetidine (CalBiochem), wortmannin 
(CalBiochem), chlorpromazine (CalBiochem), amiloride (CalBiochem), ouabaine 
(CalBiochem), mitoxantrone (Ralenova), CaCl2· 2 H2O – calcium chloride dihydrate 
(Merck), digitonin (CalBiochem), Pluronic F127, propidium iodide (Sigma), calcein-
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AM, fumitremorgin C, 100 bp DNA ladder Plus (0.5 mg DNA/mL), (PeQlab), DNA 
ladder loading buffer (6×) (PeQlab); EDTA – ethylene diamine tetraacetic acid 
(VWR), EGTA – ethylene glycol tetraacetic acid (CalBiochem), EtdBr – ethidium 
bromide (Merck), ethanol (100 %) (VWR), Fura-2/AM – Fura-2-acetoxymethyl ester 
(SIGMA), Giemsa dye (Roth), glucose (water-free) (Riedel de Haen), HEPES – 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (Roth), PIPES -piperazine-N,N´-bis(2-
ethanesulfonic acid) (VWR), DTT - dithiothreitol (VWR), CHAPS - 3-[(3-
cholamidopropyl)-dimethyl-ammonio]-1-propanesulfonate (Roth), K2HPO4 – 
dipotassium hydrogen phosphate (Merck), KCl – potassium chloride (Merck), 
methanol (Fluka), MgCl2 · 6 H2O – magnesium chloride hexahydrate (Merck), 
Na2HPO4 - disodium hydrogen phosphate (Fluka), NaCl – sodium chloride 
(Grüssing), SDS – sodium dodecyl sulfate (Roth), Tris (Roth), Trypsin-EDTA 0.5% 
(Gibco), NaOH – sodium hydroxide (Roth), proteinase K (≥ 30 U/mg) (Roth), 
Ribonuclease A (RNase A; 90 U/mg) (Roth) and for FACS analysis - RNase 10 mg/L 
(Qiagen), 18% formaldehyde (Riedel-de Haen), glycine, 1% OsO4 in H2O, Pb(NO3)2 
(Merck), 25% glutaraldehyde, Glycider 100, propylene oxide, 2,4,6-tris(dimethly-
aminomethyl)phenol (Epon; Serva), 0.5% tannic acid (Mallinckrodt), polioform 
powder, uranyl acetate (Plano). Dr. Bernhard Biersack synthesized all test compounds 
according to literature procedures (Lawrence, Patterson et al. 2006; Schobert, 
Biersack et al. 2009), illudin M was purified by Sebastian Knauer (Schobert, Biersack 
et al. 2008; Knauer, Biersack et al. 2009). 
Antibodies: glial fibrilary acidic protein (GFAP; Invitrogen), streptavidin-conjugated 
horseradish peroxidase (HRP; Sigma A8924), phalloidin-biotin, anti-mouse IgG 
Alexa 594 (A11005), anti-rabbit Alexa 594 chicken, and 4'-6-diamidino-2-
phenylindole (Invitrogen), anti-mouse neuron specific βIII-tubulin (SDL3D10) and 
goat anti-mouse streptavidin Alexa Fluor 488 conjugate (S32354) (Sigma). 
2.1.3 Solutions and buffers 
Antibiotics-antimycotic solution Penicillin G (Na-Salt) 10 000 units/mL, 
Streptomycin-Sulfat 10 000 µg/mL, 
Amphotericin B 25 µg/mL in 0,85 % PBS buffer  
MTT solution  0.5mg/mL MTT solved in PBS buffer 
DMSO solution 10 % SDS in 99.4 % DMSO / 0.6 % acetic acid 
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PBS buffer  8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4•12H2O,  
pH = 7.4 0.24 g KH2PO4 per 1 L  
Caspase buffer  20 mM PIPES, 100 mM NaCl, 10 mM DTT  
pH = 7.2  freshly prepared, 1 mM EDTA, 0.1% (w/v) 
CHAPS, 10% (w/v) sucrose, in 1 L of dH2O 
Ca-buffer  120 mM NaCl, 5 mM KCl, 2 mM MgCl2•6H2O,  
pH 7.4 1.5 mM CaCl2•2H2O, 125 mM HEPES, 10 mM 
glucose for 1 L; stored at 4 °C 
Cs-buffer  2% BSA in 1 mL Ca buffer, 5 μL of Pluronic 
F127 (20% in DMSO)  
 -for Ca2+ assay   + 0.8 μL Fura-2/AM (5 mM in DMSO) 
EtdBr staining solution 250 mL 0.5 × TAE buffer,100 µL of 1 % EtBr 
solution 
EtdBr washing solution 250 mL 0.5×TAE buffer 
DNA-lysis-buffer 10 mM Tris-HCl (pH 8.5), 5 mM EDTA, 200 
mM NaCl, 0.2 % SDS 
PBS (for DNA isolation) 137 mM NaCl, 27 mM KCl, 100 mM Na2HPO4,  
pH 7.4 2 mM K2HPO4 
1×TAE  40 mM Tris-HCl, 20 mM Acetic Acid, 10 mM  
pH 8.18-8.29 EDTA 
50xTAE 2 M Tris-acetate, 0.05 M EDTA [242 g Tris +  
pH 8.0  57,1 mL ice-cold acetic acide + 100 mL 0.5 M 
EDTA in 1000 mL H2O 
1xTBE 0.09 M Trizma-Base, 0.002 M EDTA  
pH 8.3 
1×TE  10 mM Tris-HCl, 1 mM EDTA; 37 °C 
pH 8.0  
FPLC/Buffer A 10 mL 1M Tris-HCl pH 7.4, 12.4 mL 4 M NaCl, 
add to 1 L dH2O 
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FPLC/Buffer B 10 mL 1M Tris-HCl pH 7.4, 250 mL 4 M NaCl, 
add to 1 L dH2O 
Denatured 1% agarose gel 1 g agarose, 100 mL dd H2O boiled with1 
minute in microwave, 0.03 M NaCl, 1 mM 
EDTA 
Denaturation buffer  0.03 M NaOH, 1 mM EDTA 
DNA-Loading-buffer   6 mL Glycerol, 20 mg Xylenecyanol, 1 mL 5x 
TBE, 3 mL H2O 
5x[γ]ATP buffer 0.18 M MgCl2, 0.5M imoidazol, 1 mM 
spermidin, 1mM EDTA, 1 mM ADP, 0.05 M 
DTT in H2O   
10x Klenow buffer 0.5 M Tris-Cl (pH 7.2), 0.1 M MgSO4, 0.001 M 
DTT 
5xTranscription buffer 0.2 M Tris-HCl (pH 7.5), 0.05 M NaCl, 0.03 M 
MgCl2, 0.01 M spermidin 
Stock solution of 40% acrylamide 38% AA + 2% bis-AA [38 g Acrylamide + 2 g 
N,N’-methylenbisacrylamide] in 100 mL H2O  
Stock solution of 30% acrylamide 29% AA + 1% bis-AA [38 g Acrylamide + 2 g 
N,N’-methylenbisacrylamide] in 100 mL H2O  
Blue-loading buffer 40% (w/v) Sacharose in H2O, 0.1% (w/v) 
Bromphenol-blue, 0.1% (w/v) Xylencyanol  
Lysis buffer I 10 mM Tris-base (0.6057g); 60 mM KCl 
(2.235g); 1.2 mM EDTA (0.1791g); 1 mM 
DTT (1 µL 1M), add 500 mL dH2O  
Lysis buffer II 10 mM 1 µL 1 M DTT 
5xNER buffer 0.22 M HEPES (pH 7.8 with KOH), 0.035 M 
MgCl2, 2.5 mM DTT, 100 µM dNTP (except 
that used to label the reaction – 20 µM), 200 
mM phosphocreatine, 17% glycerol, 1.5 
mg/mL bovine serum albumin (BSA) 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Media and supplements  
 MEM and E-MEM (Eagle’s minimum essential) media were purchased from 
Sigma. Ham’s 12, D-MEM (Dulbecco’s modified eagle medium), NeuroBasal media, 
Insulin-Transferin-Selenium (ITS) were bought from Gibco, Invitrogen, B27 
supplement, fetal calf serum (FCS), antibiotic–antimycotic solution, gentamycin, 3 
mM retinoic acid, 10% poly-lysine, and glutamine from Gibco-BRL-Life. 
2.1.4 Cell cultures  
The cells were cultured as "monolayer cultures" or growth as “suspension” in 
75 cm2, 125 cm2 flasks resp. Ø 15 cm Petri dish. The cell cultures were incubated at 
37°C / 5% CO2 in different culture media. 
Cancer cells:  
Human melanoma 518A2 cells were obtained from the department of oncology and 
hematology of the Martin-Luther-University, Halle, and cultured in D-MEM with 
10% FBS, 0.55% antibiotic-antimycotic solution and 0.3% gentamycin. The cells 
were continuously passaged once a week by 0.05% trypsin solution and new flask 
was seeded with 105 cells. 
Human leukemia HL60 cells were obtained from the department of oncology and 
hematology of the Martin-Luther-University, Halle, and cultured as “suspension” in 
RPMI medium supplemented with 5% FBS, 0.55% antibiotic-antimycotic solution 
and 0.3% gentamycin.  
Human cervix carcinoma (KBv1+Vbl) and breast carcinoma (MCF-7+Top) cells were a 
gift from the department of pharmacy, University of Regensburg (Kuhnle, Egger et al. 
2009). The cells were passaged each 3rd - 4th day and ¼ was used for new flask 
(~2×106 cells/mL). The KBv1/KBv1+Vbl cells were cultured in D-MEM with 10% 
FBS, 0.55% antibiotic-antimycotic solution and 0.3% gentamycin, without/with 340 
nM vinblastine. The MCF-7/MCF-7+Top cells were grown in E-MEM supplemented 
with 5% FBS, without/with 550 nM topotecane.  
Human colon adenocarcinoma cells (HT-29/HT-29+Colc) were obtained from the 
Institute for Surgical Research, Philipps University Marburg and were cultured in 
RPMI medium supplemented with 5% FBS, without/with 62.5 nM colchicine (Kok, 
Veldman et al. 2000).  
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Neural cells:  
Neuroectodermal stem cells NE-4C, primary mouse astrocytes (Schlett and Madarasz 
1997; Kornyei, Szlavik et al. 2005), glioma cell lines: rat glioma C6 [ATCC No.: 
CCL-107] and human astroglioma U87 [ATCC No.: HTB-14], non-neural mouse 
fibrosarcoma cells WEHI 164 (Huszti and Madarasz 2002). Cells were maintained 
under a moisture-saturated atmosphere (95% humidity, 5% CO2) at 37 °C in 75 mL 
culture flasks (Nunc, Germany). They were serially passaged using 0.05% trypsin / 
0.02% EDTA (PAA Laboratories, Cölbe, Germany). 
2.1.5 Cell counting using Neubauer chamber  
 
 Trypsinated cells in suspension were centrifuged, repipetted in a fresh media 
and 10-fold volume dilution was prepared (Vf = 270 µL of PBS + 30 µL of cell 
suspension). The counting grid pattern in Neubauer chamber is designed to allow the 
standard cell counting procedure to be followed. About 10 to 15 µL of cell-containing 
sample was pipetted into the counting chamber through one of the ports. Liquid 
spread inside the chamber and replaced air. The volume of the counting chamber, 
which has dimensions of 1 mm × 1 mm × 0.1 mm (in depth) and the volume is given 
in cubic centimeters (cm3 = mL). The cell counting chamber was placed under a 
microscope with a typical magnification of 100. The microscope was focused onto the 
grid pattern and the cell particles (Figure 2- 1). The counted cell number was 
multiplied by dilution factor (Vf) and by the volume of the counting chamber. The cell 
concentration was recalculated according to the following equation (Equation 2- 1). 
 
Equation 2- 1 Calculation of the cell concentration 
 
 
! 
cell number /mL =
total cell number
number of quadrats
"Vf "10
4
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Figure 2- 1. The Neubauer chamber cell counting. The counting chamber consists from two pattern grids. 
Detail from one of them is cartooned bellow. The cells, animated as open rings, in the corners A-D are 
counted (in direction of gray arrow); black points represent the cells aside of counted area. 
2.2 Methods 
2.3 Cytotoxicity - MTT assay 
 MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) was 
used to estimate the amount of viable cells, which are able to reduce it to a violet 
formazan dye (Mosmann 1983). Many factors could affect the final result and 
therefore reproducibility of the established IC50 concentrations has to be proved.  
 The MTT assay was performed according to literature (Grotemeier 2006). The 
cells (1 – 0.5 ×105 cells/mL) were cultured for 12-24 hours depending on the growth 
progress. Cell incubation (5% CO2, 95% humidity, 37 °C) was followed by treatment 
with test compounds. Stock solutions of the complexes were dissolved in DMF. 
Dilutions were prepared using PBS buffer. DMF (and DMSO) belong to the group of 
water-miscible organic solvents.  
 In the mixture, the solubility of the drug is changed, hence, precipitation can 
occur and non-homogeneous suspension sometimes appears. Despite of this 
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behaviour all dilutions were prepared in media, required for certain cell types, and 
precipitation occurred rarely. As shown in the dilutions scheme in Table 2- 1, test 
substances at varying dilutions (200 – 0.5 µM) were prepared in a 96-well microplate. 
Plates with grown cells were modified, 50 µL of old media was removed and 50 µL 
of new media were pipetted from the plate containing the different drug 
concentrations (Table 2- 1). Blank and solvent controls were treated identically. After 
24 or 48 hours 50 µL of media was discarded and 5.5 µL of MTT 0.5 % solution was 
added. After formation of the formazan crystals inside the cells (Figure 2- 2; after ~1-
2 hours), the precipitate was dissolved with 100 µL of the DMSO solution. In the case 
of the neural cells formazan was dissolved in acidified (0.08 M HCl) isopropanol and 
measured immediately. 
Table 2- 1 Test-substances dilutions scheme 
 Dilutions of different substances 
Row 1 2 3 4 5 6 7 8 9 10 11 12 
Substance Media [µL] 
A 
B 
C 
D 
E 
F 
G 
H 
6 29
4 
15
0  
Dilution  
with 150 µL  Series of dilutions from column 1 to 2; from 3 to 4; … X X 
 µM 200 100 50 25 12.5 6.5 3.75 1.9 0.9 0.47 - - 
Dilutions are placed (50 µL) into a cell-plate with final concentration 
Row 1 2 3 4 5 6 7 8 9 10 11 12 
final 100 50 25 12.5 6.5 3.75 1.9 0.9 0.47 0.26 ctrl* ctrl* 
* Control cells used as blank and solvent controls 
 The absorbance at 570 nm and 630 nm was measured with an automatic 
microplate reader. All experiments were carried out at least in triplicate; the 
percentage of viable cells was calculated as the mean ± SD relative to controls set to 
100%. Final IC50 values were calculated using the GraFit 3.0 program (Equation 2- 2),  
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Equation 2- 2 Calculation of IC50                        
€ 
y = A
1+ xIC50
 
 
 
 
 
 
s  
where A are percentage of the recalculated absorbance, y is Y range, x is 
concentration of the substance on the x axis and s is slope factor of the curve 
 
 
Figure 2- 2 Example of the MTT test plate with melanoma 518A2 cells. Metabolically active 518A2 cells 
reduced yellowish MTT solution onto the violet formazan (crystals are solved in DMSO solution inside of 
the wells).  
2.4 Cellular drug uptake 
2.4.1 Temperature effect 
 Cells (5x105 cells/mL) were grown on 96-well (filtration) plates. First, 
endocytosis was tested parallel in two identical plates by temperature change. Two 
plates were identically pipetted with test compounds in various concentrations 
ranging from 50 µM to 300 µM. One plate was kept under ~4°C; another at 37°C in 
the dark. After 3.5 h and/or 5 h vitality of the cells in both plates was analysed by 
MTT test described in chapter 2.3. After 24 hours inhibitors were applied to final 
concentrations of 0.5 mM cimetidine, 0.1 mM tetraethylammonium (TEA), 10 nM 
wortmannin, 14 µM chlorpromazine, 10 µM amiloride, or 5 µM ouabaine. The 518A2 
cells were pre-incubated with these inhibitors for 15 minutes and then treated with the 
required concentration of the test substance or reference compounds. After 3.5 hours / 
5 hours cell vitality was measured by MTT tests. The insoluble formazan crystals 
were washed with distilled water, dissolved in DMSO and the absorbance of the 
resulting filtered solution was measured. The difference of absorbance at 570 and 630 
nm was calculated relative to the controls (untreated cells) and to the cells treated 
with the inhibitors.  
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 The cytotoxicities of the test compounds were cross validated by comparison 
with their effects on cells which were not incubated with an inhibitor and with the net 
effect of the respective inhibitor in cells not exposed to any test compounds.  
2.4.2 ICP-MS measurements of Pt-content  
 The cells were seeded in 6-well plates and grown for 24 hours, then optionally 
treated with the respective inhibitor for 15 minutes. Complex 2 (100 µM) was added 
and incubation continued for 3.5 hours. The cells were trypsinized, centrifuged (800 
rpm, 5 minutes) and washed with PBS. Samples were dissolved in 10 mL of pure 
water and measured by Inductively Coupled Plasma Mass Spectrometry ICPMS 
(Agilent 7500ce, Cetac ASX-510). Concentrations were calculated in µg/L. For 
samples pre-incubated with inhibitors, a relative inhibition of uptake was calculated 
with respect to the platination of inhibitor-free cells, which were set to 100%.  
2.4.3 Western blot analysis 
 This experiment was performed in the laboratory of Prof. Olaf Stemmann, 
Genetics Department - University Bayreuth by his PhD student Andreas Brown. Cells 
were collected by centrifugation, suspended in a SDS-PAGE sample buffer, 
sonificated to shear genomic DNA and boiled at 95 °C for 15 minutes. The resulting 
cell suspension was passed through a 27-gauge needle. The combined extracts were 
separated on a gradient SDS-PAGE gel and transferred to a PVDF membrane. The 
individual proteins were detected by means of anti-goat polyclonal OCT-1 (N-12) (sc-
19809), anti-goat polyclonal OCT-2 (C-13) (sc-19814) and anti-alpha-tubulin (12G10 
mouse monoclonal from hybridoma supernatant) primary antibodies and appropriate 
secondary antibodies conjugated with HRP (Sigma Aldrich). 
2.5 Sub-cellular microscopy methods 
2.5.1 Time-lapse microscopy 
 This work I performed in the Laboratory of Dr. Emília Madarasz with 
introduction and special assistance help of Dr. Környei.  Cells were grown on IBIDI 
dishes in a customary microscope stage incubator (37 °C, 5% CO2). Time-lapse 
recording was performed (in the laboratory of Dr. Madarász) with a computer-
controlled Zeiss Axiovert 200M microscope equipped with 10- and 20-fold objectives 
and an AxioCam MRm digital camera.  
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2.5.2 Immunocytochemistry 
 This work I performed in the Laboratory of Dr. Emília Madarasz with 
introduction and special assistance help of Dr. Környei.  The cells (518A2 melanoma, 
astroglia) grown on poly-L-lysine-coated optical-glass cover slips were X-crossed 
(Kornyei, Czirok et al. 2000) before treatment and then fixed with 4% 
paraformaldehyde in PBS for 20 minutes at room temperature. The cells were 
permeabilised with Triton X-100 (0.1% v/v in PBS; 5 minutes). Nonspecific 
antibodies were blocked by incubation with 3% FBS in PBS (room temperature, 1 h). 
α-GFAP antibody (rabbit, DAKO) was used in a dilution of 1:2000 and was 
visualized by anti-rabbit IgG Alexa 594 (1:1000). Phalloidin-biotin was applied in a 
1:1000 dilution followed by avidin-Alexa 488 (1:800). Fluorescence images were 
captured manually on a Zeiss Axiovert 200M microscope fitted with 20–60 fold zoom 
and a Zeiss AxioCam MRm digital camera.  
2.5.3 ELISA - In situ detection of neural β-tubulin level 
 This work I performed in the Laboratory of Dr. Emília Madarasz with 
introduction and special assistance help of Dr. Környei. The neurons, grown in 24-
well plates, were incubated for 24 hours with test compounds. After incubation 
neurons were washed with PBS containing 0.5% TritonX 100 for 10 minutes. Specific 
biotin-conjugated anti-mouse βIII-tubulin antibody (1:1000) was incubated for 1 hour 
at room temperature. After washing step avidin-peroxidase (Sigma) diluted in PBS 
was applied and used in 1:1000 dilution. The antibody binding was visualized by 3.3’-
diaminobenzidine (DAB, Sigma). Percentage of βIII-tubulin was recalculated 
regarding to untreated control neurons. 
2.5.4 Microscopic observations of the cells by Giemsa staining   
 A 6-well-plate was prepared by attaching round optical-glass slides (Ø 1.5 cm) 
to the bottom of the wells. A confluent cell layer in a Petri dish was trypsinized and 
diluted with medium giving a concentration of 0.75 × 105 cells/mL. A volume of 2 
mL of this diluted suspension was added to each well, so that the round optical-glass 
slides were completely covered. The cells were incubated at 37 °C and 5 % CO2 for 
about 24 hours. Subsequently to this pre-incubation, an X-cross was performed with 
10 µL tip (Kornyei, Czirok et al. 2000) and test compounds were added to the wells 
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(one substance per well). Moreover, DMF were added to a further well (1:1000 
dilution of DMF), while another well contained just the plain cell culture as a negative 
control. Then the cells were incubated (5 % CO2 and 95 % humidity, 37 °C). The 
assay was carried out after various incubation periods. Afterwards, the medium was 
discarded and the adherent cells were washed with PBS, followed by a washing step 
with a mixture of PBS and methanol (1:1.5). In order to fix the cells on the surface of 
the glass plates, they were covered with methanol for 15 minutes. Subsequently, the 
methanol was discarded and the cells were washed with fresh methanol. In order to 
stain the melanoma cells, the glass plates were completely covered with a 1:15 
dilution of Giemsa dye for 5 minutes. The Giemsa dilution was prepared from a 
mixture of methanol and demineralized H2O (7:3). After adding tap water to the wells 
(about twice the volume of the Giemsa dilution) and another two minutes of 
incubation, the aqueous Giemsa solution was discarded. The cells were carefully 
washed with demineralized H2O before they were fixed and dried on the microscope 
slides. Pictures of the different cell samples were taken by using an optical 
microscope (320× magnification) and the software Axio Vision (AxioVs 40 V 
4.5.0.0; Carl Zeiss Imaging Solutions GmbH). The analysis of the pictures was 
performed by AxioVision program. 
2.5.5 Transmission electron microscopy 
 This work I performed in the Electron Microscopy Laboratory (University of 
Bayreuth) under guidance of Dr. Geimer and his student Dirk Scholz (introduction 
and special assistance help). I appreciate the help of Melina Fischer for taking the 
micrographs: Fig 3-20 a,d,f,g,i and Fig 4-13 d,e,h during analysis of my prepared 
TEM samples. My TEM samples were also used for her bachelor work (Geimer and 
Fischer 2008). Melanoma 518A2 cells were plated on pieces of aclar film, incubated 
for 24 hours, exposed to 100 µM of compound 1 or 2 for 20 minutes and flat-
embedded for transmission electron microscopy. For this reason cells were fixed in 
0.1 M HEPES, 4 mM CaCl2 containing 2.5% glutaraldehyde, pH 7.2, for 4 hours at 
room temperature. After three rinses with 0.1 M HEPES, 4 mM CaCl2, pH 7.2, cells 
were postfixed with 1% osmium tetroxide in distilled water for 45 minutes at 4 °C, 
rinsed three times in distilled water and incubated in 1% uranyl acetate in distilled 
water for 1 hour at 4 °C. Dehydration of the samples in an ethanol series, infiltration 
with Epon, and flat embedding was performed according to standard procedures. Dr 
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Stefan Geimer / Rita Grotjahn performed ultrathin sectioning (60–70 nm) cut and 
mounted onto pioloform-coated copper grids. Sections were stained with uranyl 
acetate and lead citrate (Reynolds 1963) and viewed with a Zeiss CEM 902 
transmission electron microscope at 80 kV. Micrographs were taken using EMS EM 
film.  
2.6 Apoptosis - DNA degradation  
2.6.1 Alkaline single cell gel electrophoresis  
 The bottom agar was prepared from an already prepared 1 % normal melting 
point (A-NMP) agarose gel (Zoldakova and Rymarczyk 2009). It was boiled in a 
microwave oven and then diluted with TAE of the same volume (total volume ~13 
mL). The middle layer agar consisted of 1 % of low melting point agarose (A-LMP, 
15 mg per 1.5 mL) and was prepared in an Eppendorf tube using a heat block (95 °C) 
to dissolve the agarose. After dilution in order to obtain 0.5 % LMP agarose gels were 
refrigerated until usage.  
Treatment: Drug dose response was conducted either without direct light or in the 
dark. Aliquots of 200 μL were taken from the suspension culture of HL60 cells and 
pipetted into Eppendorf tubes. Then, 2 μL of illudin M (0.1 mM diluted in RPMI 
medium) were added to reach a final concentration of 1 μM illudin M in the cell 
suspension. The control sample was treated without illudin M. Then the samples were 
put in the incubator over a period of 10 minutes or 5 minutes, respectively. 
Repair: For measuring the rate of DNA repair the samples were centrifuged (5 
minutes, 800 rpm) after incubation with illudin M. The pellet was resuspended in 
fresh RPMI (same volume as the supernatant) and then the samples were incubated 
experimentally for 2 hours or 1.5 hours, allowing repair of the DNA. 
Preparation of the microgels: The gel for the bottom layer was prepared in a glass 
Petri dish, with the latter having been previously washed with 70 % ethanol and dried 
in an oven. Then, 5 mL of hot liquid 0.5 % NMP agarose were pipetted into the Petri 
dish and evenly distributed. It solidified at room temperature. From this gel the first 
layer was cut out (3.8 x 1.8 cm) and carefully placed on a microscope slide (washed 
and oven dried to prevent residual fibres). When the gel in the Petri dish was not 
needed anymore, it was stored in TAE buffer in order to avoid desiccation. 
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Depending on the cell number in the incubated samples, 10 - 17 µL cell suspension 
was mixed with 75 to 90 µL 0.5 % LMP agarose, so that the mixture contained 
approximately 10,000 cells. Immediately after mixing, 10 µL of the cell agarose 
mixture were pipetted onto one half of the bottom layer. While the first sample was 
left to solidify at room temperature the second one was prepared in a similar manner 
and pipetted onto the other half of the bottom layer. 
After solidification the cell layer was covered with a second layer of 0.5 % LMP 
agarose. The prepared 0.5 % LMP agarose was melted in the heat block and 
approximately 200 to 300 µL were pipetted on top of the cell layer. The microgel was 
kept at 4 °C for 5 minutes to allow for the solidification of the agarose.  
Lysis and Electrophoresis: The microgel was placed in a small glass Petri dish and 
immersed in a prechilled lysing solution and kept for 1 h on ice in the dark. This 
procedure was used to lyse the cells and permit the DNA to unfold (Singh, McCoy et 
al. 1988). Before the microgel was placed into the horizontal electrophoretic unit, it 
was rinsed in bidistilled water. The short sides of the microgel were in contact with 
the walls of the platform unit in a way that the cell dots were not lined up one after the 
other concerning the direction of current flow. Then, the buffer reservoirs were filled 
with chilled electrophoresis buffer until the liquid completely covered the gel. The 
microgel was allowed to equilibrate in the buffer for 20 minutes in order to facilitate 
unwinding of the DNA. The equilibration was followed by a 20-minute 
electrophoresis at 25 V and ~ 200 mA using an electrophoresis compact power 
supply. Before and during electrophoresis the unit was kept on ice and in the dark. 
 The visualisation of DNA damage was performed with an Axiovert 135 
microscope, equipped with an excitation filter of 515 – 560 nm and an emission filter 
of 590 nm. The stained gels were illuminated with a blue-light transilluminator. 
Images were taken at 200 and 320 magnifications using an AxioCam MRc5 camera, 
which was attached to the microscope and the image analysis software AxioVision 
Rel. 4.6. For estimation of DNA damage, a minimum of 50 cells from each sample 
was scored using TriTek CometScoreTM version 1.5 (free software program). 
2.6.2 Cell cycle analysis  
 518A2 melanoma cells (106) were treated with the test compounds, positive 
(250 µg/mL nocodazole) / negative (DMF) controls and then harvested at certain time 
intervals (12, 18 and 24 hours). The cells were washed, re-suspended in 200 µL PBS, 
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and incubated with 8 mL of 70% ice-cold ethanol for fixation. They were centrifuged, 
washed with PBS, and re-suspended in 1 mL of a PBS solution of 3.8 mM sodium 
citrate and 50 µg/mL propidium iodide with freshly added RNase A (Krishan 1975). 
After 1 hour incubation at 37 °C the concentration of double-stranded DNA in the 
samples was determined by measuring (The FACS analysis was performed in the 
laboratory of Prof. Olaf Stemmann, Genetics Department - University Bayreuth with 
special assistance of his PhD student Andreas Brown) the emission (570 nm) of its 
fluorescent adducts excited at 488 nm, using a Beckman CYTOMICS FC 500 
cytometer.   
2.6.3 DNA fragmentation 
 The DNA of cancer cells was isolated after the cells have been treated with 
several test compounds. In order to detect whether the applied chemical compounds 
caused a DNA fragmentation agarose gel electrophoresis was carried out with the 
isolated DNA samples. After incubation for 24 hour (5 % CO2, 95 % humidity, 37 °C) 
the negative control and the treated cell cultures were trypsinized. Then, the cell 
suspensions of the samples were transferred into falcon type tubes (50 mL). 
Following a centrifugation step (800 rpm, 5 minutes), the supernatant was discarded 
and the pellets were washed twice with 2 mL of PBS. During these washing steps the 
cell suspensions were transferred into 2 mL Eppendorf reaction tubes. Subsequently, 
the cell pellets were frozen at -20 °C and melted again in a 37 °C water bath. This 
freezing/melting-process was repeated three times. Cell pellets were resuspended in 1 
mL of lysis buffer and incubated at 60 °C for 5 minutes. Before incubation at 60 °C 
for 1 hours, RNase A (5 µL) and Proteinase K (2.5 µL) were added to each sample. In 
order to precipitate proteins after cell lysis, 250 µL of 5 M NaCl were pipetted to the 
lysis buffer and the suspension was mixed carefully by inverting the reaction tubes 
several times, which were then kept on ice for 15 minutes. Following a centrifugation 
at 10,000 rpm for 15 minutes the supernatants with the solved DNA were collected 
and transferred into a new tube (2 mL), while the pellets of proteins were thrown 
away. To precipitate the DNA, ice-cold ethanol (100 %) was filled into the tube up to 
a total volume of 2 mL. The samples were carefully mixed by inversion of the 
reaction tubes and kept at -20 °C overnight to increase the DNA yield. The tubes were 
centrifuged (10,000 rpm, 10 minutes) and after washing twice with 70 % ethanol, the 
DNA pellets were dried using a vacuum centrifuge. The DNA was solved in 1× TE 
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buffer (10-20 µL depending on the amount of DNA) and the samples were stored at 4 
°C. For gel electrophoresis the DNA samples were heated (50 °C, ~ 20 minutes), 3 µL 
of loading buffer was added to 7.5 µL of each sample and the DNA was applied to a 
1.5 % agarose gel. The 100 - 3000 bp-DNA ladder was mixed with 1 µL of its own 
loading buffer as well as 5 µL of ddH2O according to the manufacturer protocol. The 
electrophoresis was carried out at 85 V and 25 mA in 1× TAE buffer for 3 hours. To 
visualize the DNA bands, the gel was stained with an ethidium bromide staining 
solution and examined under UV light. Pictures of the stained DNA gels were taken 
using the software BioCapt (Version 11.02 for Windows). 
2.7 Interaction of complex with DNA in vitro  
2.7.1 Electrophoretic mobility shift assay with native agarose gel  
 The interaction of test compounds with pBR322 plasmid DNA was studied by 
agarose gel electrophoresis according to the literature (Chowdhury, Huq et al. 2005). 
Briefly, 6 µL aliquots of pBR322 plasmid DNA (conc. 73.5 mg/mL) solved in TE 
buffer were incubated in the presence of increasing complex concentrations (0, 5, 20, 
40, 60 µM) dissolved in DMSO. Incubation was carried out in the dark at 37°C for 24 
h. Samples containing 1.5 mg of plasmid DNA were loaded onto a 1% agarose gel, 
and electrophoresis was carried out in 1 × TEA buffer for 4 h at 66 V. The gel was 
then stained in the same buffer containing ethidium bromide (1 mg/mL) and 
visualized with a transilluminator. The band intensities were analyzed using Image 
Tools software. 
2.7.2  Circular dichroism - secondary structure of DNA-complex  
 This work I performed in the Laboratory of Prof. Viktor Brabec, introduced by 
Dr. Kostrhúnová. The circular dichroism (CD) method is applied for the study of 
optical activity of (macro) molecules in solution (Alison Rodger and Nordén, 1997). 
Circular dichroism is the difference in absorption of left and right circularly polarized 
light, which could be changed after interaction with reactive Pt complexes. All 
measurements were performed on a Jasco Spectropolarimeter. The concentration of 
Pt-complexes covalently bound to DNA was established after DNA dialysis in 0.01 M 
NaClO4. After reaction of calf thymus DNA with the corresponding Pt complex for 24 
hours CD spectra were measured under following conditions: Start wavelength 450 
nm; End wavelength 220 nm; Step resolution 0.5; Speed 200; Accumulation 3; 
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Response 0.25 s; Band With 2; Sensitivity 20 millidegrees. CD spectra were 
measured in ellipticity Δε [M-1.cm-1]. Blank, 0.01M NaClO4, was measured for each 
spectrum. Spectrum maxima at wavelength 246 nm and 278 nm were read and 
compared with spectra of untreated DNA.  
2.7.3 Melting temperature of DNA-complex adducts 
 This work I performed in the Laboratory of Prof. Viktor Brabec, introduced by 
Dr. Kostrhúnová, Dr. Malina. Samples for measurements of Tm curves were taken 
from the CD experiments. The absorbance was measured in a mono-block of a 
spectrophotometer (Varian Cary 4000). 
2.7.4 Mono- and bifunctional adduct study 
 This work I performed in the Laboratory of Prof. Viktor Brabec, introduced by 
Dr. Kostrhúnová. The oligonucleotide 5’-CCT CTC CTT GGT CTC CTT CTC-3’ 
was synthesized on an Applied Biosystems solid-phase synthesizer and purified by 
ion-exchange FPLC. The single-stranded DNA was allowed to react with a 
stoichiometric amount of the platinum complex (1:1 ratio). The platinated 
oligonucleotides were purified by FPLC. It was verified by platinum FAAS and by 
optical density measurements that the modified oligonucleotide contained just one 
platinum atom. It was also verified using DMS footprinting (Brabec and Leng 1993; 
Leng and Brabec 1994) that in the platinated top strands the N7 position of both 
neighbouring guanines was not accessible for reaction with DMS. DMS methylates 
the N7 position of guanine residues in DNA, producing alkali-labile sites (Maxam and 
Gilbert 1980). However, if N7 is covalently bound to platinum, it cannot be 
methylated. The oligonucleotides were then treated with hot piperidine and analyzed 
by denaturing polyacrylamide gel electrophoresis. For the nonmodified 
oligonucleotides, shortened fragments due to the cleavage of the strand at the two 
methylated guanine residues were observed in the gel. The platinated strands were 
allowed to anneal with nonplatinated complementary strands in 50 mM NaCl plus 1 
mM Tris-HCl with 0.1 mM EDTA, pH 7.4. FPLC purification and FAAS 
measurements were carried out on a Pharmacia Biotech FPLC System with a MonoQ 
HR 5/5 column and a Unicam 939 AA spectrometer equipped with a graphite furnace, 
respectively. 
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2.7.5 Radioactive 3’-ends labelling of plasmid DNA  
This work I performed in the Laboratory of Prof. Viktor Brabec, introduced by Dr. 
Kostrhúnová, Dr. Zerzánková.  
Incorporation of [γ-32P]dATP: an aliquot of linear plasmid DNA (~1 µg) was 
dissolved in a total volume of 10 µL with 2 µL of 5x[γ]ATP buffer, 2 µL of 24% 
aqueous polyethylene glycol (PEG). One of the last components were 1 µL of [γ-
32P]ATP and 1 µL of T4 polynucelotide kinase. Reaction mixture was incubated for 
30 minutes at 37°C and loaded into pre-prepared sephadex G-50 column in total 
volume of 100 µL. Radioactively labeled pSP 73 KB was collected and used in the 
experiment. 
Incorporation of [α-32P]dATP: An aliquot of linear plasmid DNA (~1 µg  ≈ 3 µL of c 
= 334.9 µg/mL) was solved in the total volume of 10 µL with 1 µL of Neb II buffer, 1 
µL of enzyme Klenow fragment and 5 µL of water. After all components 1 µL of [α-
32P]dATP was placed. Reaction mixture was incubated for 30 minutes at 37°C and 1 
µL of Klenow fragment was added and incubated for additional 30 minutes. After 
loading onto the pre-prepared Sephadex G-50 column in a total volume of 100 µL, 
radioactively labeled plasmid DNA was collected and used for the next experiments. 
2.7.6 Interstrand cross-links study in denatured agarose gel 
 This work I performed in the Laboratory of Prof. Viktor Brabec, introduced by 
Dr. Kostrhúnová, Dr. Zerzánková. Plasmid DNA pSP 73 (2464 bp) was cleaved using 
restriction enzyme EcoRI (5’-G•AATTC-3’). Linear DNA was deproteinised 
(phenol:chloroform mixture), precipitated (2 x 100% ethanol; 1/10 of sodium acetate) 
and dissolved in dH2O.  
For ethidium bromide staying: Linear pSP73 KB was incubated with test compounds 
at various rb values and incubated in the dark for 24 hours at 37°C (after dialysis the 
Pt-content was verified by FAAS or ICP). A denatured 1% agarose gel was kept in 
denaturation buffer overnight. Samples with loading buffer (6x) and 0.03 M NaOH 
were loaded onto the gel in freshly prepared denaturation buffer. The gel was running 
overnight with 0.5 V/cm. After neutralization the gel was kept in 1xTBE at 4 °C for 
30 minutes. After ethidium bromide staining the gel was visualised on a 
transluminator.   
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For radioactive labelling: An aliquot of DNA was incubated with radioactive [γ-
32P]dATP according to 2.7.5. Radioactive linear DNA was purified 
chromatographically via a Sephadex G-50 column and the intensity was measured on 
a Geiger-Müller counter. Labelled linear DNA was mixed with nonradioactive DNA 
at various rb values of the corresponding Pt complex and incubated at 37°C in the dark 
for 24 hours. A denatured 1% agarose gel was kept overnight in denaturation buffer. 
Samples containing loading buffer and 0.03 M NaOH were loaded onto the gel in 
freshly prepared denaturation buffer. The gel was running over-night at 0.5 V/cm. The 
gel was dried under vacuum and a sensitive imaging plate was placed onto the gel. 
After 3 hours autoradiograph were read with a Fujifilm reader.  
The autoradiogram shows interstrand cross-links with platinum (IEC/Pt) and single-
strand DNA (IEC/DNA). The quantification of random distribution of Pt-based cross-
links in the DNA was performed by Poisson equation of the IECs (Equation 2- 3) 
(Jones, Zhen et al. 1991), 
Equation 2- 3 Poisson distribution of interstrand cross-links. 
€ 
Pt /DNA = 2 × 2464 × rb ;
IEC/DNA = −ln(ss) ;
IEC /Pt = IEC /DNAPt /DNA
 
 
where 2464 – plasmid base pairs number; ln(ss) – negative ln (fraction of DNA 
molecules free of IECs). 
2.7.7 Inhibition of RNA synthesis 
 This work I performed in the Laboratory of Prof. Viktor Brabec, introduced by 
Dr. Nováková, B. Lišková. The whole experiment was performed according to the 
instructions of the Promega kit manual of Riboprobe® in vitro Transcription systems 
(Lemaire, Schwartz et al. 1991). Plasmid DNA pSP 73 KB (2455 bp) was cleaved by 
restriction enzymes, Nde I and Hpa I, and two fragments of specific size were 
obtained. After phenol deproteination followed by DNA precipitation with ethanol, 
the DNA was dissolved in 0.01 M NaClO4. The linear DNA fragment (212 bp) was 
treated with the corresponding platinum complex (rb = 0.02) for 24 hours at 37°C.  
After incubation ⅔ of the sample was dialysed and the real concentration of Pt was 
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measured by FAAS analysed. The modified DNA (⅓) was placed into the reaction 
mixture of 1 x transcription buffer in the presence of all four NTPs (ATP, GTP, CTP, 
UTP) and the radioactive isotope [α-32P]dCTP at 37°C for 1 hour. In the case of 
nucleotide sequence analysis the reaction mixture was enriched with one of the 3’-
dNTP terminators (3’-dATP, 3’-dGTP, 3’-dCTP, 3’-dUTP). Precipitation of the RNA 
transcript and the free nucleotides was carried out in 100% ethanol and 2.5 M 
ammonium acetate. The sediments were dissolved in water and precipitated again in 
80% ethanol with 1 M ammonium acetate, washed with 100% ethanol and dried 
under vacuum for 10 minutes. The radioactivity of the aliquots was optimised with 
RNA-loading buffer for 250 Bq (1 Bq = 2.70×10−11 Ci = pulse pre seconds) on the 
Geiger-Müller counter. The denatured polyacrylamide (PAA) gel (PAA: 50% urea = 
19:1; 0.3 mm thin) for RNA inhibition consisted of two parts. At first, the bottom gel 
was prepared from 8% acryl amide with 30 µL of 25% APS + 50 µL TEMED in 50 
mL and polymerized ~6 hours before loading.  Electrophoresis was performed in 1 x 
TBE buffer approximately for 90 minutes, 1 V/cm (length of electrophoresis glasses 
40 cm). The bottom glass was removed and a sensitive imaging plate was placed onto 
the gel. After 3 hours a Fujifilm reader took autoradiographs and the plate was de-
excitated by Eraser.  
2.7.8 Measurement of DNA-Pt content  
2.7.8.1 Samples preparation for FAAS 
 This work I performed in the Laboratory of Prof. Viktor Brabec, introduced by 
Dr. Nováková. The amount of platinum in DNA samples was measured on a Zeeman 
Flame Atomic Absorbtion Spectrophotometer (FAAS).  First, the platinum 
concentration was recalculated (Equation 2- 3) from known concentrations of DNA 
according to the sensitivity of the FAAS method, which is varying between 1x10-6 – 
5x10-7 M of Pt. Samples were diluted in water and the experimental rb value was 
calculated.  
2.7.8.2 Samples preparation for ICP-OES 
 Pt contents were measured via Inductive Coupled Plasma Optical Emission 
Spectroscopy (ICPOES, BayCEER service). First, salmon sperm DNA (10 mg) was 
dissolved in 0.9 mL of TE buffer and 10 mM NaClO4. The chalcone-Pt complex was 
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dissolved in DMF to a final concentration of 100 µM. Negative controls contained 
just DMF, while 100 µM cisplatin (CDDP) served as a positive control. The DMF 
content per mL was 1%. After 48 h of incubation the samples were poured into the 
doubled volume of 100% ethanol, left standing overnight, and the resulting DNA 
precipitates were collected. They were washed with 70% ethanol, DMF and 
centrifuged (10 minutes, 8200 rpm). The pellets obtained were washed again with 
70% ethanol, re-dissolved in 200 µL of TE buffer and 200 μL of DMF for 1 hour, and 
finally DNA was precipitated with 100% ethanol, washed and lyophilized. The DNA 
samples obtained were treated at 170 °C in a sealed vial with a mixture of 0.5 mL 
each of HNO3 and HCl for 7 hours. After cooling to room temperature the resulting 
solutions were filled up with water up to a volume of 10 mL and submitted to ICP-
OES. 
2.8 Apoptotic signals 
2.8.1 Colorimetric caspase assay  
 The caspase assay employs N-acetyl-Asp-Glu-Val-Asp-p-nitroaniline (Ac-
DEVD-pNA) as a substrate for caspase-3 enzyme and the irreversible inhibitor Ac-
DEVD-CHO. The HL 60 leukaemia cells were incubated with or without 1 µM of test 
compounds (dissolved in DMF). For each sample 6 million cells were used during a 
24 hours incubation time, washed twice with PBS, centrifuged at 1200 rpm, and the 
pellet was stored at -20°C until used.  
 The cellular activity of caspases was studied in cell lysates, which were 
obtained by multiple freeze-thaw procedure in the presence of caspase buffer 
(Thornberry 1994). The assay was carried out in a total volume of 100 µL in a 96-
well plate (Greiner bio-one). Crude extracts were diluted 10-fold with caspase buffer; 
caspase-inhibitor DEVD-CHO (Biomol) was added in 20 µM final concentration and 
incubated for 15 minutes at 37°C. The substrate for caspase 3 (Ac-DEVD-pNA) was 
supplied in a concentration 200 µM and absorbance was measured at 405 nm using 
MWG-Biotech micro-plate reader. Measurements were performed every 15 minutes 
over 3 hours. The initial rate of hydrolysis was determined from observed progress 
curves with/without inhibitor. The cleavage of caspase-substrate was calculated only 
from the initial slope of the absorbance vs. time curves (the linear portion of the 
progress curves). Concentration of cleaved substrate and rate of released p-
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nitroaniline [pmol/min/μg of protein] was calculated basing on the extinction 
coefficient of pNA (9920 M-1.cm-1) with initial slope kinetic in minutes.  
2.8.2 Intracellular concentration of Ca2+  
 The cells were incubated with/without test compounds, harvested, and cell 
pellets were resuspended in 2 mL of Ca-buffer. Cell concentrations were established 
for each sample. A centrifugation step (800 rpm) of the samples followed for 5 
minutes, before the cell pellets were resuspended in fresh Ca-buffer. The samples 
were adapted to a density of 1.3 × 106 cells/mL. After resuspending the pellets in the 
individual volumes of Ca2+-buffer, 0.75 mL of the sample was mixed with 0.25 mL of 
Ca2+-suspension in a 1.5 mL Eppendorf vial followef by incubation in the dark for 30 
minutes. A centrifugation (800 rpm, 5 minutes) as well as a washing step with Ca2+-
buffer followed. The resulting pellets were resuspended in 0.5 mL of fresh Ca2+-buffer 
and kept in the dark for another 15 minutes. 
 The fluorescence of the samples was measured in a 3 mL glass cuvette (2 mL 
Ca2+-buffer, 0.5 mL sample) at the emission wavelength (Em = 510 nm) during a time 
period of 10 minutes using a fluorescence spectrometer. The excitation wavelength 
was Ex(1) = 340 nm and Ex (2) = 380 nm. About 3 minutes after starting of the 
measurement 10 µL of digitonin were added to the cuvette and later 50 µL of EGTA 
were pipetted into the sample. The fluorescence signals were visualized using VL 
WinLab Version 4.00.03.   
2.9 Drug resistance  
2.9.1 Activity of P-gp transporters in KBv1 cells - calcein assay 
 This assay was carried out with slight modifications according to a literature 
procedure (Kohno, Kikuchi et al. 1988). Briefly, KBv1/KBv1+Vbl cells were 
trypsinised on the 3rd or 4th day after passaging and washed with PBS at 25 °C. Cells 
(1.3×106/mL) were resuspended in 0.75 mL of Ca-buffer and 0.25 mL of Cs-buffer 
was added. The samples were mixed with 50 µM of test substances, shortly vortexed 
and incubated for 15 minutes. Calcein-AM was added to achieve a concentration of 1 
µM. After incubation (10 minutes, 37 °C, 5% CO2), and centrifugation (800 rpm, 5 
minutes, 4 °C) a cell pellet was obtained which was rinsed once with ice-cold PBS 
and re-suspended in 0.5 mL of Ca-buffer. The fluorescence of calcein (λEx = 485 nm, 
λEm = 535 nm) was measured in a black 96-well microplate on a TECAN Infinite 
2. Material and Methods 
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F200 plate reader.  Data were analysed and calculated relative to a positive control 
(verapamil).  
2.9.2 Activity of BCRP transporters in MCF-7 cells - mitoxantrone assay 
 The assay was carried out according to literature procedures (Kuhnle, Egger et 
al. 2009). MCF-7+Top cells were incubated with 20 µM mitoxantrone in 70% ethanol 
and vortexed. 10 µM of the test compounds dissolved in DMF were added to allow 
maximal mitoxantrone uptake into the cells over a period of 30 minutes at 37 °C. 
After centrifugation (800 rpm, 5 minutes, 4 °C) the cells were washed twice with 
PBS, pipetted into a black microplate together with the positive control fumitremorgin 
C (FTC) and the negative control (only DMF). The plates were immediately placed in 
a TECAN fluorescence plate reader and the mitoxantrone fluorescence was measured 
at 620 nm excitation and 670 nm emission wavelengths. Three wells of each plate 
contained the internal standard FTC (10 µM). Its cellular fluorescence was taken and 
set to 100% BCRP inhibition. 
2.9.3 Repair DNA synthesis by human cell extracts 
This work I performed in the Laboratory of Prof. Viktor Brabec, introduced by Prof. 
Dr. Kašpárková, Muchová T, Suchánková T. Preparation of cell free extract CFE: 
Cells were seeded into the flasks and were grown as monolayer. Trypsinated cells 
were washed with ice-cold PBS; the pellet was carefully re-suspended in 1 mL of 
lysis buffer I and was kept on ice for 10 minutes. After centrifugation (800 rpm 4°C 
10 minutes) the pellet was carefully re-suspended by lysis buffer II and directly 
centrifuged as previously described.  Into the pellet 0.5 mL of nuclear extration buffer 
III was added and the sample was slowly rotated for 30 minutes at 4°C. After 
centrifugation (15 minutes, 12 000 rpm, 4°C) the supernatant was put into a new 
Eppendorf vial, which was directly frozen at -80°C.  
The measurement of DNA repair by CFE was performed according to literature 
procedures (Henderson 1999). Repair DNA synthesis by cell-free extracts CFE was 
assayed using pUC19 plasmid. Each reaction of 50 mL contained 600 ng of 
nonmodified pBR322 and 600 ng of nonmodified or platinated pUC19, 2 mM ATP, 
30 mM KCl, 0.05 mg mL-1 creatine phosphokinase (rabbit muscle), 20 mM each of 
dGTP, dATP, and dTTP, 8 mM dCTP, 74 kBq of [α-32P]dCTP in a buffer composed 
of 40 mM HEPES–KOH, pH 7.5, 5 mM MgCl2, 0.5 mM dithiothreitol, 22 mM 
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creatine phosphate, 1.4 mg of bovine serum albumin/mL, and 20 mg of CFE from the 
HeLa S3 or melanoma 518A2 cells. Reactions were incubated for 3 h at 30°C and 
terminated by adding Na2H2EDTA to a final concentration of 20 mM, SDS to 0.6%, 
and proteinase K to 250 mg mL-1. After incubation for 20 minutes, the products were 
extracted with one volume of 1:1 phenol/chloroform. The DNA was precipitated from 
the aqueous layer by the addition of 0.1 volume of 3 M sodium acetate and 2.5 
volumes of ethanol. After 30 minutes of incubation at –20 °C and centrifugation at 12 
000 g for 30 minutes at 4 °C, the pellet was washed with 0.2 mL of 80% ethanol and 
dried in a vacuum centrifuge. DNA was linearized before electrophoresis on a 1% 
agarose gel. After staining with ethidium bromide, the agarose gel was dried under 
vacuum and an autoradiograph was prepared (Fujifilm reader). The autoradiograph 
was analysed using the AIDA program. The experiments were carried out in 
quadruplicate. 
2.9.4 Reaction of Pt-complex with glutathione   
 The assay was performed according to (Ishikawa and Ali-Osman, 1993). 
Briefly, glutathione (GSH; 3.33 mM) was incubated with 1.67 mM cisplatin (or 
complexes 1, 2, 3) in 1 mL of PBS at 37 °C. At different time points (48 hours 
period), 20 µL aliquots of the reaction mixture were taken, diluted with 980 µL of 
PBS, and the absorption spectra of the resulting solutions were measured by 
(Zoldakova and Schreder 2009) scanning spectrophotometry (Shimadzu UV-160 
spectrophotometer).  
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Effects of chalcone (1) 
 Chalcones are 1,3-diaryl-2-propen-1-ones which build the core of many 
biologically active compounds (Biersack, 2009; Zoldakova, 2010). The 
methoxysubstituted chalcone (1) (Figure 3- 3) has shown high antitumor activity 
against leukaemia cells due to efficient tubulin polymerisation inhibition (Ducki et al., 
1998). Because of its high activity and easy preparation chalcone (1) was chosen for 
testing and for further modifications leading to various platinum(II) and ruthenium(II) 
conjugates aiming at more potent drug candidates with multiple and synergistic 
modes of action. 
 
Figure 3- 1 Structure of the tubulin binding chalcone (1). 
3.1 Inhibition of cell growth - MTT assay 
 The MTT assay is widely used as a rapid and sensitive method for the 
screening of the cytotoxic activity of anticancer drugs. It bases on the tetrazolium salt 
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide), which is turned into 
a formazane dye in the mitochondria of living cells. The formation of this formazane 
dye can be quantified colorimetrically. Hence, this assay was used to characterize 
chalcone cytotoxicity on different cell lines.   
3.1.1  Neural cells  
 Chalcone (1) targets tubulin and microtubules (Hadfield et al., 2003). In 
addition, chalcone derivatives isolated from the stem bark extract of a Brazilian 
medicinal plant (Myracrodruon urundeuva) displayed neuroprotective properties 
(Nobre-Junior et al., 2009). Tubulin-rich cells of neural origin (astroglia, U87, 
neurons, NE-4C, C6) were obtained and assayed in the laboratory of Dr. Emília 
Madarasz (Neural Cell Biology Institute in Budapest, Hungary). Relative 
cytotoxicities of chalcone (1) against the neural cells as well as for WEHI 164 mouse 
fibrosarcoma are listed in Table 3- 1. 
 The murine astroglia cells remained resistant to compound 1 during the whole 
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48 h incubation period (Table 3- 1). The human U87 glioma cells responded well 
upon prolonged exposure. The primary neurons were likewise sensitive to a 
prolonged treatment with 1. Surprisingly, the sensitivity of C6 rat glioma cells with 
IC50 (48 h) ~150 nM for chalcone treatment could be promising for further 
pharmacological investigations. NE-4C cells, derived from the fore- and midbrain 
vesicles of p53-deficient 9-day-old mouse embryos (Schlett and Madarasz, 1997), 
were also strongly sensitive towards 1 after exposure for 48 h. The tested WEHI 164 
fibrosarcoma cells were less sensitive than NE-4C or glial C6 cell towards chalcone 
(1) (IC50 > 10 µM).  
Table 3- 1: Inhibitory concentrations (IC50 in µM) of chalcones (1) in various neural (astroglia, neurons, NE-
4C, U87, C6) and non-neural cells (WEHI 164). 
Cell line Astroglia U87 Neurons NE-4C C6 WEHI 164 
24 h (1) 55 ± 5 45 ± 5 38 ± 6 2.8 ± 0.6 0.5 ± 0.08 11 ± 1 
48 h (1) 33 ± 3 0.6 ± 0.3 1.3 ± 0.1 0.024 ± 0.001 0.15 ± 0.02 15 ± 3 
 
 The in vitro cytotoxicities of chalcone (1) vary within the series of tested cell 
lines. It was shown that activation of p53 leads to apoptosis by affecting the cell cycle 
in the G1/S phase (Eliyahu et al., 1984; Finlay et al., 1989). The tumor suppressor 
protein p53 is involved in the prevention of cancer development. Obtained 
cytotoxicity results are indicating p53-independent mechanism of chalcone (1) due to 
rapid activity in NE-4C cells (after 48h IC50 ~24 nM). The specificity of complex 1 to 
glioblastoma (U87 and C6) cells differed dramatically when compared with neural 
astroglia cells (factor of ~100). How can we rationalize this observation?  
The PI3K/Akt pathway plays a significant role for endocytotic drug uptake 
(see chapter 3.2.2). Remarkably, the PI3K/Akt pathway is highly up-regulated in 
gliomas due to deletion or mutation of tumor suppressor lipid phosphatase (PTEN). 
PTEN activation is associated with tumor malignancy (Puli et al., 2010). In addition, 
recent studies of glioma cells (including U87) have shown that the activation of the 
Akt-pathway induces premature senescence (Lee et al., 2010). It is possible that a 
correlation exists between up-regulation of PI3K/Akt pathway and higher cytotoxicity 
in gliomas. 
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3.1.2 Cancer cells expressing ABC-transporters  
ABC-transporters pump drugs out of cancer cells and are responsible for 
chemoresistance (de Bruin et al., 1999; Rabik and Dolan, 2007; Robey et al., 2007). 
Their interference with chalcone (1) was investigated by using various non-neural 
cancer cells: MCF-7 breast, KBv1 cervix and HT-29 colon carcinomas. Each of these 
cell lines expresses a specific member of the ABC-transporters family. The protein 
expression can be enhanced in the presence of a suitable inducer or substrate (c.f. 
Materials and Methods). Hence, the cells were grown in the presence of specific 
substrates of their transporters (Table 3- 2).  
Table 3- 2: Inhibitory concentrations (aIC50 in µM) of chalcone (1) in various ABC-transporter expressing 
cells. 
Cell line MCF-7 MCF-7+Top KBv1 KBv1+Vbl HT-29 HT-29+Colc 
24 h (1) 10.7 ± 1.3 12.5 ± 3.1 1.6 ± 0.1 2.0 ± 0.3 43 ± 3 37 ± 6 
48 h (1) 13.4 ± 1.1 1.6 ± 0.1 0.7 ± 0.05 0.2 ± 0.04 37 ± 1 24 ± 6 
aValues are derived from concentration-response curves obtained by measuring the percentual 
absorbance of vital cells relative to untreated controls (100%) after 24 and 48 h exposure of selected 
cells to test compounds in the MTT assay. Values represent means of at least three independent 
experiments ± standard deviation.  
 By long-term exposure to topotecan resistant MCF-7+Top cells were obtained 
which overexpress exclusively BCRP (breast cancer resistance protein). Chalcone (1) 
revealed cytotoxic activity in these MCF-7+Top cells [IC50 (24 h/48 h) ~ 12 / 1 µM]. It 
showed the same IC50 value in +wild type MCF-7 cells after 24 h, which remained 
constant for up to 48 hours. Resistant KBv1+Vbl cells overexpressing P-gp were 
obtained by treating the cells with vinblastine. Chalcone (1) was highly and 
comparably efficacious against both cell lines with a slight edge for the vinblastine-
treated cells.  
 HT-29 cells feature a high amount of multi-resistance protein 3 (MRP3) and a 
low amount of MRP1. Treatment of HT-29 cells with colchicine shift this ratio by 
overexpressing MRP1 and cutting back on MRP3 (Kok et al., 2000). Although 
chalcone (1) was little active in HT-29 cells, it showed a little bit higher activity in the 
HT29+Colc cells. The net effect was positive and the efflux of chalcone (1) was reduced 
in HT29+Colc cells.  
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3.1.3 518A2 melanoma and HL60 leukemia cells  
 Human 518A2 melanoma and suspension HL60 cells served, as reference cells 
since they do not express any ABC-transporter. The cytotoxicity of 1 in 518A2 cells 
reached IC50 values of 11.5 ± 0.6 µM after 24 hours of incubation, which increased 
almost 12-fold (IC50=1.0 ± 0.4 µM) after 48 hours. A longer exposure led again to a 
decrease of the IC50 values (32 ± 7.5 nM after 96 hours) (Schobert et al., 2009).  
 
Figure 3- 2 Cytotoxicity of chalcone (1) on (A) 518A2 and (B) HL60 cells after 48 hours treatment. The solid 
lines are calculated IC50 curve-fits from equation 2-2 analysed by GraFit program. 
The activity of 1 against HL60 leukemia cells was 1000-fold higher in comparison 
with the 518A2 melanoma cells (IC50 24 h/48 h = 1.7 ± 0.4/ 0.17 ± 0.03 nM). The 
dose-response curves for the 518A2 and HL60 cells (Figure 3- 2) show an unusual 
biphasic profile which originates from its tubulin binding properties and, at high 
concentration, from an additional cytotoxic mode of action (see chapter 4.1.3.).  
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3.2 Cellular uptake of chalcone (1) 
Chalcone (1) is known for its tubulin binding activity. Hence, it should enter the 
cell by passing the membrane and trigger an action inside of the cell. In order to 
ascertain how 1 enters the cells, several inhibition-based studies were performed.  
3.2.1 Inhibition of endocytosis by temperature change 
 It is well known that the process of endocytosis is virtually halted at 
temperatures below 16 °C (Punnonen et al., 1998; Stirling et al., 2009). In this work 
the conditions were optimized for 518A2 melanoma cells at 4 °C and for the drug 
concentration close to IC50. Generally, the IC50 drug concentration approximates an 
inflection point of the dose-response curve. From the mathematical point of view, the 
greatest sensitivity and response toward changes is achieved at the inflection point. 
Moreover, for the small changes a linear dependence might be assumed. 
After 3.5h incubation with 100 µM chalcone (1) ~50% of the cells were 
alive/dead. Almost twice as many 518A2 melanoma cells survived exposure to 100 
µM of 1 at 4°C when compared to 37°C, which is an indication of this chalcone being 
taken up mainly via endocytosis (Figure 3- 3).  
 
Figure 3- 3 Vitality of 518A2 cells after 3.5 h exposure to chalcone (1) (100 μM; grey bars). Vital cells were 
determined by MTT assay at 37 °C and 4 °C. Vital cells of untreated controls (hatched bars) set to 100%.  
3.2.2 Inhibition of the uptake of chalcone (1) with specific inhibitors 
Based on previous results, the detailed mode of uptake of chalcone (1) was 
studied. Specific inhibitors were used to inhibit pertinent pathways of drug entry 
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under the same conditions as described in chapter 3.2.1. Kapp et al. carried out similar 
studies by blocking individual transporters with specific inhibitors (Kapp et al., 2006).  
 Some endocytotic processes are dependent on a sodium gradient, which can be 
slowed down by ouabaine, an inhibitor of the Na+/K+ pump (Ivanov et al., 2004). 
Macropinocytosis, a special form of endocytosis, depends on a Na+/H+ exchanger that 
can be blocked by amiloride (Kapp et al., 2006; Meier et al., 2002). The enzyme 
phosphatidylinositol 3-kinase (PI3-kinase) plays a central role in the down-stream 
signalling cascade associated with macropinocytosis by F-actin microfilament 
rearrangement and can be inhibited by the fungal metabolite wortmannin (Zhang et 
al., 2003). Clathrine-mediated endocytosis can be blocked by chlorpromazine (Nawa 
et al., 2003). Alternative ways for the entry of positively charged complexes into cells 
involve copper transport receptor 1 proteins (Ctr1) and organic cation transporters 
(OCT- 1/2). The OCT conveys positively charged substances and may be inhibited by 
cimetidine (inhibitor) or tetraethylammonium chloride (TEA; competitor). 
 After optimisation of the inhibitor concentration, the influence of all these 
inhibitors on the uptake of chalcone (1) into 518A2 melanoma cells was examined as 
these cells lack all sorts of influx pumps. To this end, the cells were pre-incubated 
with non-toxic concentrations of the respective inhibitors for 15 min before chalcone 
(1) was added and its cytotoxicity was measured by the pertinent MTT assay. Figure 
3- 4a illustrates the effects of the individual inhibitors on the cytotoxicity of chalcone 
(1) (grey bars) against 518A2 cells. An increase in cell vitality indicates interference 
with the uptake of 1(Figure 3- 4b).  
Treatment of 518A2 cells with 100 µM chalcone (1) for 3.5 h in the absence of any 
inhibitor left 40% of the cells alive. Pre-incubation with 5 µM ouabaine left 67 ± 5% 
of the cells alive. This means that ca. 40% of chalcone (1) were accumulated by the 
cells via Na+/K+-dependent endocytosis. Addition of 10 µM amiloride led to 55 ± 2% 
of surviving cells. This corresponds to an uptake of ca. 24% via Na+/H+ pump driven 
macropinocytosis. Addition of 14 µM chlorpromazine resulted in ca. 50% of vital 
cells, which speaks for 18% uptake through clathrine-mediated endocytosis. In the 
presence of 10 nM wortmannin the percentage of vital cells decreased to 48 ± 3 %, 
indicating a contribution of 13% from PI3-kinase associated macropinocytosis. 
Interestingly, the inhibitory effect of wortmannin was time-dependent and most 
pronounced at the beginning (1-2 hours – data not shown) of the incubation with 1. 
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Inhibition of OCT-1/2 and Ctr1 had little influence (2-3%) on the cytotoxicity of 1. 
 
 
Figure 3- 4a) Effects of the individual inhibitors on the cytotoxicity of chalcone (1). b) Contribution of 
various pathways to the accumulation of chalcone (1) (grey bars) by 518A2 melanoma cells as calculated 
from the attenuation of their cytotoxicity (from a) upon addition of specific inhibitors. 
All these inhibitors interfere with endocytotic processes by inhibiting different 
types of transporters. A pronounced effect of the PI3-K inhibitor after short-term 
treatment may indicate a switch between various uptake pathways. 518A2 cells are 
mTOR positive and PI3-K/Akt-signalling regulates mTOR activity (Beuvink et al., 
2005; Biersack et al., 2010) whose expression may be affected by chalcone (1). 
Hence, any inhibition of PI3-kinase might postpone the cytotoxic effect of 1. Indeed, 
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addition of chalcone (1) led to phosphorylation and activation of the Akt-protein as 
shown by Western blot analysis (Antje Grotemeier, personal communication).  
3.3 Cellular and sub-cellular observations 
3.3.1 Inhibition of drug uptake monitored via time-lapse recording 
To verify the results from the uptake studies employing specific inhibitors, 
time-lapse micrographs of 518A2 cells pre-treated with 10 µM amiloride (an inhibitor 
of the Na+/K+ pump and related endocytosis) were taken. First, cells were treated with 
chalcone (1) alone. After a few minutes, cell motility and detachment increased 
(Figure 3- 5). After pre-treated with 10 µM amiloride, cells detachments and 
enhanced cell motility is postponed. These results are in line with aforementioned 
data (in chapter 3.2.2), where overall % uptake via Na+/H+ pump depending 
endocytosis (which is inhibited by amiloride) was ~25%. 
 
Figure 3- 5 Inhibition of chalcone uptake. Time-lapse recording micrographs of 518A2 melanoma cells 
incubated with 10 µM chalcone (left) and pre-treated with 10 µM amiloride (right), an inhibitor of 
endocytosis (micropinocytosis). 
 
3.3.2 Altered cell shapes in cells treated with chalcone (1)  
3.3.2.1 Altered cell shape in neural cells 
Neurons are particularly rich in tubulin and so are well suited to test agents 
affecting microtubule organisation. Their regular growth requires microtubules being 
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transported from the cell body all the way down into the axon (Hasaka et al., 2004). 
The effect of chalcone (1) on the structure, development and movement of a network 
of rat neurons was now monitored by time-lapse microscopy (Hegedus et al., 2000).  
 
Figure 3- 6 Neuron treated with chalcone (1) and its retraction process of dendrites and axon back to soma. 
The left picture shows neuron taken in the time of 0 minutes. The square is zoomed in the next Figure 3- 7. 
The right picture shows a neuron taken after long time exposure (1 hour 39 minutes) and the retraction 
processes are finished with dendrites debris. 
 
Neurons treated with 10 µM of the test compounds showed a retraction 
(Figure 3- 6) of their processes back to the soma within 20 – 30 minutes Figure 3- 7.  
 
Figure 3- 7 Blow up of the white window shown in the Figure 3- 6  – time course of the axon retraction after 
addition of chalcone (1). 
 
The anticancer agent combretastatin A-4 binds to the colchicine-binding site 
of β-tubulin and interferes with the polymerization of tubulin.  
Chalcone (1) is a surrogate of combretastatine A-4 and its inhibition of tubulin 
polymerization was proved (Schobert et al., 2009). The neurons derived from mice 
brains showed similar behaviour (Figure 3- 8a, b) as isolated rat neurons. Neurons got 
closer to each other; their bodies were swelling and aggregating.  
 Most of the neural network lost its integrity and processes were disconnected 
from the cells bodies of adjacent neurons.  
Altered neuron shapes after treatment with chalcone (1) may depend on the 
inhibition of tubulin polymerization and may indicate possible microtubule disruption 
in the cells.  
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Figure 3- 8 a) left: Untreated mice neurons with prolonged axons (arrowheads); right: Retraction of neural 
axons back to soma or decay (arrowheads) upon treatment with 10 µM of chalcone (1). Triangles are 
pointing at the missing neural connection. b) Zoomed neuron. 
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 These dramatic morphological changes were observed at low drug 
concentration. How it is possible that the IC50 value of 1 in neural cells is relatively 
high after 24 hours (~38 µM)? Cytotoxicities, as obtained from MTT-test, depend on 
the functional mitochondria. Thus, a trypan blue staining experiment was performed 
after 24 hours to qualitatively establish amount of dead cells. It proved that most of 
the neurons remained alive despite of the pronounced morphological changes (Figure 
3- 9).  
 
Figure 3- 9 Neurons after 24h incubation with chalcone (1) after Trypan Blues staining. Neurons showing 
blue somas are dead (right).   
Similar experiments were performed with p53-deficient K11 stem cells 
derived from NE-4C stem cells (Madarasz, personal communication). The stem cells 
were treated with retinoic acid to promote differentiation to neurons (Figure 3- 10), 
and then they were treated with chalcone (1). 
Control K11 cells have well defined neural networks; some cells were even 
still in the process of differentiation (Figure 3- 11).  
 
Figure 3- 10 Differentiation of K11 cells to neurons in the presence of 3 mM retinoic acid. The left figure 
shows undifferentiated cells. After treatment with 3 mM retinoic acid the K11 cells formed neurons (on the 
right). 
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The K11 cells treated with chalcone (1) (1 µM) lost most of their neural connections 
after 24 hours and the K11 (undifferentiated) cells were rounded or showed irregular 
cell-shape in contrary to the control cells. 
 
Figure 3- 11 K11 cells treated with different concentration of chalcone (1) after 24 hours.  
 An increased concentration chalcone (1) (10 µM) caused a complete depletion 
of neuronal network in K11 cells. Cell-debris remained visible as black dots (Figure 
3- 11). Apparently, neural K11 cells are very sensitive towards chalcone (1), which is 
in line with the observed cytotoxicity of chalcone (1) in the parent NE-4C cells 
(24h/48h incubation, IC50 =2.8 ± 0.6/0.024 ± 0.001 µM).  
3.3.2.2 Altered cell shape in cancer cells 
Changes of the 518A2 melanoma (adherent cells) and leukaemia HL60 
(suspension cells) cells were investigated via the time-laps recording method. These 
cells were chosen because both cell lines show different principle of proliferation and 
living. The cytotoxic impact of chalcone (1) on the HL60 cells is very high (IC50 
24/48h =1.7/0.17 µM in chapter 3.1.3). The HL60 cells changed their cell shape from 
the elliptic to irregular shape immediately after treatment with 1 (Figure 3- 12).  
 
Figure 3- 12 Altered cells shape of suspension cells treated with chalcone (1). Shape of the control cells (left) 
was for many cells rounded with similar cell size. After incubation with 10 µM chalcone (1) the shape of 
HL60 became irregular and with variable cells size. Many cells were seen with vesicle “ghost” shown by 
yellow arrowheads.  
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Many cells swallowed and dead cells regurgitated their content in the form of “ghost” 
vesicles These effects were irreversible; the cells did not recover with time and the 
amount of cell-debris increased. 
 An analogous experiment was performed with adherently growing 518A2 
melanoma cells, which formed a tightly attached monolayer on the surface of the mini 
Petri dishes. Overall, dynamics and motility of untreated cells were slow as they 
underwent merely negligible morphological changes. Only a few cells detached from 
the monolayer within the first two hours. In contrast, exposure of 518A2 cells to 
chalcone (1) led to an immediate rounding and an enhancement of motility and cell 
shrinking dynamics (Figure 3- 13).  
 
Figure 3- 13 Altered cell shape of 518A2 with chalcone (1). Dynamics and motility of untreated cells (left) vs. 
518A2 cells treated with chalcone (1) (right). 
 The cells readily dissociated from the monolayer and their form turned from 
flat to spherical. This behaviour is in line with the generally accepted mechanisms of 
tubulin binding agents (TBAs) (Lippert, 2007) involving activation of RhoA/RhoA 
kinase, an intracellular coordinator of cytoskeletal rearrangement of microtubules and 
actin. However, in the case of chalcone (1), the 518A2 cells were able to repair the 
shrinkage effects and most of them spread again after three hours (Figure 3- 14). 
Thus, several aspects of chalcone (1) mechanism remained unresolved. Structural cell 
reorganization based on actin filaments and microtubule rearrangement is well known 
and important in many cell processes e.g. cell cycle. Hence, further experiments were 
necessary to clarify the mechanism of action of chalcone (1) during apoptosis. 
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Figure 3- 14 Re-attachment of recovered 518A2 cells after treatment with chalcone (1), after 1h (left) and 3h 
(right).  
3.3.3 Actin re-distribution induced by chalcone (1) 
3.3.3.1 Actin distribution in astrocytes 
An immunocytochemical analysis of the morphological changes of the actin 
filaments of astrocytes initiated by the chalcone (1) was carried out. Antibodies 
against astrocyte-specific GFAP intermediate filaments (glialfibrillary acidic protein) 
were employed to visualize the astroglial cells and phalloidin labelling was used to 
identify actin filaments. The micrographs showed that both types of filaments, actin 
(in green) and GFAP (in red), were disintegrated upon treatment with chalcone (1), 
mainly the actin filaments near the cell membrane. The GFAP filaments shrank only 
in the vicinity of the cell nuclei, which remained unaffected. Figure 3- 15 shows 
typical effects of chalcone (1) on astrocytes after 72 hours. These findings are in line 
with the observed weak cytotoxic activity of 1 in astrocytes (IC50 ~50 µM).  
 
Figure 3- 15 Immunostaining of astroglia cells untreated (left) and treated with 10 µM chalcone (1) for 72 h 
(right). Blue: nuclei stained with DAPI (4',6-diamidino-2-phenylindole); green: actin cytoskeleton stained 
with phalloidin; red: glial fibrillary acidic proteins (GFAP). White arrowheads indicate the edge of cell 
membranes. The pictures were taken with a fluorescence microscope (Zeiss Axiovert 200M) with a 63 x oil 
immersion objective and the scanning module at 1024 x 1024 pixel resolution.  
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Similar effects on the filament distribution in astrocytes were observed after treatment 
with chalcone (1) for just 24 hours (Figure 3- 16). 
 
Figure 3- 16 Immunostaining of astroglia cells untreated (upper part) and treated with 10 µM chalcone (1) 
after 24 hours. Blue: nuclei stained with DAPI (4',6-diamidino-2-phenylindole); green: actin cytoskeleton 
stained with phalloidin; red: glial fibrillary acidic proteins (GFAP). DIV means days in vitro.  
3. Effects of chalcone (1)  
3.3-51 
 
The level of GFAP just started to diminish, the effect on mitochondrial function was 
minimal or none (MTT assays showed 100% vitality compared with control). 
3.3.3.2 Actin distribution in 518A2 cells 
Similarly, fluorescence micrographs of immunostained 518A2 cells revealed a 
significant breakdown of the actin network when treated with chalcone (1) (Figure 3- 
17).  
 
Figure 3- 17 Immunostaining for actin of untreated 518A2 cells (top row), and 518A2 cells after 24 h 
incubation with 10 µM chalcone (1) (bottom row). Blue: nuclei stained with DAPI (4',6-diamidino-2-
phenylindole); green: actin cytoskeleton stained with phalloidin.  
The attached cells got closer and formed spherical structures after treatment with 1 for 
24 hours. Facing the previous results (Figure 3- 14) we can conclude that those cells 
were unable to repair and cannot proliferate. The actin of 518A2 cells was mostly 
concentrated around the nucleus while further damages remained unclear. It is very 
likely that the damage of filaments induced by chalcone (1) is not the only signal 
leading to cell death. 
3.3.4 Microscopic observations of 518A2 cells by Giemsa staining 
In the previous chapter 3.3.3, the effect of chalcone (1) on filaments 
distribution was revealed. It was shown that the chalcone (1) is able to inhibit in vitro 
microtubule polymerization (Schobert et al., 2009), and the experiments with neural 
cells confirmed effect on the microtubule-based network system. While the nuclei of 
neural cells remained separate, the nuclei of 518A2 cells were located too close 
together. Therefore, internucleosomal DNA cleavage was monitored using Giemsa 
dye and examined under a light microscope. 
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First of all, the cytotoxic effect of the chalcone (1) (11 µM, i.e. IC50 concentration) on 
the proliferation as well as on the attachment of the adherent cells was analyzed upon 
exposure for 24 hours. The X-cross method was performed as it is described in the 
material and methods part. The cell behaviour was the same as it was observed in the 
previous experiments. Control cells were wide and spreads with a typical shape, the 
nuclei were well defined by a nuclear envelope with condensed chromatin visible as 
dark-blue dots. The number of cells decreased more rapidly after treatment with 1 
than in the control sample. 518A2 cells got close to each other and formed brunches 
with visible nuclear envelope. In this case, late apoptotic or dead cells were likewise 
visible as spread cells with purple cytoplasm. The cells did not grow over the X-cross 
scratching line that was performed before treatment. On the other hand, the control 
cells grew over the X-cross (Figure 3- 18). 
 
Figure 3- 18 Samples of 518A2 cells treated with test compounds were stained with Giemsa dye after 24 
hours of incubation. Untreated control cells served as a reference. Colchicine 62.5 nM, chalcone (1) - 11 µM, 
mixture: 31.3 nM of colchicine + 5.5 µM of chalcone (1). 
Since chalcone (1) is an analogue of the anticancer agent combretastatin A-4, which 
binds to the colchicine-binding site of α-tubulin and interferes with the 
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polymerization of tubulin (Kanthou and Tozer, 2002), the effect of colchicine at its 
IC50 concentration (62 nM) was studied on 518A2 cells as well. The cell number after 
colchicine treatment decreased rapidly. The cells formed only a few brunch-like 
structures and they were slightly pink-purple, some were spread, some were still 
rounded. Surprisingly, no nuclei envelope was observed. This cell behaviour is 
different from that after treatment with chalcone (1). The combination of both drugs 
(31.3 nM of colchicine + 5.5 µM of 1) gave a mixture of the individually described 
phenotypes (Figure 3- 18). The cell number decreased but not as rapidly as after 
colchicine or 1 treatment. The cells came closer to each other, however, not as close 
as in the treatment with 1 alone. The nucleus envelope was hardly detectable in most 
cases. Colchicine differs structurally from chalcone (1). Hence, varying tubulin-
binding mechanisms, cellular uptake mechanisms, and non-tubulin targets might play 
a role for the observed differences between chalcone (1) and colchicine in cancer 
cells.  
3.3.5 Transmission electron microscopy 
During apoptosis, the mitochondrial network is fragmenting which results into 
smaller and more numerous mitochondria (Mancini et al., 1997). The large 
mitochondrial network consists of externally extended and interconnected 
mitochondrial filaments and acts as an electrically united system (Westermann, 2008). 
The mitochondrial population mostly consists of short and long tubules, which 
migrate along the microtubule tracks (Chan, 2006). Any disruption of the 
microtubules/actin skeleton, e.g., by treatment with chalcone (1), might severely 
affect the mitochondrial trafficking and may cause mitochondrial disorganization.  
In order to visualize effects of chalcone (1) on mitochondria, additional 
experiments with 518A2 cells were performed. The cells were treated with 0.1 mM 
chalcone (1) for 15 minutes, kept in fresh medium for ca. 1 hour, and finally 
monitored using transmission electron microscopy (TEM). Mitochondria of cells 
treated with the chalcone (1) were highly condensed and mainly localized at the apical 
side of the cells. While untreated control cells appeared prolate and undifferentiated 
having filopodia on the rim (Figure 3- 19a), cells incubated with chalcone (1) adopted 
a rounded shape (Figure 3- 19b, c). A similar morphological change has been reported 
for H460 non-small cell lung cancer cells treated with combretastatin A-4 (CA-4) 
(Vitale et al., 2007). In addition, the chalcone-treated 518A2 cells showed blebs on 
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their surface. In comparison with untreated cells, the large mitochondrial population 
of treated cells was localized close to membrane and nucleus having disorganized or 
condensed cristae (Figure 3- 19c).  
 
Figure 3- 19 Transmission electron micrographs of 518A2 cells illustrating the differentiation process 
induced by in vitro exposure to chalcone (1) (a) Untreated, undifferentiated control cell, black bar = 1.1 µm; 
(b/c) cell exposed to chalcone (1) (100 µM) for 15 min, black bar = 1.7/1.1 µm. Performed according to 
section 2.5.5.  
They frequently displayed dislocated inner membranes (Figure 3- 20e). Only a small 
percentage of the untreated control cells were found in G2/M phase with visible 
centrioles. The maintenance of the microtubule integrity plays a pivotal role in 
stabilization of the pericentriolar matrix. This is consistent with the notion that the 
microtubule depolymerising effect of chalcone (1) leads to a mitotic catastrophe and 
thus to an arrest in G2/M phase. A similar mitotic failure has been reported for H460 
NSCLC cells treated with CA-4 (Vitale et al., 2007). At higher resolution, treated 
cells also revealed stress fibers (Figure 3- 20h). Multivesicular bodies (Figure 3- 20g) 
or autophages with double membranes were visible in most of the analyzed cells 
(Figure 3- 20f). Control cells and treated cells also differed concerning the state of 
their mitochondria, centrioles and Golgi apparatus (GA). The GA was frequently 
located next to the centrosomes or nuclei envelopes and showed no fragmentation 
after chalcone (1) treatment (Figure 3- 20f). After treatment with 1, many cells 
showed visible centrioles (Figure 3- 20b). The occurrence of centrioles as a result of 
aberrant chromosome segregation could be due to DNA damage (possibly in tandem 
with defective checkpoints) or to a destabilization of the spindle apparatus (Castedo et 
al., 2004; Vitale et al., 2007) 
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Figure 3- 20 TEM images of organelles in 518A2 cells. a, d: untreated cells with image a showing the cross 
and longitude section through the centrioles and image d showing mitochondria with cristae invaginations 
surrounded by endoplasmic reticulum. b, c, e, f, g, h, i: cells treated with chalcone (1). Images c, e, g, i show 
mitochondria at various stages of inner-membrane destruction and/or highly condensed contents (black 
arrowheads). Some mitochondria formed multi-lamellar bodies in image g (white thick-arrows). The 
formation of multivesicular bodies is shown in image f (green push-pin). For comparison, centrioles in 
control (a) and chalcone (b) are shown in blue rings. The frequently visible Golgi apparatus was pointed 
with red arrows. Stress fibers are visible in image h. Image f: black bar = 0.4 µm (valid for each image).  
Performed according to section 2.5.5.    
3.4 DNA degradation of chalcone (1) during apoptosis  
3.4.1 Cell cycle analysis  
 Chalcone was found to arrest cells of the human T24 and HT-1376 bladder 
cancers in the G2/M phase (Shen et al., 2007). According to the previous results 3.3.5, 
speculation could be made about the apoptotic mechanism. An effect similar to the 
one observed in human T24 and bladder cancers could be expected for chalcone (1), 
too. Effects on the cell cycle progression of melanoma 518A2 cells treated with 
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chalcone (1) was analysed by FACS (Figure 3- 21) after DNA staining with 
propidium iodide (PI).  
 
Figure 3- 21 (A) Flow cytometric analysis of 518A2 melanoma cells stained with propidium iodide. Cells 
were treated with 250 µg/mL nocodazole (B) or with 10 μM chalcone (1) (C). Panel (D) summarises the 
results: G1 phase (dark grey), S phase (light grey) and G2/M phase (medium grey). The FACS 
measurements and analysis were performed with special assistance of Andreas Brown. 
About 63% of untreated 518A2 cells were in G1 phase after 18 h, 24% in S phase and 
13% in G2/M phase. 518A2 cells treated with 250 µg/L nocodazole, a synthetic 
analogue of taxol, were mainly in sub-G1 phase after 18 h, a shorter 12 h exposure led 
to 76% of the cells being in G2/M phase. The presence of 10 µM of chalcone (1) 
revealed a similar effect arresting 61% in G2/M phase after 18 h incubation. Thus, 
further studies were performed regarding DNA degradation and chalcone-DNA 
interactions.  
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3.4.2 DNA fragmentation from isolated cells 
The defined fragmentation of DNA via activated endogenous nucleases is 
characteristic of apoptosis (Arends et al., 1990; Bortner et al., 1995; Hughes and 
Cidlowski, 2000). During apoptosis, activation of certain endonucleases initiates 
DNA cleavage and the chromatin is degraded into two distinct fragments: 
nucleosomal fragments (multiples of 180-200 bp) and large fragments (30- to 50-kb). 
Since previous results showed high sensitivity of HL60 cells towards 1 (IC50=1.7/0.17 
µM), these leukaemia cells were exposed to 1 for 24 hours. The DNA of the treated 
cells was isolated and analyzed by agarose gel electrophoresis. 
 
Figure 3- 22 Degraded DNA isolated from HL60 cells after treatment with chalcone (1). The DNA samples 
were applied to 1.5% agarose gel in lane C: sample of salmon sperm DNA for comparison, lane: 1 is DNA 
extract from cells treated with 0.25 mM chalcone; lane M: marker from 100-3000 bp. 
Intact chromosomal DNA (lane C) and DNA from cells treated with 1 (lane 1) did not 
move in the agarose gel and remained in the loading well (Figure 3- 22). Only a ~100 
bp band of DNA was visible in the control. After treatment with 1 lane 1 shows a 
strong band at 200 bp together with a lot of undefined bigger fragments which the 
control lane C does not show. Since proteinase K was added to the lysis buffer, no 
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active endogenous or exogenous deoxyribonuclease (DNase) should be present in the 
sample, which could have cleaved the chromosomal DNA after its isolation.  
3.5 Characterization of DNA-chalcone interactions  
Several DNA binding molecules act via intercalation (Neidle, 1979; Waring, 
2006). For instance, the chalcone analogue AMC [AMC, 1-(4'-aminophenyl)-3-(4- 
N,N-dimethylphenyl)-2-propen-1-one] gave evidence for DNA intercalation (Shah et 
al., 2008). However, chalcones (1,3-diphenyl-2-propen-1-ones) are generally not 
known for their DNA-intercalating or DNA-binding behaviors, yet, some pivotal 
experiments were performed to study potential interactions of chalcone (1) with 
DNA. 
3.5.1 Electrophoretic mobility shift assay of plasmid DNA  
A large number of agents bind to duplex DNA in a covalent or non-covalent 
manner. The electrophoretic mobility shift assay (EMSA) is an important technique 
for the study of putative interactions between a drug candidate and DNA  
 
Figure 3- 23 Interaction of pBR322 plasmid DNA with increasing concentrations of chalcone (1). Top: open 
circular form (oc). Bottom - supercoiled form (sc). Concentrations of chalcone (1) increase from left to 
right: lane 1-2-3-4-5 ≈ 0-5-20-40-60 μM. Samples were applied on a 1% agarose gel for 3 h, 65-85 V in TAE 
buffer.  
Hence, gel electrophoresis was carried out in order to investigate the conformational 
changes and damages caused to non-genomic pBR322 plasmid DNA due to the 
covalent binding with chalcone (1). The supercoiled form (sc) shows higher mobility 
and runs faster than the one-nicked open circular form (oc). Apparently, chalcone (1) 
did not cause any visible changes in the applied pBR322 plasmid DNA (Figure 3- 23).  
3.5.2 Secondary structure study of DNA-chalcone (1) interactions 
 Circular dichroism (CD) is a useful means for the study of DNA interactions 
of molecules in solution (Alison Rodger and Nordén, 1997) in order to obtain more 
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information about the global changes in DNA conformation (Vrana et al., 1986) 
(Brabec et al., 1990).  
 First of all, the conformation of tested calf thymus (ct) DNA was compared 
with profiles (Ivanov et al., 1973) A-, B- and Z-DNA CD spectra (Figure 3- 24). 
 
Figure 3- 24 Comparison of CD spectra of different DNA forms with calf thymus (ct) DNA (10-4 M dissolved 
in 0.01M NaClO4). CD signals of chalcone (1) and blank (0.01M NaClO4) are included. Spectra of A-, B-, C 
(Z)-DNA’s (Ivanov et al., 1973). 
The CD spectrum of ct DNA was very similar to B-DNA conformation 
crossing the zero line at about 260 nm. For canonical B-DNA conformation, the 
maximal ellipticity is reached at 275 nm and the minimum at 245 nm. Chalcone (1) 
showed no significant CD band within the investigated wavelength range. 
In the next step ctDNA was incubated with 1 at various ri values for 24 hours. 
The blank spectrum was subtracted from the measured CD spectra and the obtained 
CD signal was re-calculated considering the molar DNA concentration (10-4 M) 
(Figure 3- 24). The intensity of the positive CD band at 275 nm is increased as a 
consequence of DNA-chalcone interaction. Similarly, the negative CD band at 245 
nm decreased (Figure 3- 25A). To avoid unspecific interaction and to remove 
unbound or free chalcone (1), 12 hours lasting dialysis against 0.01 M NaClO4 was 
performed. The concentration of ctDNA was determined and the molar ellipticity (∆ε) 
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spectra were compared with non-dialysed sample. No significant changes were 
observed in the positive CD band. However, the decrease in the negative band was 
more pronounced for the dialysed sample.  
 
Figure 3- 25 Molar ellipticity spectra of ct-DNA and effect of chalcone (1). CD spectra, in units of 
millidegrees were converted to ∆ε  using the concentration of the DNA. A) Effect of rb = 0.4 chalcone (1) on 
ct DNA and spectrum of the dialysed sample (dotted line) were compared with untreated ct DNA. B ) Effect 
of dialysed 1 samples with increasing rb: 0.08 (dotted line), 0.16 (full line) and 0.4 (dashed line). As a 
reference untreated ctDNA was used. 
 In Figure 3- 25B, the effect of dialysed chalcone-DNA samples with 
increasing rb initiate ratio (rb = 0.08, 0.16, 0.4) was compared with non-modified 
ctDNA. The intensity of the positive CD band increased and of the negative CD band 
decreased with increasing concentrations of 1. Hence, a dose-dependent interaction 
between chalcone (1) and DNA occurs.  
3.5.3 Melting temperatures of DNA-chalcone (1) adducts 
Thermal denaturation of DNA provides basic information on thermodynamic 
stability. In this experiment the temperature is increased constantly. Heating of the 
sample results in denaturation of DNA, the initially double-stranded DNA is 
disconnected and both strands are separated. The midpoint of the transition is called 
melting point (Tm). DNA-bound compounds are able to (de-)stabilize DNA and thus 
(decrease) increase the Tm value.  
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Although no electromobility shift with plasmid DNA was observed, previous 
CD spectra showed DNA changes in the presence of 1. Therefore, melting curves 
were measured in order to clarify the DNA interaction of chalcone (1). Dialysed CD 
samples were used for this experiment. The denaturing temperature of unmodified 
ctDNA was 65 ± 1°C. Addition of chalcone (1) at the highest rb value decreased the 
Tm value negligibly to 64.2 ± 0.9°C (data not shown). This result led to the 
conclusion that the interaction between chalcone (1) and ctDNA is very weak.  
3.6 Activation of caspases after chalcone (1) treatment 
 Caspases are proteases, which are involved in apoptosis. They exist as inactive 
zymogens which are activated via proteolysis when cells undergo apoptosis 
(Thornberry et al., 1997). After treatment with chalcone (1), HL60 cells were 
monitored up to 24 hours. Figure 3- 26 shows the initial rate of cleavage of the 
substrate, DEVD-pNA, for caspase-3.  
 
Figure 3- 26 Monitoring of caspase-3 activity in cell lysates of control HL60 cells and after chalcone (1) 
treatment. The caspase-3 inhibitor DEVD-CHO (20µM) was pre-incubated for 15 minutes at 37°C. The 
cleavage of caspase-3 (Ac-DEVD-pNA) (200 µM) substrate was measured at 405 nm. The initial velocity of 
hydrolysis was determined from the linear portion of the progress curve. It measures the total amount of 
active enzyme presented in the cell lysate. 
 
In the case of chalcone (1) the activity of caspase-3 is dramatically increased after 12 
hours of incubation and reaches a constant value (initial velocity = 1.65 µM.min-1). 
The HL60 control cells exhibited a 6-7-fold lower cleavage activity. 
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3.7 Interference with ABC transporters 
The role of efflux transporters in the detoxification of cancer cells represents 
one of the main topics of pharmaceutical studies. The interaction of chalcone (1) with 
drug transport proteins like ABCB1 (P-gp) (Hyde et al., 1990; Simstein et al., 2003; 
Smith et al., 2001) or BCRP (Borst et al., 1997) was investigated in a substrate- or 
inhibitor-like fashion.  
3.7.1 Chalcone (1) efflux via P-glycoproteins  
Calcein-AM is taken up and pumped out via diffusion because of the 
membrane permeability given by the hydrophobic AM-linker. However, inside the 
cell the AM-fragment can be cleaved by esterases producing highly fluorescent 
calcein which is, however, not membrane permeable anymore. Then, P-gp proteins 
exclusively perform the efflux of calcein. Thus, an inhibition of P-gp proteins leads to 
accumulation of the calcein in the cell whose fluorescence can be measured.  
P-gp overexpressing KBv1+Vbl cervix carcinoma cells (Schwab et al., 2003) 
and their wild type parent cells were treated with chalcone (1) in the presence of 
calcein-AM (Figure 3- 27). 
 
Figure 3- 27 Calcein-AM assay: % inhibition of P-gp drug transporters in KBv1 and KBv1+Vbl cells by 50 
µM of chalcone (1) (grey bars) relative to the inhibition by verapamil (hatched bars) after 15 min exposure. 
White bars: negative control.  
As a positive control, the fluorescence intensity of KBv1+Vbl cells treated with 
50 µM of the clinically established chemosensitiser verapamil (Schwab et al., 2003; 
Sharom, 1997) was set to 100 %. Surprisingly, wild-type KBv1 cells under the same 
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conditions reached only ~45% of the calcein fluorescence of the resistant KBv1+Vbl 
cells. Possibly, they obtained additional ways to eliminate calcein-AM or calcein, a 
phenomenon which is not without precedence (Marchan et al., 2008; Oku et al., 
1995). Calcein fluorescence in KBv1 cells was also relatively low in the absence of 
verapamil. Treatment with chalcone (1) virtually led to the same fluorescence 
intensities in both resistant and wild type cells.  
3.7.2 Chalcone (1) efflux via BCRP proteins 
MCF-7 breast carcinoma cells produce BCRP drug transporters and after 
treatment with topotecan (550 nM over 40 generations) the concentration of the 
BCRP protein was increased (MCF-7+Top cells). The mitoxantrone assay is based on 
the active export of the fluorescent dye mitoxantrone via BCRP transporters. The 
effects of chalcone (1) on the fluorescence of intracellular mitoxantrone in MCF-7 
and MCF-7+Top cells relative to that of the specific BCRP inhibitor fumitremorgine C 
(Oku et al., 1995) and to a negative control of cells treated only with mitoxantrone are 
shown (Figure 3- 28).  
 
Figure 3- 28 Mitoxantrone assay: % inhibition of BCRP drug transporters in MCF-7 and MCF-7+Top cells 
by 10 µM of chalcone (1) (grey bars) relative to fumitremorgine C (hatched bars) after 30 min exposure. 
White bars: self-fluorescence of cells treated with mitoxantrone alone (negative control).   
 Chalcone (1) led to doubled mitoxantrone fluorescence in either cell line 
relative to the negative control, thus, they are likely competitive substrates for the 
BCRP proteins. 
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3.8 Conclusion 
 Chalcone (1) is preferentially accumulated by endocytosis. It vigorously 
depolymerised microtubules and actin filaments in neural and cancer cells and proved 
to be effective in damaging mitochondria and in arresting cancer cells in the G2/M 
phase. These observations are consistent with the notion that the microtubule 
depolymerising effect of chalcone (1) leads to mitotic catastrophe and thus to an arrest 
in the G2/M phase. A similar mitotic failure has been reported for H460 NSCLC cells 
treated with CA4(Vitale et al., 2007).  
 Morphologically, 1 led to a rounding and detachment of 518A cells and an 
enhancement of their motility and cell shrinking dynamic. This behaviour is in line 
with the generally accepted mechanisms of tubulin binding agents (TBAs) (Lippert, 
2007) involving activation of RhoA/RhoA kinase, an intracellular coordinator of 
cytoskeletal rearrangement of microtubules and actin. In my experiment with 1, 
518A2 cells were able to repair the shrinkage effects and most of them spread again 
after three hours. The results from the transmission electron microscopy experiments 
with 518A2 cells treated with the chalcone (1) are likewise in accordance with its 
effects on the cell cycle. The maintenance of the microtubule integrity plays a pivotal 
role in stabilizing the pericentriolar matrix. The occurrence of centrioles as a result of 
aberrant chromosome segregation could be due to DNA damage (possibly in tandem 
with defective checkpoints) or to a destabilization of the spindle apparatus (Castedo et 
al., 2004; Vitale et al., 2007). However, the DNA binding activity of 1 is rather 
minimal.  
 
 
 
 
 
 
4. Results and Discussion 
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Effects of chalcone-Pt (2) 
 Initially, the chalcone dichloridoplatinum(II) (6-aminomethylnicotinate) 
complex 2 (chalcone-Pt) was chosen as an example of a chalcone Pt-conjugate 
(Biersack, 2009; Schobert et al., 2009). The extraordinary 6-aminomethylnicotinate 
ligand system was chosen due to previous anticancer investigations on terpene Pt(II) 
conjugates, where this ligand system proved to be much more active against 518A2 
melanoma cells than saturated ligand systems (Bernhardt et al., 2008). 
 
Figure 4- 1 Structure of the chalcone-Pt conjugate 2.  
4.1 Inhibition of cell growth - MTT assay  
4.1.1 Neural cells  
The relative cytotoxicities of conjugate 2 against tubulin-rich cells of neural 
origin were analysed (Table 4- 1). Normal mouse astroglia did not reveal pronounced 
sensitivity towards the compound during the whole 48 h incubation period, while 
human U87 glioma cells were initially refractory to 2, yet, they responded well upon 
prolonged exposure. The primary neurons were sensitive to a prolonged treatment, 
too. Strongly cytotoxic effects of 2 were observed against C6 rat glioma cells with 
IC50 (48 h) values of ~170 nM and likewise against NE-4C stem cells derived from the 
fore- and midbrain vesicles of p53-deficient 9-day-old mouse embryos (Schlett and 
Madarasz, 1997) after exposure for 48 h.  
Table 4- 1: Inhibitory concentrations IC50 (µM) of chalcone-Pt (2) in various neural and non-neural WEHI 
164 cells (MTT-assay) after incubation for 24 and 48 hours. 
Cell line Astroglia U87 Neurons NE-4C C6 WEHI 164 
 24 h (2) 100 - 60 ± 8 2.4 ± 0.7 0.38 ± 0.02 9 ± 1 
 48 h (2) 100 ± 4 0.14 ± 0.08 1.5 ± 0.3 0.04 ± 0.02 0.17 ± 0.02 24 ± 4 
- IC50 was not reached 
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The WEHI 164 fibrosarcoma cells, which were included for comparison purposes, 
remained resistant to the chalcone platinum complex 2.  
4.1.2 Tumor cells expressing ABC-transporters 
ABC-transporters pump drugs out of cancer cells and are responsible for 
chemoresistance. Their interference with 2 was investigated by using various human 
cancer cells expressing these transporters, such as MCF-7 breast, KBv1 cervix and 
HT-29 colon carcinomas (Table 4- 2). These cells had been grown in the presence of 
specific substrates of their transporters to stimulate their overexpression. By long-
term exposure to topotecan resistant MCF-7+Top cells over-expressing exclusively 
BCRP (breast cancer resistance protein) were obtained. Chalcone-Pt (2) exhibited a 
distinctly lower activity in both MCF-7 cell lines. Resistant KBv1+Vbl cells over-
expressing P-gp were obtained by treating the wild type cells with vinblastine. 
Complex 2 was highly efficacious against both KBv1 cell lines with a slight edge for 
the resistant KBv1+Vbl. HT-29 cells feature a high amount of multi-resistance protein 3 
(MRP3) and a low amount of MRP1. When treated with colchicine, HT-29 cells shift 
this ratio by overexpressing MRP1 and cutting back on MRP3 (Cummings et al., 
2004; Kok et al., 2000). Chalcone-Pt (2) was little active in HT-29 cells but 
performed a little bit better in the HT29+Colc cells. A similar trend was observed for 
cisplatin (chapter 5.3.1.). According to literature (Kok et al., 2000) colchicine-
induced overexpression of MRP1 is accompanied by changes in sphingolipid 
composition. It has to be mentioned that the sphingolipid metabolism is performed in 
Golgi apparatus (cf. chapter 4.3.5) 
Table 4- 2: Inhibitory concentrations IC50a (µM) of chalcone-Pt (2) for various ABC-transporter expressing 
cells (MTT-assay). 
Cell line MCF-7 MCF-7+Top KBv1 KBv1+Vbl HT-29 HT-29+Colc 
 24 h (2) 40 ± 2 34.6 ± 3.6 0.8 ± 0.09 1.2 ± 0.3 76 ± 4 47 ± 1 
 48 h (2) 28 ± 4 18 ± 1.2 0.5 ± 0.03 0.12 ± 0.02 38 ± 6 24 ± 0.7 
aValues are derived from concentration-response curves obtained by measuring the percentual 
absorbance of vital cells relative to untreated controls (100%) after 24 and 48 h exposure of selected 
cells to test compounds in the MTT assay. Values represent means of at least three independent 
experiments ± standard deviation.  
4.1.3 Cancer cells  
 HL60 leukaemia cells and 518A2 human melanoma cells served as control cells, 
which do not overexpress any ABC-transporter. They were likewise chosen for 
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cytotoxicity tests for chalcone-Pt (2) via MTT assay. The cytotoxic activities, 
represented as IC50 (µM) values, were evaluated from a plot of percent cytotoxcity 
against the sample concentrations. Figure 4- 2 shows the cytotoxicity profiles of 
agaist 2 against HL60 and 518A2 cells. A biphasic activity of was observed for 2 very 
similar to the profile of the previously tested chalcone (1) (chapter 3.3.3).  
 
Figure 4- 2 Dose response curves (MTT assay) of chalcone-Pt (2) in 518A2 (A) and HL60 cells (B).  
Their vitality rapidly decreased after treatment with 2 (IC50’s in Table 4- 3). Similar 
results were reported for parent chalcone (1) revealing high (nM) activity against 
K562 leukemia cells (Ducki et al., 1998; Schobert et al., 2009).  
Table 4- 3 Inhibitory concentrations IC50a (µM) of chalcone-Pt (2) in HL60 leukaemia and 518A2 melanoma 
cells (MTT-assay). 
Compound/ 
Cell line 2 (24 h) 2 (48 h) 
HL60 0.57 ± 0.15 0.26 ± 0.01 
518A2 21 ± 0.7 3.4 ± 0.9 
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 The adherently growing 518A2 cells responded better after longer exposure to 
complex 2 giving IC50 values of ~3.4 µM (48 h) and 57.2 ± 11 nM (96 h) (Schobert et 
al., 2009). It was also shown that conjugate 2 exhibited excellent antiproliferative 
activities with similar magnitude and cell line specificity as shown for chalcone (1) 
(Schobert et al., 2009).  
4.2 Cellular uptake of chalcone-Pt (2) 
In order to ascertain whether the platinum complex 2 is crossing the cell 
membrane by endocytosis, a temperature-dependent experiment was performed. The 
experimental conditions for 518A2 melanoma cells were optimized for conjugate 2 
and applied for all uptake experiments.  
4.2.1 Inhibition of endocytosis by temperature change 
Treatment of 518A2 cells with 200 µM chalcone-Pt (2) was carried out at two 
different temperatures, 37°C and 4°C. Untreated cells served as a reference (Figure 4- 
3). 
 
Figure 4- 3 Time dependent effect of 518A2 cells after 3.5 h exposure to chalcone (2) (200 μM; black bars). 
Vital cells were determined by MTT assay at 37 °C and 4 °C. Vital cells of untreated controls (hatched bars) 
were set to 100%. 
The cytotoxic effect of 2 on the melanoma cells was not postponed after their 
incubation at 4°C and showed almost identical data with incubation at 37°C, which 
left ca 40% cells alive. This result opened another question: How does chalcone-Pt 
enter the cells?  
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4.2.2 Inhibition of drug uptake with specific inhibitors 
A detailed analysis of chalcone-Pt (2) uptake was carried out. Specific 
inhibitors were used to inhibit several pathways of drug entry with the same 
concentrations and timing as described in chapter 4.2.1. Alternative ways for the entry 
of platinum complexes into cells involve copper transport receptor 1 proteins (Ctr1) 
and human organic cation transporters (OCT). Gust et al. studied their relevance by 
switching off individual transporters with specific inhibitors (Kapp et al., 2006). The 
OCT conveys positively charged substances and may be inhibited by cimetidine 
(inhibitor) or by tetraethylammonium chloride (TEA; competitor).  
Based on the low temperature experiments, the role of endocytotic processes 
appears to be minor. Several endocytotic inhibitors were used to block different 
transporters and/or ion-porters. Endocytosis depends also on the Na+/K+ pump 
depending sodium gradient, which is inhibited by ouabaine (Ivanov et al., 2004). 
Macropinocytosis, a distinct form of endocytosis, depends on Na+/H+ exchange that 
can be blocked by amiloride (Kapp et al., 2006; Meier et al., 2002). The enzyme 
phosphatidylinositol 3-kinase plays a central role in the down-stream signalling 
cascade associated with macropinocytosis by F-actin microfilament re-arrangement, 
and can be inhibited by the fungal metabolite wortmannin (Zhang et al., 2003). 
Clathrine-mediated endocytosis can be blocked by chlorpromazine (Nawa et al., 
2003).  
The inhibitors doses were varied to find out the concentration range with 
negligible toxic effects on the cells within the given time range. After optimisation, 
their influence on the uptake of chalcone-Pt (2) into 518A2 melanoma cells was 
examined. First of all, the cells were pre-incubated with non-toxic concentrations of 
the respective inhibitors for 15 min before the chalcone-Pt (2) was added, and its 
cytotoxicity was measured by the common MTT assay. Figure 4- 4 illustrates the 
effects of the individual inhibitors on the cytotoxicity of complex 2 (black bars) 
against 518A2 cells and so indirectly also the share that the various transport 
pathways blocked by these inhibitors have in the uptake of 2.  
The previously described results were confirmed, i.e, treatment of the cells 
with 200 µM chalcone-Pt (2) in the absence of any inhibitors for 3.5 h left 40 ± 5% of 
the cells vital. Pre-incubation with 5 µM ouabaine (Na+/K+) attenuated the 
cytotoxicity of 2 by ca. 24% leaving 58 ± 4% of the cells alive.  
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Clathrine-dependent endocytosis contributed marginally (ca 14%) to the 
uptake of complex 2. Uptake of 2 via Na+/H+ pump driven macropinocytosis seemed 
to play no role. Cell entry of complex 2 took place mainly via OCT (32%) as shown 
by an increase of viable cells to ca. 61% and via Ctr1 (20%) as the addition of 8 nM 
CuCl2 increased the percentage of viable cells to ca. 55%.  
 
Figure 4- 4: Contribution of various pathways to the accumulation of complex 2 (black bars) by 518A2 
melanoma cells as calculated from the attenuation of their cytotoxicity upon addition of specific inhibitors. 
4.2.3 Western blot analysis of OCT1/2 in melanoma 518A2 cells 
The copper transporters Ctr1 exist in all eukaryotic cells (Petris, 2004). It is 
known that cisplatin is transported via OCT1 (=SLC22A1 and OCT2 (=SLC22A2) 
transporters (Zhang et al., 2006). Koepsell et al. and others have assessed the 
organ/tissue distribution of the various types of Organic Cation and Carnitine 
transporters and have found evidence for their presence in pertinent cancer cell lines, 
too (Koepsell et al., 2007). An abundance of OCT’s transporters in tumor cells was 
assumed (Schobert et al., 2009) but the expression of studied transporters in 518A2 
cells was not confirmed, yet. Therefore, the presence of the solute carrier transporters 
family (SLC22A1-2) in tested melanoma 518A2 cells and cervix carcinoma KBv1+Vbl 
cells has been identified by Western blot analysis. The blots showed the presence of 
several bands after staining with organic cation transporters-1. The band showing ~54 
kDa size was indentified as organic cation transporter-1. Several isoforms of OCT-1 
found in humans are known (UniProtKB). The primary antibody of OCT-1 
recognized the N-terminus of the transporter. The N-termini of OCT-1 and OCT-2 
transporters showed highly (~85%) conserved amino-acid sequences. Hence, staining 
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against the OCT-2 C-terminus was likewise carried out and it was possible to detect 
this protein in 518A2 cells, too. 
It was shown for the first time that both melanoma 518A2 and KBv1+Vbl cells 
readily express organic cation transporters (OCT-1 and OCT-2).  
 
Figure 4- 5 Detection of organic cation transporters in 518A2 and KBv1+Vbl cells by Western blot analysis; 
α-tubulin serves as a control.  The shown experiment was performed by Andreas Brown.  
4.2.4 Platinum contents of 518A2 cells treated with 2 (via ICP-MS) 
To confirm the uptake results the platinum content of 518A2 cells optionally 
pre-incubated with individual inhibitors (5 µM ouabain, 500 µM cimetidine, 100 µM 
TEA) was determined after treatment for 3.5 h with 200 µM of complex 2. The 
maximum amount of 2 taken up in the absence of the mentioned inhibitors was 4 
µg/L Pt per mg cells. The Pt-content of cells pre-incubated with 5 µM of the Na+/K+-
pump inhibitor ouabain was reduced to 1.3 µg/L per mg cells corresponding to a 
decrease in uptake of 2 by 68% (Table 4- 4).  
Table 4- 4 Pt-content by ICP-MS of 518A2 cells treated for 3.5 h with 200 µM complex 2. 
Incubation of 518A2 cells  Amount of Pt 
[µg/L] /mg cells 
Decrease of uptake 
[%]  
200 µM chalcone-Pt (2) 4 ± 1.1 0 
 5 µM ouabain + 200 µM (2) 1.3 ± 0.1 68 ± 6 
500 µM cimetidine + 200 µM (2) 1.6 ± 0.2 60 ± 9 
 100 µM TEA + 200 µM (2) 0.8 ± 0.2 79 ± 21 
Pre-incubation with the OCT inhibitor cimetidine diminished the Pt-uptake by 
ca. 60%. An even greater reduction (80%) of the Pt-content was found in cells pre-
incubated with 100 µM tetraethylammonium chloride (TEA), a competitive substrate 
for OCT. The effects of the various inhibitors on the uptake of complex 2 differ 
significantly when determined from the decrease of the platinum content versus the 
cytotoxicity assays. 
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The ICP-MS results advocate a 2–3.5 times greater inhibitory effect when 
compared to those from the MTT tests. While cytotoxicity is a complex phenomenon 
elicited by, yet not restricted to the effects of the intact drug administered, the 
platinum content is just the amount of platinum inside of and attached to the cells.  
Taken together, these results represent strong evidence for the Na+/K+-pump 
driven endocytosis and OCT’s as the main mechanisms of accumulation of platinum 
complex 2 by 518A2 melanoma cells. 
4.3 Cellular and sub-cellular observations 
4.3.1 Inhibition of drug uptake monitored by time-lapse microscopy 
To verify the results from the uptake studies employing specific inhibitors 
time-lapse micrographs were taken from 518A2 cells pre-treated with 10 µM 
amiloride, an inhibitor of endocytosis. The cells treated with complex 2 showed the 
same effects of cell rounding and increased motility as without addition of amiloride 
(Figure 4- 6). This finding corroborates that the Pt-complex 2 relies on dedicated 
transporters (OCT‘s and Crt1). 
 
Figure 4- 6 Time-lapse recording micrographs of 518A2 melanoma cells pre-treated with 10 µM amiloride 
(bottom), an inhibitor of endocytosis (macropinocytosis), and incubated with 10 μM Pt-complex 2 (top).  
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4.3.2 Altered cell shapes of cells treated with chalcone-Pt (2)  
4.3.2.1 Altered cell shapes in neural cells 
Neurons are particularly rich in tubulin and so are well suited to test agents 
affecting microtubule organisation. Neurons treated with 10 µM 2 caused only an 
incomplete disruption of the networks (Figure 4- 7).  
Some cells got closer to each other; their bodies were swelling and 
aggregating. Most of the somas coagulated and neural network processes were 
disconnected from the cell bodies of adjacent neurons.  
 
Figure 4- 7 Altered cell-shape of neurons treated with chalcone-Pt (2). Left: untreated neurons with 
prolonged axons (arrowheads); right: upon incubation with 10 µM 2 some axons (arrowheads) retracted 
and most somas coagulated (arrows).  
4.3.2.2 Altered cell shapes in 518A2 cells 
An analogous experiment was performed with 518A2 melanoma cells, which 
were initially attached as a monolayer to the surface of the mini Petri dish. Overall, 
dynamics and motility of untreated cells was slow as they underwent merely 
negligible morphological changes. Only a few cells detached from the monolayer 
within the first two hours. In contrast, exposure of 518A2 cells to chalcone-Pt (2) has 
led to a rounding and an enhancement of motility and cell shrinking dynamic already 
after 15 minutes (Figure 4- 8).  
The cells readily dissociated from the monolayer and their form turned from 
flat to spherical. This behaviour is in line with the generally accepted mechanisms of 
tubulin binding agents (TBAs) (Lippert, 2007) involving activation of RhoA/RhoA 
kinase, an intracellular coordinator of cytoskeletal rearrangement of microtubules and 
actin. In the experiment with conjugate 2, 518A2 cells were able to repair the 
shrinkage effects and most of them spread again after three hours. 
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Figure 4- 8 Altered cell-shape of 518A2 cells treated with chalcone-Pt (2). Left: untreated 518A2 melanoma 
cells (control); right: effect upon treatment with 10 µM of complex 2.  
4.3.3 Actin distribution induced by chalcone-Pt (2) 
4.3.3.1 Actin distribution in astrocytes 
An immunocytochemical analysis of the morphological changes of the actin 
filaments of astrocytes initiated by conjugate 2 was carried out and compared with the 
behaviour of 518A2 melanoma cells.  
Antibodies to astrocyte-specific GFAP intermediate filaments (glialfibrillary 
acidic protein) were employed to visualize the astroglial cells and phalloidin labelling 
was used to identify actin filaments. The micrographs showed that both types of 
filaments, actin (in green) and GFAP (in red), were disintegrated upon treatment with 
the test compound, most pronouncedly the actin filaments near the cell membrane. 
The GFAP filaments shrank only in the vicinity of the cell nuclei, which remained 
unaffected. Figure 4- 9 shows typical effects of chalcone-Pt (2) on astrocytes.  
Their proliferating activities are clearly visible by spread GFAP and actin 
connections forwarded into the unoccupied place. The GFAP and actin filaments 
concentrated around the nuclei. The space in the vicinity of the cell membrane stayed 
empty. 
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Figure 4- 9 Immunostaining of astroglia cells untreated and treated with 1 µM chalcone-Pt (2) for 72 h 
(right). Blue: nuclei stained with DAPI (4',6-diamidino-2-phenylindole); green: actin cytoskeleton stained 
with phalloidin; red: glial fibrillary acidic proteins (GFAP). White arrowheads indicate the cell membrane.  
4.3.3.2 Actin distribution in 518A2 cells 
Fluorescence micrographs of immunostained 518A2 cells were performed. 
Similarly to the results obtained from the astrocytes, a significant breakdown of the 
actin network was evocated after treatment with chalcone-Pt (2) (Figure 4- 10).  
 
Figure 4- 10 Actin immunostaining of untreated 518A2 cells and cells treated with 10 µM Pt-complex 2 for 
24 hours (bottom row). Blue: nuclei stained with DAPI (4',6-diamidino-2-phenylindole); green: actin 
cytoskeleton stained with phalloidin; bar represents 50 µm scale. 
4.3.4 Microscopic observations of 518A2 cells by Giemsa staining 
An effect of conjugate 2 on filament distribution was discovered in the 
previous chapter 4.3.3. It was shown recently that 2 is able to inhibit in vitro 
microtubule polymerization (Schobert et al., 2009), and the described neural 
experiments confirmed effects on its microtubule-based network system. In neural 
cells nuclei remained untouched but in 518A2 cells nuclei were close together. 
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Therefore, internucleosomal DNA cleavage was monitored with Giemsa staying and 
examined under a light microscope. Using a 10 µL tip, the plate was scratched to 
form letter X (cf. material and methods part).  
The cytotoxic effect of the 22 µM chalcone-Pt (IC50 concentration) on the 
proliferation as well as on the attachment of the adherent cells was analyzed upon 
exposure for 24 hours Figure 4- 11. The altered cell shape was very similar to that 
already observed in the previous experiments. The control cells were wide and spread 
with typical 518A2 shapes, the nuclei were well defined by their nuclear envelope 
showing condensed chromatin as a dark blue–dots. The scratched X-cross disappeared 
during incubation for 24 hours. The number of chalcone-Pt (2) treated cells decreased. 
These 518A2 cells got close to each other and formed aggregates with visible nuclear 
envelopes. Some late apoptotic or dead cells were visible featuring spread cells with 
purple cytoplasm. 
 
Figure 4- 11. Samples of 518A2 cells treated with test compounds were stained with Giemsa dye after 24 
hours of incubation. Untreated control cell served as a reference. Applied concentrations: colchicine 62.5 
nM, chalcone-Pt (2) 22 µM, mixture: 31.3 nM of colchicine + 11 µM of chalcone-Pt (2).   
The effect of the known tubulin inhibitor colchicine on 518A2 cells has not been 
investigated, yet. Therefore, similar experiments were performed with colchicine (62 
nM) on 518A2 cells. The cell number of colchicine treated cells rapidly decreased. 
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The cells occasionally formed aggregated structures. Surprisingly, no nuclei 
envelopes were observed and all cells were slightly pink-purple, some were spread, 
and some were still rounded. This cell behaviour is different from that observed for 
chalcone-Pt (2). The combination of both drugs in using halved IC50 concentrations 
(31.3 nM of colchicine + 11 µM of the chalcone-Pt) led to a mixture of the 
individually described phenomena Figure 4- 11. The cell number decreased but not as 
rapidly as after single agent-treatments with colchicine or 2. The nucleus envelope 
was hardly detectable in most of the cells. Colchicine structurally differs from 
chalcone-Pt (2). It is possible that their effect on α–tubulin binding in in vitro tubulin 
polymerization experiments could be similar, however, in living cells additional 
mechanisms like the uptake can play a key-role. It is also possible that the chalcone 
fragment has a different binding mechanism and/or a higher affinity to different kinds 
of tubulin. 
4.3.5 Transmission electron microscopy 
Morphological and sub-cellular effects of conjugate 2 on 518A2 melanoma 
cells were studied by transmission electron microscopy (TEM). The cells were treated 
with 0.1 mM chalcone-Pt (2) for 15 minutes, kept under fresh medium ~1 hour and 
monitored using transmission electron microscopy (TEM). The mitochondria 
population is more condensed in drug-treated cells (in Figure 4- 12 visible as 
prolonged darker dots) in comparison to untreated cells. While untreated cells 
appeared prolate and undifferentiated showing filopodia for cell attachment on the 
rim, cells incubated with chalcone-Pt (2) adopted a rounded shape. A similar 
morphological change has been reported for H460 non-small cell lung cancer cells 
treated with combretastatin A-4 (CA-4) (Vitale et al., 2007). In addition, the treated 
518A2 cells showed blebs emerging on their surface. Untreated cells appeared 
undifferentiated revealing filopodia residues for cell attachment around the cell edge 
(Figure 4- 12). Control cells and treated cells also differed concerning the state of 
their mitochondria, centrioles and Golgi apparatus (GA). Upon treatment with 100 
µM 2 for 15 min a rounded cell shape and blebs emerging on the surface was 
observed.  
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Figure 4- 12 Transmission electron micrographs of 518A2 cells illustrating the differentiation process 
induced by in vitro exposure to chalcone-Pt (2). An untreated, undifferentiated control cell was compared 
with a cell exposed to 100 μM 2 for 15 min. The arrowheads point at the rounded cell shape and blebs 
emerging on their surface. Black bar = 2.5 µm. Performed according to section 2.5.5.  
Mitochondrial populations usually consist of short and long tubules, which 
constantly migrate along microtubule tracks (Chan, 2006). Any disruption of the 
microtubules/actin skeleton, e.g., by treatment with chalcone-Pt (2), should severely 
affect the mitochondrial trafficking and cause mitochondrial disorganization. 
Mitochondria of cells treated with chalcone-Pt (2) were highly condensed and 
localized mainly at the apical side of the cells. They frequently displayed dislocated 
inner membranes (Figure 4- 13c, e, f). Only a small percentage of the untreated 
control cells were found in the G2/M phase having visible centrioles. After treatment 
with 2, many cells had visible pro-centrioles (Figure 4- 13b), which is an indication 
for an arrest in the G2/M phase. This observation is in line with results from the cell 
cycle analysis described above. Stress fibers (Figure 4- 13h) were observed less 
frequently than in cells treated with 2. Multivesicular bodies and autophages appeared 
very often (Figure 4- 13f, h, i), their double membranes were visible in most of the 
analyzed cells. Maintenance of the microtubule integrity plays a pivotal role for the 
stabilization of the pericentriolar matrix. The tubulin depolymerising effect of 2 leads 
to mitotic catastrophe and thus to an arrest in G2/M phase. These observations are 
consistent with similar mitotic failures of H460 NSCLC cells treated with CA-4 
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(Vitale et al., 2007). The occurrence of centrioles as a result of aberrant chromosome 
segregation could be due to DNA damage (possibly in tandem with defective 
checkpoints) or to a destabilization of the spindle apparatus (Castedo et al., 2004; 
Vitale et al., 2007).   
 In 518A2 cells the Golgi apparatus (GA) is frequently located in the vicinity 
of centrosomes or nuclei envelopes. However, a fragmentation of the GA was 
observed in 518A2 cells treated with complex 2 (in Figure 4- 13b, c, f, i as red 
arrows). The fragmentation of the GA is, however, an early event that occurs 
independently of major changes to the actin and tubulin cytoskeleton (Mukherjee et 
al., 2007). The GA undergoes irreversible fragmentation during apoptosis partially as 
a result of caspase-mediated cleavage of several Golgi-associated proteins (Mukherjee 
et al., 2007). 
 
Figure 4- 13 TEM images of organelles in 518A2 cells a, d: untreated cells with image a showing the 
longitude section through the centrioles and image d shows mitochondria with cristae invaginations 
surrounded by endoplasmic reticulum. b, c, e-i cells treated with 2. Image e shows mitochondria at various 
stages of inner-membrane destruction, image f the formation of multivesicular bodies (arrowheads). Some 
mitochondria were highly condensed (i, g stars) and some formed multi-lamellar bodies (arrows). Stress 
fibers are visible in panel h. Black bar = 0.4 µm.  Performed according to section 2.5.5.  
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4.4 Activation of caspase-3 after chalcone-Pt (2) treatment 
 Caspases involved in apoptosis exist as inactive zymogens that become 
activated proteolytically when cells are undergoing apoptosis (Thornberry et al., 
1997). HL60 cells were monitored up to 24 h and the suspension cells were 
continuously treated with complex 2. The initial rate of cleavage of the colorimetric 
substrate for caspase-3 was determined (Figure 4- 14).  
 In the case of chalcone (1) the activity of caspase-3 is dramatically increased 
after 12 hours of incubation and reaches a constant value of 1.65 µM. On the other 
hand, in the presence of chalcone-Pt (2) an increase in activity of caspase-3 is 
observed after 15 hours. Control HL60 cell extracts had minimal cleavage activity 
(~0.25 µM). 
 
Figure 4- 14 Time dependent caspase-3 activity in HL60 cells after chalcone-Pt treatment (1 µM). The assay 
was carried out in a total volume of 100 µL. Crude extract of 6 million cells was 10-fold diluted with caspase 
buffer. Substrate for caspase-3 (Ac-DEVD-pNA) was supplied in concentration 200 µM and absorbance at 
405 nm was measured using micro-plate reader. To subtract unspecific protease activity, caspase-inhibitor 
DEVD-CHO was added in 20 µM final concentration and incubated for 15 minutes at 37 °C.  
4.5 The role of DNA degradation during apoptosis  
4.5.1 Effects of conjugate 2 on chromosomal DNA  
Fragmentation of chromosomal DNA and degradation of nuclear matrix is 
typical for apoptotic cells. Activation of endonucleases initiates DNA cleavage and 
chromatin is degraded into two distinct fragments: nucleosomal length fragments 
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(multiples of 180-200 bp) and large (30- to 50-kb) fragments. Level of DNA 
fragmentation has characteristic-banding pattern commonly known as an "apoptotic 
ladder" (Peitsch et al., 1993). 
The cytotoxic activity of 2 against KBv1+Vbl cells was ~1 µM. Thus, 24 hours 
incubation was performed followed by DNA isolation and electrophoretic analysis 
(Figure 4- 15). Indeed, treatment with conjugate 2 caused apoptotic laddering and 
strong bands of ~200 bp.  
 
Figure 4- 15 DNA fragmentation in KBv1+Vbl cells after treatment with 1 µM chalcone-Pt (2). Control cells, 
lines 1 and 2. Cells treated with chalcone-Pt (2), line 3. Commercially available DNA ladder between 3kbp -
100bp was used, line 4. Electrophoresis was carried out on a 1.5% agarose gel for 4 h at 12V/cm.  
4.5.2 Cell cycle analysis  
 Chalcone (1) was found to arrest cells of the human T24 and HT-1376 bladder 
cancers in the G2/M phase (Shen et al., 2007). We now assessed the cell cycle 
progression of melanoma 518A2 cells treated with chalcone-Pt (2) by FACS analysis 
after DNA staining with propidium iodide (PI) (Figure 4- 16).  
The FACS analysis showed 63% of untreated 518A2 cells in G1 phase, 24% in S 
phase and 13% in G2/M phase after 18 h. 518A2 cells treated with 250 µg/L 
nocodazole, a synthetic analogue of taxol, were mainly in sub-G1 phase after 18 h, a 
shorter 12 h exposure led to 76% of the cells in G2/M phase. 518A2 cells treated with 
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10 µM of Pt-complex 2 stopped in G2/M phase (59%) which is typical for chalcones, 
but the amount of cells in G1 phase increased as well (19%). 22% of the cells stayed 
in the S phase. For comparison, treatment with cisplatin led to 69% of 518A2 cells 
arrested in G1 phase. 
 
Figure 4- 16 Flow cytometry analysis of 518A2 melanoma cells stained with propidium iodide. The cells 
were treated with 250 µg/mL nocodazole or with 10 µM of 2 or cisplatin. The FACS measurements and 
analysis were performed with special assistance of Andreas Brown. 
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Probably, complex 2 has a dual impact on the cell cycle of 518A2 melanoma cells 
combining the effects of Pt-complexes and of combretastatin A-4 analogues. To 
dismiss a conceivable hydrolytic cleavage of 2 during incubation, 100 µM of 
dichlorido(6-aminomethylnicotinic acid)platinum(II), the assumed hydrolysis product 
of ester 2, was tested but had no effect on the cell cycle at all. The DNA binding 
activity of 2 was found to be four times lower than that of the good DNA-binder 
cisplatin (Schobert et al., 2009). This could be a reason of the lower cells number 
arrested in G1 phase upon treatment with 2.  
4.6 DNA interaction with conjugate 2  
 Up to date, chalcones (1,3-diphenyl-2-propen-1-one) are not known as 
intercalating or DNA-binding agents. Contrary to the chalcones, platinum based 
derivatives like cisplatin are well known DNA-binding agents (Lippert, 1999). The 
main objective of this study is the elucidation of DNA binding properties of Pt 
conjugates with chalcone (1). In order to pinpoint the role of platinum in the 
anticancer effect of conjugate 2, its DNA binding behaviour was investigated in 
greater detail.  
4.6.1 Electrophoretic mobility shift assay of plasmid DNA  
 Agarose gel electrophoresis was applied for the investigation of 
conformational changes and damages caused to non-genomic DNA (plasmid DNA). 
The supercoiled circular form (sc) of plasmid DNA possesses higher mobility than the 
one-nicked open circular form (oc).  
 Many reports provided evidence for platinum interaction with DNA (Brabec, 
2002; Brabec and Balcarova, 1993; Brabec et al., 1990). The unwinding ability of 2 
on plasmid DNA was investigated in absence or presence of 0.01 M NaClO4. In 
general, perchlorate allows hydrolysis of Pt complexes (Butour et al., 1990). 
Surprisingly, in the absence of perchlorate no changes were visible in the DNA 
mobility of pBR322 plasmid DNA after addition of chalcone-Pt (2) (Figure 4- 17A).  
 In the presence of perchlorate, increased concentrations of 2 incurred dos-
dependent unwinding of negatively supercoiled pUC19 DNA (Figure 4- 17B). The 
amount of plasmid sc-form was reduced with increasing rb value. The increasing drug 
concentration led to increased intensity of oc-form probably due to DNA-nicks.   
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Figure 4- 17 Interaction of plasmid DNA with increasing concentrations of chalcone-Pt (2). Open circular 
form (oc - nicked plasmid). Supercoiled form (sc - closed negatively supercoiled plasmid). 
Electrophoretogram A) pBR322 DNA incubated with 2 (dissolved in DMF) for 24 hours in different 
concentrations (line 1-5 ≈ 0-5-20-40-60 µM) applied in 1% agarose gel for 3 h, 65-85 V in TAE buffer. B) 
Unwinding of supercoiled pUC19 plasmid DNA modified by 2 (resolved in NaClO4) with rb 1-7 ≈ 0.003, 
0.011, 0.019, 0.025, 0.032, 0.07. 
4.6.2 Kinetic of DNA binding by chalcone-Pt (2) 
 The previous experiments confirmed the binding ability of chalcone-Pt (2) in 
plasmid DNA. For the next experiments the kinetic of binding and the maximum 
amount of Pt able to bind to DNA was investigated.  
Initially, compound 2 caused platination of calf thymus DNA and rb values 
were determined via FAAS (Figure 4- 18).  
 
Figure 4- 18 Kinetic of chalcone-Pt binding into the calf thymus DNA in 0.01 M NaClO4 (rb-molar ratio of 
platinum bound to nucleotides).  
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The binding activity curve reached a maximum of 55% Pt (relative to rb) after 48 h. A 
higher concentration of 2 caused (yellowish) precipitation of the whole DNA after 18 
hours of incubation. Due to this limitation only a few experiments were performed.  
4.6.3 DNA secondary structure changes  
 To gain further information on the structural changes induced by platinum 
complex 2, circular dichroism (CD) spectra of modified DNA were recorded (Figure 
4- 19). It has already been mentioned in chapter 3.5.2 that the CD spectrum of ct 
DNA is very similar to the spectrum of B-DNA (crossing the zero line at 260 nm). 
The spectrum of conjugate 2 alone showed no changes (Figure 4- 19-A). Conjugate 2 
had no intrinsic CD signals so that any CD signal above 350 nm can be attributed to 
the interaction of complex 2 with DNA. Below 300 nm differences from the untreated 
DNA spectrum were visible due to DNA perturbation by complex 2. The spectrum of 
complex 2 bound to ct DNA showed positive CD bands centered at 278 nm and a 
negative CD band at 245 nm (Figure 4- 19-B,C). The CD spectra of DNA modified 
by increasing concentration of 2 indicate that the binding results in conformational 
alterations in the double-helical DNA. Increased binding of 2 to ct DNA decreased 
positive CD and increased negative CD.  
 
Figure 4- 19 Comparison of chalcone-Pt CD spectra with calf thymus (ct) DNA (10-4 M) dissolved in 0.01M 
NaClO4. A) Profiles of chalcone-Pt (2) and blank (0.01M NaClO4) were measured. Panels B and C show 
molar ellipticity spectra of ctDNA affected by chalcone-Pt (2). CD spectra were converted to ∆ε  using the 
concentration of DNA. B) Effect of rb = 0.009, 0.02 of (2) on ctDNA and C) effect of dialysed (2) samples 
with increasing rb= 0.009, 0.02. Complex-free ctDNA served as a reference.  
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4.6.4 Melting temperatures of DNA-chalcone-Pt (2) adducts  
The melting points (Tm) of DNA modified by chalcone-Pt (2) were measured. 
Drug-modified DNA could be (de) stabilized and thus (decrease) increase its Tm. For 
these measurements the dialysed samples from the CD experiments were used. 
Denaturating temperature of unmodified ctDNA was 61 ± 1°C. Addition of complex 2 
decreased the Tm value up to 56 ± 4 °C at rb = 0.02. Higher concentrations could not 
be used because of precipitation. 
Table 4- 5 Melting points (Tm) of dialysed DNA modified with complex 2 at various rb values. 
ri 0 0.009 0.02 0.04 0.05 
Tm [°C] 61 57 (-3) 56 (-4) 61 59.2 (-2) 
 
 It can be concluded that the interaction between the Pt complex 2 and ctDNA 
had rather minor destabilising effects because of the slight decrease of the melting 
points.  
4.7 Drug resistance 
4.7.1 Interference with ABC transporters 
The interaction of chalcone conjugate 2 with drug transport proteins like 
ABCB1 (P-gp) (Hyde et al., 1990; Simstein et al., 2003; Smith et al., 2001) or BCRP 
(Borst et al., 1997) in a substrate- or inhibitor-like fashion was investigated in this 
chapter.  
4.7.1.1 Chalcone-Pt (2) efflux via P-glycoproteins  
P-gp overexpressing KBv1+Vbl cervix carcinoma cells (Schwab et al., 2003) 
and their wild type parent KBv1 cells were treated with chalcone-Pt (2) in the 
presence of calcein-AM (Figure 4- 20). The inhibition of P-gp leads to cleavage of 
calcein-AM taken up by the cells resulting into the formation of fluorescent calcein. 
As a positive control, the fluorescence intensity of KBv1+Vbl cells treated with 50 µM 
of the clinically established chemosensitiser verapamil (Schwab et al., 2003; Sharom, 
1997) was set to 100 %. Surprisingly, wild-type KBv1 cells reached under the same 
conditions only ~45% of the calcein fluorescence of the resistant KBv1+Vbl cells. 
Possibly, they have other ways to eliminate calcein-AM or calcein, which is not 
without precedence (Marchan et al., 2008; Oku et al., 1995). Calcein fluorescence in 
KBv1 cells was also relatively low in the absence of verapamil. Treatment with Pt-
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complex 2 was more effective in the KBv1+Vbl cells, in both cell lines conjugate 2 
showed half of the activity of verapamil.  
 
Figure 4- 20 Calcein-AM % inhibition of P-gp drug transporters in KBv1 and KBv1+Vbl cells by chalcone-Pt 
(2) (50 µM, black bars) relative to the inhibition of KBv1+Vbl cells by verapamil (50 µM, hatched bar) after 
15 min exposure. White bars: negative control.  
4.7.1.2 Chalcone-Pt (2) efflux via BCRP proteins 
MCF-7 breast carcinoma cells express BCRP drug transporters. When treated 
with topotecan (550 nM over 40 generations) MCF-7 cells start to over-express these 
proteins (MCF-7+Top cells). The mitoxantrone assay is based on the active export of the 
fluorescent dye mitoxantrone through BCRP, which enters the cells via diffusion. The 
effects of 2 on the fluorescence of intracellular mitoxantrone in MCF-7 and MCF-
7+Top cells relative to that of the specific BCRP inhibitor fumitremorgine C (Oku et al., 
1995) and to a negative control of cells treated only with mitoxantrone are shown in 
Figure 4- 21. Both compounds gave rise to a doubling of the mitoxantrone 
fluorescence in either cell line relative to the negative control and so are likely to be 
competitive substrates for the BCRP proteins.  
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Figure 4- 21 Mitoxantrone % inhibition of BCRP drug transporters in MCF-7 and MCF-7+Top cells by 10 
µM each of chalcone Pt (black bar) relative to fumitremorgine C (hatched bar) after 30 min exposure. 
White bar: fluorescence of cells after addition of mitoxantrone (negative control).  
4.7.2 Interaction of chalcone-Pt (2) with glutathione 
Glutathione (GSH) plays a key role in the metabolism and mechanism of 
anticancer action of platinum drugs (Townsend and Tew, 2003). DNA damaging 
agents such as cisplatin get frequently deactivated by the high concentrations of 
glutathione and glutathione-S-transferase, which are present in resistant tumor cells 
(McIlwain et al., 2006; Pompella et al., 2007; Tsuchida and Sato, 1992).  
Depletion of GSH levels usually leads to an enhanced cytotoxicity of cisplatin 
(Fuertes et al., 2003), and maybe of the complexes 2 as well. Two possible binding 
sites for GSH exist in complex 2: the metal center (280 nm) and the ß-carbon atom of 
the propenone linker (~360 nm), both are shown in Figure 4- 22A. In order to identify 
the site at which S-nucleophiles prefers to attack, reaction of 2 was monitored with an 
excess of GSH at 37°C over two days. The reaction of GSH with compound 2 and 
dichlorido(6-aminomethylnicotinic acid)Pt(II) (= nic-Pt), the putative hydrolysis 
product of 2, (Schobert and Biersack, 2005) was monitored by measuring the 
absorbance at 280 nm (Ishikawa and Ali-Osman, 1993). The absorption band at this 
wavelength is indicative of the covalent binding interaction of platinum complexes 
with the thiolate group of GSH. The progress of the reactions was slow and they were 
finished only after 24 hours (Figure 4- 22B).  
4. Effects of chalcone-Pt (2)  
4.7-89 
 
 
Figure 4- 22 (A) Scheme of the reaction between GSH and chalcone-Pt. Time-dependent relative absorbance 
at 280 (shown in (B) and 360 nm (C) of the reaction of two equiv. GSH (3.33 mM) with chalcone (1) 
(squares), 2 (black dots), and nic-Pt (asterisks) in 1 mL of PBS (pH 7.4) at 37°C. Curves obtained from 
mono-exponential fitting; apparent rate constants at 280 nm (B) were 0.38 and 0.94 h–1 for 2 and nic-Pt, 
respectively. At the same time, reactions observed at 360 nm (C) showed rate constants 0.56, 0.28 and -0.015 
h-1 for chalcone (1), 2 and nic-Pt. 
 
The reaction between GSH and nic-Pt was the fastest one. Although complex 2 
showed a high affinity to GSH, its cytotoxicity in GSH-rich HCT-116 cells was 
comparable to that observed in 518A2 cells (1 ± 0.1 μM). Absorbance decrease was 
detected at 360 nm with time (Figure 4- 22C). The 
π-electron flow was distorted in chalcone and, 
consequently, absorbance was affected. The 
reaction changed from a yellowish solution to a 
colourless one (Figure 4- 23, (Zoldakova and 
Schreder, 2009)).  
 
Figure 4- 23 The yellowish solution turned colourless after reaction of 2 with GSH. 
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4.8 Conclusion 
 The uptake of the Pt conjugate 2 into 518A2 melanoma cells occurs mainly 
via the organic cation and copper related transporters. Insofar, complex 2 resembles 
oxaliplatin, which was shown to be an excellent substrate for the human organic 
cation transporters OCT-1 and OCT-2. (Zhang et al., 2006) 
 The platinum complex 2 was highly efficacious against cells overexpressing 
P-gp transporters. The results obtained from calcein-AM assays showed that complex 
2 inhibits the efflux functionality of P-gp by acting as a genuine inhibitor or a 
modulator. As a consequence, complex 2 was more efficacious in multi-drug resistant 
cancer cells featuring this particular ABC-transporter, e.g., KBv1+Vbl. Complex 2 
showed a high affinity towards GSH, however, its cytotoxicity in GSH-rich HCT-116 
cells (1 ± 0.1 µM) was comparable to that observed in 518A2 cells (IC50 ~3.4 µM). 
Chalcone-Pt (2) was little active in HT-29 cells but distinctly more so in HT29+Colc 
cells. Colchicine-induced overexpression of MRP1 is accompanied by a changed 
sphingolipid composition (Kok et al., 2000). Sphingolipid metabolism is performed in 
the Golgi apparatus. Vigorous fragmentation of Golgi apparatus after treatment with 2 
was observed via transmission electron microscopy. It could be an indication that the 
sphingolipid pathway plays a crucial role in the metabolism of complex 2.  
  Chalcone-Pt (2) was shown to depolymerise microtubules and actin filaments 
in neural and cancer cells. It proved effective in damaging mitochondria. In 518A2 
melanoma cells the good tubulin binder colchicine led to different morphological 
changes compared with compound 2. These results also support the assumption of 
different molecular mechanisms of action for 2 being based not only on tubulin-
disruption. 
 The DNA binding abilities of conjugate 2 were confirmed by changes in the 
secondary structure of ctDNA and unwinding of supercoiled plasmid DNA. Cell cycle 
analyses on complex 2 led to arrested cancer cells in G2/M phase. Additionally, it led 
to a slight accumulation of cells in the G1 phase, probably as a reminiscent of the 
effect of cisplatin. Hence, chalcone-Pt (2) has a dual impact on the cell cycle of 
518A2 melanoma cells by combining the effects of active Pt-complexes and of 
chalcones or combretastatin A-4 analogues in general.  
 
 
5. Results and Discussion  
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Effects of chalcone-DAP-Pt (3) 
The platinum conjugate chalcone-DAP-Pt (3) is a chimera of the 
combretastatin A-4 analogous m-hydroxychalcone (1) and a dichloride 
(diaminopropionate)Pt(II) fragment featuring a close analogue of conjugate 2 
possessing a saturated 2,3-diaminopropionate N,N-ligand (Biersack, 2009; Zoldakova, 
2010). 
 
Figure 5- 1 Structure of chalcone-DAP-Pt (3). 
5.1 Inhibition of cell growth - MTT assay 
5.1.1 Tumor cells expressing ABC-transporters 
ABC-transporters pump drugs out of cancer cells and are responsible for 
chemoresistance. Their interference with chalcone-DAP-Pt (3) was investigated by 
using various cancer cells rich in these transporters such as KBv1 cervix and HT-29 
colon carcinomas. These cells had been grown in the presence of specific substrates 
of their transporters to stimulate their overexpression (Table 5- 1). A comparison with 
cisplatin was performed for all tested cell lines. 
Table 5- 1: Inhibitory concentrations (aIC50 in µM) of compound (3) and cisplatin (CDDP) in various ABC-
transporter expressing cells. 
Cell line MCF-7+Top KBv1 KBv1+Vbl HT-29 HT-29+Colc 
24 h (3) * 1.5 ± 0.5 0.4 ± 0.1 48 ± 2 >77  
48 h (3) * 0.1 ± 0.08 0.1 ± 0.05 36 ± 4 30 ± 3 
24 h 
(CDDP) 20 ± 3.2 * 17 ± 3 66 ± 3.1 44 ± 1.3  
48 h 
(CDDP) 9 ± 1.4 * 10 ± 2.5 39 ± 3.8 23 ± 4.1 
aValues are derived from concentration-response curves obtained by measuring the percentual absorbance of vital 
cells relative to untreated controls (100%) after 24 and 48 h exposure of selected cells to test compounds in the 
MTT assay. Values represent means of at least three independent experiments ± standard deviation.  
*Not tested  
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 Resistant KBv1+Vbl cells overexpressing P-gp proteins were obtained by treatment 
with vinblastine. Conjugate 3 was highly efficacious against KBv1 cells even after 
long time exposure, in both cell lines similar IC50 values (~100 nM) were reached. 
Cisplatin is a known substrate of P-gp proteins (Hori et al., 1993; Komatsu et al., 
2000) and its cytotoxicity against KBv1+Vbl was 100-times lower compared with 
conjugate 3.  
 HT-29 cells feature a high amount of multi-resistance protein 3 (MRP3) and a 
low amount of MRP1. Chalcone-DAP-Pt (3) was only little active in both HT-29/HT-
29+Colc cell lines. MRP1 and BCRP (breast cancer resistance protein) cause cisplatin 
resistance, which was confirmed from these results (Rabik and Dolan, 2007).  
5.1.2 Cancer cells  
 The antiproliferative activity of chalcone-DAP-Pt (3) was evaluated in MTT-
assays against HL-60 leukaemia, 518A2 melanoma, and HCT-116 colon carcinoma 
cells (Figure 5- 2, Table 5- 2). All of the mentioned cancer cell lines complex 3 
showed the highest activity against HL-60 leukemia cells. The high effect of 3 in the 
leukaemia cells is not surprisingly amplified since leukaemia cells are quite sensitive 
to both combretastatin A-4 derivatives and DNA-binding compounds (Ducki et al., 
1998) (Ochoa, 1969). 
Table 5- 2 Inhibitory concentrations a IC50 (µM) of compound 3 and cisplatin (CDDP) when applied to 
518A2 melanoma, HL-60 leukaemia, and HCT-116 colon carcinoma cells. 
Cell line 24 h (3) 48 h (3) 24 h (CDDP) 
48 h 
(CDDP) 
HL60 0.013 ± 0.009 0.001 ±0.0006 2.5 ± 1 0.5 ± 0.3 
518A2 5 ± 1.7 0.373 ± 0.004 21 ± 5.3 9 ± 2.3 
HCT-116  0.79 ± 0.05 - 17 ± 0.2 
The finding that complex 3 is superior in efficacy against the melanoma cells is at 
variance with test results recently obtained for a series of terpene-Pt-complex 
conjugates which inhibited the growth of 518A2 melanoma cells most when bearing a 
6-aminomethylnicotinate rather than a diaminopropionate ligand (Bernhardt et al., 
2008; Schobert et al., 2007). The relatively low IC50 values of the platinum complex 3 
in the glutathione-rich HCT-116 colon carcinoma cells (Arnould et al., 2003) are a 
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hint at the general robustness of chalcone Pt-complex conjugates against the 
glutathione-based detoxification / deactivation mechanism of resistant cancer cells. 
 
Figure 5- 2 Cytotoxicity of chalcone-DAP-Pt (3) after treatment for 48 hours with different concentrations 
in (A) 518A2 and (B) HL60 cells.  Solid lines are curve-fits of compound 3 (black points) and cisplatin (white 
points) and were fitted by GraFit program according to equation 2-2.  
5.2 Microscopic observations of 518A2 cells by Giemsa staining 
 Internucleosomal DNA cleavage of chalcone-DAP-Pt (3) was monitored with 
a light microscope after staining with Giemsa dye. Treatment with the IC50 
concentration of 3 for 24 h showed an effect on proliferation as well as on the degree 
of attachment of the adherent cells. The untreated control cells appeared typically 
shaped and regularly spread showing well defined nuclei and condensed chromatin 
visible as dark blue dots (Figure 5- 3).  
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Figure 5- 3 Light microscopic images of 518A2 cells treated with IC50 concentrations of test and reference 
compounds for 24 hours, fixed and stained with Giemsa dye. 
Treatment of 518A2 cells with 3 led to reduced cell numbers. The cells were packed 
more densely in insular aggregates and some of them formed connective 
invaginations. Treatment with complex 3 gave rise to cells with a blue colored 
cytoplasm due to DNA platination and a rounded morphology typical of exposure to 
chalcone (1). Very late apoptotic or dead cells were sprawled out with a purple or 
even missing cytoplasm. In contrast, 518A2 cells treated with cisplatin appeared 
swelled in comparison with control cells but remained equally distributed. Exposure 
to colchicine (62 nM), the archetypal inhibitor of tubulin polymerization, rapidly 
reduced the number of 518A2 cells which no longer displayed nuclei envelopes, took 
on a pink-purple hue, and were either sprawled out or rounded. Thus, the good tubulin 
binders colchicine and chalcone-DAP-Pt (3) led to different morphological changes in 
518A2 cells which might be an indication of quite different molecular mechanisms.  
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5.3 DNA degradation of chalcone-DAP-Pt (3) during apoptosis  
 Previous results showed an extremely high sensitivity of KBv1 cells towards 
complex 3 (IC50=1.5/0.1 µM). Fragmentation of DNA through activated endogenous 
nucleases is a final commitment step characteristic for apoptosis (Arends et al., 1990; 
Bortner et al., 1995; Hughes and Cidlowski, 2000). Activation of endonucleases 
initiates DNA cleavage creating nucleosomal length fragments (multiples of 180-200 
bp) and large (30- to 50-kb) fragments.  
 The cervix carcinoma (KBv1) cells were exposed to 1.5 µM of 3 for 24 hours. 
The DNA of the treated cells was isolated and analyzed by agarose gel electrophoresis 
(Figure 5- 4).  
 
Figure 5- 4 Chalcone-DAP-Pt (3) induced DNA degradation in KBv1 cells. The DNA samples were applied 
to 1.5% agarose gel. Lane C: control – untreated cells; lane 3 is the DNA extract from cells treated with 1.5 
µM chalcone-DAP-Pt (3); lane M: 100 – 3000 bp DNA ladder for comparison. 
A huge amount of DNA remains in the loading well featuring intact chromosomal 
DNA (lane C). DNA of isolated cells treated with 3 (lane 3) likewise contained intact 
chromosomal DNA in well of electrophoresis gel. A DNA fragmentation comparable 
to the control DNA ladder could be detected in the lane containing DNA from the 
treated cells together with a large amount of ~200 bp fragments.  
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5.4 Characterization of DNA-chalcone-DAP-Pt (3) interactions  
 Several DNA binding molecules interact via intercalation (Neidle, 1979; 
Waring, 2006). DNA intercalation was observed for the chalcone analogue AMC 
[AMC, 1-(4'-aminophenyl)-3-(4-N,N-dimethylphenyl)-2-propen-1-one] (Shah et al., 
2008). Chalcone (1) is not known as intercalating or DNA-binding agent, yet, the 
Pt(II) fragment of conjugate 3 might be able to coordinate nucleobases of the DNA 
quite efficiently. 
5.4.1 Electrophoretic mobility shift assay of plasmid DNA  
 Gel electrophoresis was used to investigate the conformational change and 
damage caused to non-genomic DNA (pUC19 plasmid DNA) by covalent binding 
with chalcone-DAP-Pt (3). The supercoiled circular form (sc) possesses higher 
mobility and runs faster than the one-nicked open circular form (oc).  
In order to quantify the unwinding capacity of complex 3, its effect on pUC19 
plasmid DNA was investigated. The plasmid was incubated with 3 for 24 h at 37 °C 
at various rb values. The native agarose gel resulting from DNA modifications by 
cisplatin and 3 is shown in Figure 5- 5.  
 
Figure 5- 5 Unwinding of supercoiled pUC19 plasmid DNA modified by cisplatin (2–9): rb = 0.02, 0.03, 0.04, 
0.05, 0.06, 0.07, 0.08, 0.09; by 3: rb = 0.022, 0.032, 0.044, 0.048, 0.108, 0.096, 0.150, 0.152 (lanes 2–9). Lane 
(1): control, untreated DNA; oc = nicked plasmid; sc = closed negatively supercoiled plasmid.  
A slower migration is the result of DNA unwinding since this reduces the 
supercoiling degree. The mean unwinding angle Φ can be calculated according to 
Equation 5 - 1,  
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Equation 5 - 1 Calculation of unwinding angle   
where σ is the superhelical density and rb(c) is the rb value at which the supercoiled 
and nicked forms co-migrate (Brabec et al., 2007). Under the applied experimental 
conditions σ was calculated (Equation 5 - 1) to be –0.058. For the positive control, 
cisplatin was used taking its unwinding angle Φ = 13° at rb(0.08) (Keck MV and SJ, 
1992). Figure 5- 5 shows that complex 3 caused a significant DNA unwinding (Φ = 
21-23°). 
 The co-migration point rb(c) of DNA treated with complex 3 was reached at rb 
= 0.046 ± 0.002. The notably high level of DNA unwinding induced by 3 is even 
higher than that induced by adducts of cisplatin. 
5.4.2 Kinetic of chalcone-DAP-Pt (3) DNA binding  
 In order to pinpoint the role of the platinum fragment for the anticancer effect 
of conjugate 3 in comparison with cisplatin, the DNA binding behavior of 3 was 
investigated in detail. Initially, the metallation of calf thymus DNA by compound 3 
(75%, Figure 5- 6) was determined via FAAS.  
 
Figure 5- 6 Kinetic of chalcone-DAP-Pt binding to ctDNA in 0.01 M NaClO4.  
5.4.3 Changes of the DNA secondary structure  
 ctDNA was incubated with complex 3 at various rb values for 24 hours. 
Measured CD spectra were processed with respect to the blank and ctDNA molar 
concentration (10-4 M) (Figure 5- 7). The spectra showed that the intensity of the 
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positive CD band at 275 nm is increased as a consequence of Pt binding. Similarly, a 
decrease in negative CD band at 245 nm was observed (Figure 5- 7A). To avoid 
unspecific interaction unbound 3 was removed by dialysis against 0.01 M NaClO4.  
The concentration of ctDNA was determined and molar ellipticity (∆ε) spectra were 
compared with those of un-dialysed samples (Figure 5- 7B). A slight decrease was 
observed in both positive and negative CD bands. The decrease was more pronounced 
in the dialysed samples. The effects of dialysed samples (Figure 5- 7C) with 
increasing amount of bound 3 (ri = 0.007, 0.015, 0.03) were compared with non-
modified ctDNA. 
 
Figure 5- 7 A) CD spectra of pure ctDNA (10-4 M), chalcone-DAP-Pt (3) and of the blank medium (0.01M 
NaClO4) in millidegrees. B, C: Molar ellipticity spectra of ctDNA affected by chalcone-DAP-Pt (3) in 
millidegrees were converted to ∆ε  using the concentration of the DNA. B) Effect of rb = 0.009, 0.02 (3) on 
ctDNA. C) Effect of dialysed samples with increasing rb: 0.007, 0.015, 0.03. As a reference chalcone-free 
ctDNA was used.  
5.4.4 Melting temperatures of DNA modified with complex (3)  
 High temperature leads to the separation of the two DNA strands (DNA 
melting), which is accompanied by a hyperchromic shift. Thus, a melting point (the 
temperature at which half of the DNA is molten, Tm) can be assessed. Metal 
compounds bound to DNA influence the thermal stability of DNA. Metal binding can 
lead either to stabilization (higher Tm) or destabilization (lower Tm) of the double 
strand structure. Stabilizing factors include interstrand cross-linking and the effect of 
5. Effects of chalcone-DAP-Pt (3)  
5.4-99 
 
the positive charges. On the other hand, local distortions destabilize the double strand 
and lead to lower Tm. 
 Melting curves were recorded to characterize the DNA interaction of complex 
3. Dialyzed samples were used in these experiments. The spectra were recorded at 
high ionic strength (0.1M NaClO4) to reduce the stabilizing effect of the positive 
charge. Under these conditions the melting temperature of unmodified ctDNA was 84 
± 1°C. Chalcone-DAP-Pt (3) applied at the highest rb value decreased Tm to 78.2 ± 
0.9°C.  Hence, modification by 3 results in thermal destabilization of the double 
strand DNA structure. 
Table 5- 3 Melting temperatures (Tm) of DNA modified by 3 at various rb values in 0.1 M NaClO4, 0.5°C 
per minute at 260 nm. 
0.1M NaClO4 
rb Tm [°C] 
0 84.01 
0.015 80.12  
0.03 79.16  
0.05 78.20 
5.4.5 Mono- or bi-functional character of DNA-(3) adducts 
 Anticancer active Pt(II) complexes bind to DNA in a bi-functional way 
(Brabec, 2002; Bursova et al., 2005). Their antitumor efficiency is based on their 
ability to form bi-functional adducts (intra- or interstrand cross-links). Among the 
alterations of secondary structure such as local unwinding, bending, interstrand cross-
linking or local denaturation, the role of DNA unwinding is recognized to be 
potentially important in regulating replication and transcription functions through 
specific DNA-protein interactions. The elucidation of the binding character for 
chalcone-DAP-Pt is warranted. Therefore, suitable experiments on the role of 
Pt(II)complex 3 for the formation of DNA adducts were carried out.  
 An oligodeoxyribonucleotide duplex (21-bp) containing the single, site-
specific bifunctional adduct at G-residues of the central sequences 5’GGT/CCA was 
prepared and the formation of mono- and/or bifunctional adducts of 3 was identified 
by FPLC (Figure 5- 8). Completion of the reaction was determined from the elution 
patterns of the ion-exchange FPLC analysis of the top strands of the 5’GGT-3’ 
duplexes. The marked peaks relate to the platinated or unmodified products, 
respectively. The fractions corresponding to mono- and bifunctional adducts were 
purified by HPLC under the same conditions.  
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Figure 5- 8 The elution patterns of the ion-exchange FPLC analysis of the top strands GGT duplexes. The 
ologonucleotide was modified by chalcone-DAP-Pt. The peaks of bifunctional and monofuntional adducts 
are marked and were compared with the control peak (bottom profile).   
The 5’-ends of oligonucleotides were labelled by radioactive [γ-32P]ATP using T4-
polynucleotidekinase (T4-PNK) and purified by Sephadex G50. DNA-samples were 
analyzed on a 24% PAA gel under denaturating conditions (Figure 5- 9). The 
radioactive label was used to identify the band positions (left) in the agarose gel when 
21-mer oligonucleotides were cut out from the gel (right). Radioactive gel samples for 
bi-functional (B), mono-functional (M) adducts and control (C) oligonucleotides were 
shaken over-night to transfer radioactive bands into the water phase. DNA samples 
were precipitated, centrifuged and dissolved in water. The DNA concentration 
(spectrophotometry) and Pt concentration (FAAS) was determined and the values 
confirmed that one Pt atom corresponds to one oligonucleotide top strand. 
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Figure 5- 9 (B) Bi-, (M) Mono- functional adducts of GGT-oligonucleotide and control oligonucleotide (C) in 
a denaturated 24% PAA gel. Left: the radioactive labels were used to identify the positions of band on the 
gel when 21-mer oligonucleotides were cut out from the gel (right).  
 DMS footprinting of DNA (Brabec and Leng, 1993; Leng and Brabec, 1994) 
is used to verify the platination site at the N7 position of both neighboring guanines, 
which is not accessible to DMS, induces cleavage. Thus, platinated and nonmodified 
top strands (5’-end-labeled with 32P) were reacted with DMS. DMS methylates the N7 
position of guanine residues in DNA, producing alkali-labile sites (Maxam and 
Gilbert, 1980).  Following the methylation, the platinated samples were incubated 
with 0.2 M NaCN (2 hours, 55 °C) to remove the metal compound. 
 If guanine-N7 is coordinated to platinum, it cannot be methylated. The 
oligonucleotides were then treated with hot piperidine and analyzed by denaturing 
polyacrylamide gel electrophoresis. Two new bands appeared in the case of the 
nonmodified oligonucleotide. They correspond to fragments cleaved at the G sites. In 
the case of the monofunctional adduct, both bands are present, in a weaker fashion. 
This means that one portion of the oligonucleotides was cleaved at the G-1 site 
whereas the other portion was cleaved at the G-2 site. Both fractions cannot be 
separated under the applied conditions. In the case of the bifunctional adduct, no band 
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corresponding to cleaved oligonucleotides is present. This means that both guanine -
N7 sites are bound to Pt and thus no methylation and cleavage can occur. These 
results together with the finding that one Pt atom corresponds to one oligonucleotide 
strand indicate that one chalcone-DAP-Pt molecule was successfully coordinated to 
neighbouring guanine residues forming a 1,2-d(GpG) intrastrand cross-link (Figure 5- 
10). 
 
Figure 5- 10 Autoradiogram of the 24% PAA denaturing gel.  The oligonucleotides were 5’-end-labeled and 
submitted to DMS footprinting.  Lanes C – control, unmodified oligonucleotide. Lane M – monofunctional 
adduct of 3. Lane B – bifunctional adduct of 3. 
5.4.6 Interstrand-crosslink ability of chalcone-DAP-Pt (3) 
Cisplatin forms various types of interstrand and intrastrand cross-links (CLs) 
(Halamikova et al., 2007; Scovell and Collart, 1985). Cisplatin and platinum complex 
3 were compared in terms of their capacity to form interstrand cross-links in a 213-bp 
DNA fragment, which was obtained by linearization of pSP73KB plasmid DNA with 
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EcoRI. The samples were analyzed for interstrand CLs via agarose gel electrophoresis 
under denaturing conditions as described in the experimental section. Upon 
electrophoresis, the non-cross-linked strands of 213-bp DNA labelled with 32P at the 
3’-end migrated as a 213-mer single strand, whereas the high molecular interstrand 
cross-linked strands migrated more slowly. The intensity of the more slowly 
migrating band increased with the growing number of CLs induced by 3 (Figure 5- 
11). The radioactivity of the individual bands in each lane was measured to determine 
the fractions of non-cross-linked vs. cross-linked DNA. The frequency of interstrand 
CLs was calculated using the Poisson distribution from the fraction of non-cross-
linked DNA in combination with the rb values and the fragment size. While the 
interstrand CL frequency induced by cisplatin was calculated to be ca. 6 ± 0.5%, 
which is in agreement with previous results, (Brabec and Leng, 1993) the 
corresponding value for complex 3 was 58 ± 2.3%, i.e., ten-fold higher compared 
with cisplatin. 
 
Figure 5- 11 Electrophoretic autoradiograms of 3’-end 32P-labeled 213-bp fragments of linear pSP73KB 
plasmid DNA (2455 bp) on denaturing 1% agarose gels after incubation (24 h) with cisplatin (lane 1) at rb = 
0.001, or with complex 3 (lanes 2–5) at rb = 0.00001, 0.00003, 0.0002, 0.001. Lane C = control; ICL = 
interstrand cross-linked DNA; ss = single-strand DNA.  
5.4.7 Inhibition of RNA synthesis 
The preference of complex 3 towards distinct nucleotide sequences was 
investigated by a transcription-mapping assay.  
Cleavage of pSP73KB DNA by NdeI and HpaI restriction endonucleases yields a 
212-bp fragment (a substantial part of its nucleotide sequence is shown in Figure 5- 
12) that contains a T7 RNA polymerase promotor. In vitro RNA synthesis from this 
DNA template modified by complex 3 (rb = 0.02 or 0.03) can be prematurely 
terminated at or in the proximity of the sites where the platinum complex is 
coordinated to DNA bases (Figure 5- 12A). DNA lesions originating from bis-dentate 
coordination of platinum fragments can efficiently terminate RNA synthesis at the 
position of the defect whereas monodentate coordination of Pt fragments such as 
[PtCl(dien)]+ (dien=diethylenetriamine) is insufficient for the termination of RNA 
synthesis. The major stop sites, mainly guanine and adenine residues, were proven to 
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be roughly identical for complex 3 and cisplatin (Figure 5- 12B). These results 
suggest that complex 3 preferentially binds DNA at GG and AG sites. 
 
Figure 5- 12 Inhibition of RNA synthesis by T7 RNA polymerase on the NdeI/HpaI fragment of pSP73KB 
plasmid DNA containing adducts of complex 3 or cisplatin. A: Autoradiograph of 8% PAA/8M urea 
sequencing gel; lanes: control (non-platinated template); cisplatin at rb 0.01; A, U, G and C, chain-
terminated marker RNAs; and complex 3 at rb 0.03 and 0.02 (determined by FAAS). Numbers correspond 
to the nucleotide sequence numbering of B. B: Schematic diagram of the NdeI/HpaI fragment sequence, 
arrow indicates the promoter for T7 RNA polymerase, grey dots indicate the sites corresponding to the stop 
signals in A, numbers correspond to the nucleotide numbering in the sequence map of the pSP73KB 
plasmid. 
5.5 Chalcone-DAP-Pt (3) resistance 
5.5.1 Interference with ABC transporter 
 The role of efflux proteins in the detoxification of cancer cells is being one the 
main interest of pharmaceutical studies. The interaction of chalcone-DAP-Pt (3) with 
drug transport proteins like ABCB1 (P-gp) (Hyde et al., 1990; Simstein et al., 2003; 
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Smith et al., 2001) or BCRP (Borst et al., 1997) was investigated in a substrate- or 
inhibitor-like fashion.  
5.5.1.1 Chalcone-DAP-Pt efflux via P-glycoproteins  
 P-gp overexpressing KBv1+Vbl cervix carcinoma cells (Schwab et al., 2003) 
alongside their wild type parent cells were treated with 3 in the presence of calcein-
AM (Figure 5- 13).  
 
Figure 5- 13 Calcein-AM assay: Interference of chalcone-DAP-Pt (3) with P-gp. Inhibition (in %) of P-gp 
transporters in KBv1 and KBv1+Vbl cells by 50 µM of chalcone-DAP-Pt (3) (dark blue bars) relative to the 
inhibition of cells by verapamil (hatched bars) after 15 min exposure. White bars: negative control.  
The inhibition of P-gp allows cleavage of intracellular calcein-AM forming 
fluorescent calcein. As a positive control, the fluorescence intensity of KBv1+Vbl cells 
treated with 50 µM of the clinically established chemosensitiser verapamil (Schwab et 
al., 2003; Sharom, 1997) was set to 100 %. Surprisingly, wild type KBv1 cells 
reached only ~55% of the calcein fluorescence of the resistant KBv1+Vbl cells. 
Possibly, they have other ways to eliminate calcein-AM or calcein, which is not 
without precedence (Marchan et al., 2008; Oku et al., 1995).  
Treatment with chalcone-DAP-Pt (3) led to almost the same absolute fluorescence 
intensity of calcein in both resistant and wild type cell lines. A similar effect was 
observed for chalcone (1) (Zoldakova, 2010). 
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5.5.2 DNA repair  
DNA-damage caused by chemotherapeutics such as cisplatin can be removed by 
DNA repair mechanisms leading to tumor cell survival (Brabec, 2002). In order to 
determine how readily the DNA damage induced by platinum complex 3 is repaired 
we used an assay that quantifies the extent of DNA repair synthesis by tumor cell 
extracts (Figure 5- 14).  
 
Figure 5- 14 DNA repair of pUC19 pre-treated with cisplatin or 3. Top row: untreated pBR322 DNA 
(control). Repair efficiency is given by incorporated [α-32P] dATP. Samples repaired by repair-proficient 
extracts of HeLa cells (lanes 1–4) and melanoma 518A2 cells (lanes 5–8). Cisplatin: rb ≈ 0.01; 6: rb ≈ 0.005, 
0.01, 0.015. 
The efficiency of cell-free extracts (CFE) of repair-proficient HeLa cells or 518A2 
melanoma cells to repair defects in pUC19 plasmid (2686 bp) globally modified by 3 
at rb = 0.005–0.015 or cisplatin at rb = 0.01 was ascertained by measuring the amount 
of incorporated radiolabeled nucleotide. Figure 5- 14 shows that DNA repair 
synthesis in the plasmid modified by 3 was considerably lower than that found for 
cisplatin. This effect was more pronounced in the CFE of melanoma 518A2 cells. 
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5.5.3 Reaction of chalcone-DAP-Pt (3) with glutathione 
Glutathione (GSH) plays a key role in the metabolism and mechanism of 
anticancer action of platinum drugs (Townsend and Tew, 2003). Depletion of GSH 
levels usually leads to an enhanced cytotoxicity of cisplatin (Fuertes et al., 2003). 
The reactions of GSH with complex 3 and cisplatin were monitored via the 
absorbance at 280 nm (Ishikawa and Ali-Osman, 1993). The absorption band at this 
wavelength is indicative of the binding interaction of platinum complexes with the 
thiolate group of GSH. The progress of the reactions was slow; the reactions were 
finished after 24 hours (Figure 5- 15). The reaction between GSH and nic-Pt was the 
fastest whereas 3 reacted slowly. The affinity of 3 to GSH was even lower than that of 
cisplatin, which bodes well for future tests against cisplatin-resistant tumors having 
high GSH levels. Complex 3 was shown as a poor GSH-binder compared to cisplatin. 
Moreover, its cytotoxicity was also higher (IC50 ~0.7 µM) in GSH-rich HCT-116 cells 
compared with cisplatin (IC50 ~17 µM).  
 
Figure 5- 15 Time-dependent monitoring (relative absorbance at 280 nm) of the reaction of two equiv. GSH 
(3.33 mM) with 3 (triangles) or cisplatin (circles) in 1 mL of PBS (pH 7.4) at 37°C. Curves were obtained 
from mono-exponential fitting. The apparent rate constants were 0.2 and 0.38 h–1 for 3 and cisplatin, 
respectively. 
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5.6 Conclusion 
 The new chalconyl dichlorido(2,3-diaminopropionate)Pt(II) complex 3 differs 
significantly and advantageously from cisplatin. Its superior in vitro anticancer 
activity against melanoma 518A2, leukemia HL-60 and colon carcinoma HCT-116 
cells, its capacity to platinate DNA to a larger extent inflicting much greater DNA 
unwinding and a greater amount of interstrand cross-links which are less amenable to 
DNA repair, and its robustness against deactivation by S-nucleophiles like glutathione 
make complex 3 a promising candidate for further anticancer tests. The decisive role 
of the diamino ligand leaves room for future fine-tuning and optimization.  
 Some similarities between 3 and its analogue chalcone-Pt (2) were observed 
concerning the morphological changes inflicted in 518A2 melanoma cells, which 
were quite different from those caused by cisplatin. Mode of action of complex 3 
synergistically combines the traits of DNA-binding platinum drugs and tubulin-
binding chalcones.  
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Effects of retinoic acid conjugate of illudin M (5) 
 This study is focused on the selective impact of a new retinoic acid conjugate 
(5) compared to parent illudin M (4, Figure 6- 1). Illudin M from Omphalotus 
olearius cultures was isolated according to literature procedures (Knauer et al., 2009; 
Schobert et al., 2008). Its ester with retinoic acid was synthesized via Yamaguchi 
esterification (Biersack, 2009). 
 
Figure 6- 1 Structure of illudin M (4) and of its retinoate (5). 
6.1 Inhibition of cell growth - MTT assay 
The anti-proliferative activity of compounds 4 and 5 was evaluated in a series of 
different (non-) malignant neuronal cells and multi-drug resistant tumor cells.  
6.1.1 Neural derived cell lines 
 In the neural cells compound 4 exhibited activities in the range of IC50 = 50 
nM (NE-4C neuroectodermal stem cells) to 400 nM (C6 rat glioma). Contrary, the 
retinoid conjugate 5 revealed excellent selectivity towards U87 human glioblastoma 
and NE-4C stem cells compared with mouse neuron and astrocytes and IC50 values 
still lying in the clinically relevant low one-digit micromolar range (2-3 µM).  
Table 6- 1 Inhibitory concentrationsa IC50 of compounds 4 and 5 in neural derived cells. 
Cell line neurons astrocytes NE-4C C6 U87 
24 h (4) 600 ± 120 nM 1.5 ± 0.4 400 ± 98 nM 1 ±0.3 629 ± 44 nM 
48 h (4) 190 ± 40 nM 200 ± 30 nM 50 ± 16 nM 400 ± 60 nM 130 ± 27 nM 
24 h (5) 25.5 ± 1.1 45 ± 2.4 7 ± 3.2 40 ± 4.3 37.3 ± 3.2 
48 h (5) 14 ± 2.2 33 ± 3.6 2 ± 1.2 12 ± 1.3 2.7 ± 0.7 
Compound 5 is far less toxic to neurons than the parent compound illudin M. The 
toxicity of conjugate 5 against mouse neurons is 40-70 times lower compared with 
illudin M (4) and a similar effect is observed in astroglia cells (Figure 6- 2).  
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Figure 6- 2 Dose-response curves of neurons and astroglia cells after treatment with illudin M (4) and RA 
conjugate 5 for 48 h. Neurons: 4 (open circles), 5 (open squares). Astroglia: 4 (closed circles), 5 (closed 
squares).  
 Illudin M caused cytotoxicity at the nanomolar concentration in all tested 
neural cell lines, which is an indication of very low selectivity. The retinoic acid 
derivative 5 was less cytotoxic against neurons and astroglia cells even after long-
time exposure. These results are in line with the fact that RA is an inhibitor of Jun N-
Terminal Kinase (JNK) (Lee et al., 1999). Illudin derivatives such as irofulven are 
known to induce apoptosis by a mechanism mediated via activated JNK and ERK 
kinases (Wang et al., 2002). The putative inhibition of JNK-signaling in neurons 
treated with RA or derivative 5 could probably postpone eventual toxic effects of 4.  
6.1.2 Tumor cells expressing ABC-transporters  
 Illudin M also showed high activity in KBv1+Vbl cervix carcinoma cells 
expressing Pgp transporters, however, its activity was reduced about 5-fold in the 
other multi-drug resistant MCF-7+Top breast cancer (BCRP) and HT-29 colon cancer 
(MRP-1, MRP-3) cells. Conjugate 5 showed less growth inhibiting activity than 4 
lying in the low one-digit micromolar range (Table 6- 2). However, it showed a 
different activity profile and appeared to be especially active in the MDR cell line 
MCF-7+Top reaching the activity of free illudin M in the two-digit nanomolar range.  
This is a significant result as BCRP transporters are assumed to contribute to cancer 
stem cell resistance and inefficient trespassing of the blood brain barrier (Robey et al., 
2007). In addition, this breast cancer cell line depends on estrogen signaling 
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(Levenson and Jordan, 1997) which might explain the particularly high activity of the 
retinoid 5 in these cells since retinoids also interfere with estrogen receptor-based 
pathways (Hua et al., 2009).  
Table 6- 2: Inhibitory concentrations (aIC50 in µM) of illudins (1,2) in various ABC-transporter expressing 
cells. 
Cell line MCF-7 MCF-7+Top KBv1 KBv1+Vbl HT-29 
24 h (4) 1 ± 0.0059 0.35 ± 0.13 51 ± 7.5 nM 32 ± 4.6 nM 1.5 ± 0.6 
48 h (4) 48 ± 4.9 nM 50 ± 10 nM < 24.4 nM 16 ± 1.0 nM 60 ± 8 nM 
24 h (5) 32.7 ± 1.3 2.5 ± 0.6 4.1 ± 0,16 1.6 ± 0.4 38 ± 4 
48 h (5) 2.1 ± 0.20 80 ± 15 nM 2.3 ± 0.32 1.2 ± 0.13 4 ± 1.3 
aValues are derived from concentration-response curves obtained by measuring the percentual 
absorbance of vital cells relative to untreated controls (100%) after 24 and 48 h exposure of selected 
cells to test compounds in the MTT assay. Values represent means of at least three independent 
experiments ± standard deviation.  
6.1.3 Cancer cells  
 HL-60 leukemia and 518A2 melanoma cells are examples for drug sensitive 
suspension and adherent tumor cells, respectively. Both cell lines were found to be 
extremely sensitive (nM) towards illudin M (4) already after 24 h of incubation. The 
cytotoxicity of 5 for both cell lines was randomly 100-times lower (Table 6- 3). 
Table 6- 3 Inhibitory concentrationsa (IC50 in µM) of compounds 4, 5 when applied to 518A2 melanoma and 
HL-60 leukaemia cells. 
Cell line 24 h (4) 48 h (4) 24 h (5) 48 h (5) 
HL-60 70 ± 21 nM 10 ± 5 nM 6.8 ± 2.8 4.5 ± 1.1 
518A2 35 ± 11 nM 19 ± 8 nM 5.0 ± 0.26 4.0 ± 0.75 
aValues are derived from concentration-response curves obtained by measuring the percentual 
absorbance of vital cells relative to untreated controls (100%) after 24 and 48 h exposure of selected 
cells to test compounds in the MTT assay. Values represent means of at least three independent 
experiments ± standard deviation.  
 These results were in line with already published data for 4 (Kelner et al., 1987). 
All-trans retinoic acid (RA) is known to play a major role in regulating the growth 
and differentiation of a wide variety of normal and malignant cell types and can 
inhibit cell proliferation and induce differentiation and apoptosis at the cellular level 
(De Luca, 1991). The ability of retinoids to regulate cellular processes in vivo is 
unfortunately associated with a high incidence of undesirable side effects (Boehm et 
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al., 1995). For comparison, the apoptosis inducing activity of RA was above 50 µM in 
HL60 cells after 24 h (Simoni et al., 2001). The RA-Illudin showed an enhanced 
cytotoxic activity in HL60 cells (IC50 ~7 µM).  
6.2 Cellular and sub-cellular observations 
6.2.1 Altered cell-shape in neural cells  
 Elevated RA signaling triggers axon outgrowth and, consequently, nerve 
regeneration in the adult (Maden, 2007). All-trans retinoic acid (RA) and other active 
retinoids are generated from vitamin A (retinol), but key aspects of the signalling 
pathways required to produce active retinoids remain unclear (Gudas and Wagner, 
2010). In order to induce neuron differentiation in K11 cells 3 mM RA was used 
according to the procedure described in the experimental section. Figure 6- 3 shows 
developed neural K11 cells together with some undifferentiated cells.  
 Microscopic changes of K11 cells were observed after exposure to illudin M 4 
and 5. The neural K11 network showed complete disruption of neural connections and 
its bodies after treatment with 4 (10 µM). Only a few undifferentiated K11 cells 
remained. A similar result has been observed after treatment with a smaller amount of 
4 (1 μM). After fixation only cell debris remains and the neural network lost its 
integrity completely. Contrary, treatment with the retinoic acid ester 5 showed 
benefits of neural development at both concentrations (Figure 6- 3).  
In order to evaluate the selectivity of illudins 4 and 5 towards U87 glioma cells we 
investigated a co-culture of neural cells with U87 cells and treated this culture with 
compounds 4 or 5.  
The isolated murine neurons were grown on IBIDI dishes and after 5 days a sample of 
glioma U87 cells (~25 000 cells) was added into the neural culture. After 12 hours, 
illudins 4 and 5 (1 µM) were added and the response of the different cells was 
monitored (15 – 96 hours).  
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Figure 6- 3 Top figures show microscopic observations of K11 cells treated with 3 mM retinoic acid. Middle 
and bottom figures show K11 cells treated with illudin M (4) and RA-illudin (5) for 24 hours. 
In the control samples the number of proliferating U87 cells increased with time and 
overgrew the diminishing number of differentiating neurons. The neuronal bunches 
are marked by arrowheads (Figure 6- 4). The neurons and U87 cells incubated with 
illudin M (4) showed cellular fragmentation already after 15 h, after 48 h only cell 
debris was visible. Incubation of the co-culture with RA conjugate 5 revealed a higher 
neuronal differentiation degree after 15 h compared with the control cells. After 
treatment for 48 h neurons were still present in the culture, yet, the number of U87 
cells was reduced distinctly compared with the control sample and with the situation 
after 15 h. This shows vividly the selective antitumor activity of compound 5. 
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Figure 6- 4 Co-cultivation of neural cells with U87 glioma cells in the absence or presence of 1 µM of illudin 
M (4) or RA-illudin (5). 
6.2.2 Altered cell-shape in cancer cells  
 The effects of illudins 4 and 5 on the structure, development and mobility of 
cancer cells were monitored. A monolayer of tightly attached KBv1+Vbl cells was 
observed initially. The untreated control cells were spread and underwent merely 
negligible morphological changes. Only a few cells were rounded which were 
probably dividing. In contrast, exposure of KBv1+Vbl cells to illudin M 4 led to a 
decreased cell number after 24 hours and to an enhancement of motility and cell 
shrinking (Figure 6- 5). A very similar behaviour of KBv1+Vbl cells was observed 
upon incubation with complex 5.  
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Figure 6- 5 Untreated KBv1+Vbl cervix carcinoma cells (control); middle: rounded, partially detached cells 
with increased motility after 24 hours of incubation with 50 nM of 4; right: similar effects upon treatment 
with 2 μM of complex 5. The cells were not fixed. 
 
Figure 6- 6 Time lapse microscopic observation of 518A2 cells with time after treatment (10 μM) with 
illudin M (4) and its retinoate derivative (5). 
 Time-lapse recording of the relatively less sensitive 518A2 cells also revealed 
this cell-rounding phenomenon (Figure 6- 6). After treatment with 4 cells slowly 
detached and shrinked. A slower effect was observed after treatment with 5, the cells 
readily dissociated from the monolayer and changed their form from flat to spherical. 
6.2-116 
 
6.2.3 Microscopic observations of 518A2 cells by Giemsa staining 
 Effects of Illudin M (4) and its retinoate derivative 5 were monitored for 
internucleosomal DNA cleavage after staining with Giemsa dye (Figure 6- 7). The 
test compounds were applied at a concentration of 10 µM for 12 h or 24 h and the 
effect on the proliferation as well as on the attachment of the adherent cells was 
analyzed. The total number of 518A2 melanoma cells increases in the untreated 
negative control due to normal cell proliferation. They showed typical cell-shape, 
were regularly spread. The nuclei revealed condensed chromatin visible as dark blue 
dots and they were well defined by their nuclear envelopes. Cells treated with 4 led to 
a reduced cell number after 12 hours and 24 hours. Completely destroyed (lysed) cells 
could be identified, which are characteristic of necrosis. In the Giemsa assay the 
applied concentration of 4 was ~200 times higher than its IC50 value. Thus, the strong 
cytotoxic effect was expected to appear earlier (3 hours data shown in (Zoldakova and 
Münzner, 2009Advisor: Zoldakova Miroslava)). 
 
Figure 6- 7 518A2 cells were treated with illudins 4 and 5 (10 µM) and visualized by Giemsa stain.  
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  Treatment with retinoate 5 resulted in reduced cell numbers compared with 
the untreated negative control and promoted the detachment of the cells from the glass 
slides (24h). After 12 hours still some cells were alive probably due to a more 
controlled cytotoxicity of 5. Very late apoptotic or dead cells were sprawled out 
showing purple or totally missing cytoplasm. 
6.2.4 Immunostaining of β-tubulin in treated neurons  
 Retinoic acid (RA) is involved in the induction of neural differentiation, motor 
axon outgrowth and neural patterning (Maden, 2007; Schlett and Madarasz, 1997). 
Elevated RA signalling in the adult triggers axon outgrowth and nerve regeneration 
(Maden, 2007). After immunocytochemical staining detailed analyses of the 
morphological changes initiated by the illudins 4 and 5 after 48 hours were carried out 
using primary neurons and astrocytes (Figure 6- 8A, Figure 6- 9).  
Antibodies to astrocyte-specific GFAP intermediate filaments (glial fibrillary acidic 
protein) were employed to visualize the astroglial cells. Anti-mouse neuron specific 
βIII-tubulin labelling was used to identify tubulin filaments. The micrographs showed 
that both types of filaments, β-tubulin (in green) and GFAP (in red), were dismissed 
upon treatment with illudin M 4 (Figure 6- 8A, Figure 6- 9).  
The completely opposite behaviour was observed after treatment with RA-conjugate 
5. A combined treatment of RA and 4 resulted in well-defined βIII-tubulin level, 
which was confirmed by ELISA (6.2.4.1). However, decreased intensity of GFAP 
fluorescence was observed after combination of RA with 4 similar to effect after 
treatment with compound 4 alone. Contrary, an effect comparable to RA (positive 
control) was monitored with compound 5, i.e., it helps neurons to develop well 
(Figure 6- 8B).  
6.2.4.1 ELISA measurement of βIII-tubulin  
 The levels of βIII-tubulin after treatment with illudins 4 and 5 give a similar 
result (Figure 6- 8C). While compound 5 slightly promotes neuronal growth, illudin 
M is slightly toxic at 1 µM concentration. In addition, illudin M does not preclude the 
effect of RA on neuronal growth.  
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Figure 6- 8 Microscopic observation of murine neurons (DIV16/18) after 48 h incubation in the absence or 
presence of 4 or 5 (0.1-1 µM). Primary neurons were visualized by specific immunostaining. Blue: nuclei 
stained with DAPI (4',6-diamidino-2-phenylindole); green: tubulin cytoskeleton stained with βIII-tubulin 
specific antibody; red: glial fibrillary acidic proteins (GFAP). The pictures were taken with a fluorescence 
microscope (Zeiss Axiovert 200M). B: Time lapse recording of neurons incubated with 5 (10 µM). The 
picture is taken after treatment for 8 hours. C: Levels of βIII-tubulin after 24 h exposure to different 
concentrations of illudin M (4, grey columns), RA-illudin (5, black columns) or illudin M + RA (hatched 
columns). Control – untreated neurons (set to 100%). Values and standard deviations are means of three 
independent experiments.  
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Figure 6- 9 Immunoflourescence staining of murine neurons (DIV16/18) after 48 h incubation with illudins 
4 and 5.  
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6.3 Single cell DNA damage monitoring by comet-assay  
 A large number of agents bind to duplex DNA in a covalent or non-covalent 
fashion. An important technique for studying the interaction between a drug and DNA 
is the electrophoretic mobility shift assay (EMSA). However, no band shift was 
observed after incubation with 4. McMorris et al. (1989) discovered that the extreme 
toxicity of illudin M is due to the alkylating ability in reaction with various 
nucleophiles at neutral or low pH (McMorris et al., 1989; McMorris et al., 1992; 
McMorris et al., 1996).  
 Recently, the comet assay has become a widely accepted and valuable method 
to determine DNA damage in cells and to reveal the nature of this damage. This was a 
reason to establish alkaline comet in this work (Figure 6- 10).  
 
 
Figure 6- 10 Scheme of critical steps in the alkaline (pH >13) comet assay. The basic steps of the assay 
include single cell suspension, slide preparation, lysis of cells to liberate DNA, alkaline exposure to obtain 
single-stranded DNA and express alkali-labile sites as single strand breaks, electrophoresis, neutralisation, 
DNA staining, comet visualisation and scoring. 
A suitable electrophoretic equipment was designed and an optimized comet assay was 
developed after various steps of improvements (Zoldakova and Rymarczyk, 2009). 
HL60 cells were incubated with 1 μM of illudin M (4). The control sample was 
treated without compound 4. The alkaline (pH >13) comet assay includes single cell 
investigations, which were analyzed in prepared gel-slides. The lysis of cells was 
performed under alkaline conditions to obtain single-stranded DNA. Gel-samples 
6. Effects of the Illudin M (4) and its derivative RA-Illudin (5)  
6.4-121 
 
were neutralized followed by staining with SYBR-Gold dye. Comets were visualized 
by fluorescence microscopy and the free-software TriTek CometScoreTM version 1.5 
was used for comet analysis. 
Untreated (control) cells do not suffer from any DNA damage (Figure 6- 11). The 
DNA damage caused by illudin M was expressed in various DNA-tail lengths. 
 
Figure 6- 11 Images of comets with various tail lengths. Control cells show no tail or only a very short tail 
(white arrow). Illudin M (4) treated cells gave single strand breaks (damaged DNA) in various stages, 
resulting into longer tails (arrows). 
 The fragments of damaged chromosomal DNA were released and pulled 
towards the anode and this affected the tail-length. Cells with DNA damage appeared 
as comets with small heads and very long tails. The total level of DNA fluorescence 
represented 100% and the part distributed within the tail was calculated. Thus, control 
cells were characterized by only 20 ± 3% of DNA in the tail. After 5 minutes of 
incubation with compound 4 (1 μM) 24 ± 14% single-strand breaks appeared, and 
already 50 ± 18 % single-strand breaks appeared after 10 minutes. 
6.4 Intracellular calcium concentration 
 The intracellular concentration of Ca2+ after treatment with illudin M (4) and 
RA conjugate 5 in 518A2 and HL60 cells was investigated as a sign for apoptosis 
induction in these cells (Table 6- 4). The level of the intracellular Ca2+ concentration 
in cells is usually maintained at about 10-100 nM by mechanisms including transport 
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via voltage-dependent and voltage-insensitive channels, controlled release from the 
endoplasmic reticulum (ER), and cytosolic Ca2+ buffering (Sergeev, 2005). Aside the 
regulation of vital cell functions, Ca2+ signalling was also found to play an important 
role in promoting cell death (Orrenius et al., 2003; Sergeev, 2005). A distinctly 
enhanced intracellular Ca2+ concentration was observed in the HL-60 leukemia cells 
after 24 h of exposure to compounds 4 and 5 reaching levels higher than 200 nM. This 
high Ca2+ level is very likely associated with apoptosis of these cells, which usually 
leads to increased Ca2+ levels (200-500 nM). 
Table 6- 4 Intracellular Ca2+ concentrationa of 518A2 melanoma and HL-60 leukemia cells after incubation 
with compounds 4 and 5 (24 h). Concentrations in 518A2 cells: 4 = 0.05 μM, 5 = 5.00 μM; in HL-60 cells 4 = 
0.1 μM, 5 = 7.0 μM. 
Ca2+ [nM] 518A2 HL60 
Control cells 73.1 ± 8.1 52.3 ± 9.2 
Illudin M (4) 111.0 ± 14.0 293.3 ± 4.7 
RA-Illudin (5) 82.4 ± 8.9 239.6 ± 9.4 
a Values represent means and standard deviations of three independent experiments 
6.5 Interference with ABC transporters 
The role of efflux proteins in the detoxification of cancer cells represents one the 
main interests of pharmaceutical studies. The interaction of compounds 4 and 5 with 
pertinent drug efflux proteins like ABCB1 (P-gp) (Hyde et al., 1990; Simstein et al., 
2003; Smith et al., 2001) or BCRP (Borst et al., 1997) was investigated in a substrate- 
or inhibitor-like fashion.  
6.5.1 Illudin efflux via P-glycoproteins  
 P-gp expressing KBv1+Vbl cervix carcinoma cells (Schwab et al., 2003) were 
treated with illudins 4 and 5 in the presence of calcein-AM (Figure 6- 12). Illudin M 
(4) did not surpass the fluorescence intensity of calcein in the negative control. In 
contrast, conjugate 5 was more effective and its relative fluorescence reached almost 
80% of the activity of verapamil. Wild type KBv1 cells gave very similar results. 
Possibly, they possess different ways to eliminate calcein-AM or calcein, which is not 
without precedence (Marchan et al., 2008; Oku et al., 1995).  
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Figure 6- 12 Calcein-AM assay: % inhibition of P-gp drug transporters in KBv1+Vbl and KBv1 cells by 50 
μM of illudin M 4 (grey bars) and RA-Illudin 5 (black bars) relative to the inhibition of P-gp by verapamil 
(hatched bars) after 15 min exposure. White bars: negative control.  
6.5.2 Illudin efflux via BCRP proteins 
 MCF-7 breast carcinoma cells express BCRP drug transporters. Treatment 
with topotecan (550 nM over 40 generations) leads to overexpression of this protein 
(MCF-7+Top cells). The mitoxantrone assay is based on the active export of the 
fluorescent anticancer drug mitoxantrone by BCRP transporters. The effects of 
illudins 4 and 5 compared with the specific BCRP inhibitor fumitremorgine C (Oku et 
al., 1995) and with a negative control treated only with mitoxantrone was investigated 
(Figure 6- 13). Similar to the calcein-AM assay, compound 4 did not reveal any 
inhibition. Here, conjugate 5 showed only a slight inhibition in comparison with the 
negative control. 
 
Figure 6- 13 Mitoxantrone assay: % inhibition of BCRP drug transporters in MCF-7+Top and MCF-7 cells 
by 10 μM of illudin M 4 (grey bars) and RA-illudin 5 (black bars) relative to fumitremorgine C (hatched 
bars) after 30 min exposure. White bars: fluorescence of cells treated with mitoxantrone (negative control).   
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6.6 Conclusion  
 All-trans retinoic acid (RA) shows antitumor effects against various cancers. 
For instance, exposure to 1 µM of retinoic acid caused effects progressing linearly in 
a time-dependent and dose-dependent fashion, and after treatment for 7 days cell 
growth was inhibited by approximately 65% (Lotan and Lotan, 1980). The new 
illudinyl retinoate 5 is much more effective and we were able to observe comparable 
effects already after 48 hours. Compound 5 is far less toxic to neurons, more cancer 
selective and more cell line-specific than the parent compound illudin M. Though 
illudins are highly efficacious against various tumors, their extreme toxicity precluded 
clinical applications (Kelner et al., 1987; Kelner et al., 1990). The toxicity of 
conjugate 5 against mouse neurons is 40-70 times lower compared with illudin M (4). 
Neural stem cells (NE-4C) are most sensitive; yet, the U87 glioma cells appeared to 
be more sensitive to compound 5 after prolonged exposure than primary neurons or 
astrocytes. Theses results are in line with the fact that RA is an inhibitor of Jun N-
Terminal Kinase (JNK) (Lee et al., 1999). Illudin derivatives, such as irofulven, are 
known to induce apoptosis by a mechanism mediated via activated JNK and ERK 
(Lotan and Lotan, 1980). The putative inhibition of JNK-signaling in neurons treated 
with RA or derivative 5 could probably postpone eventual toxic effects of 4. 
Compound 5 is at least 5 times more active against cancer cells than against neurons. 
 MDR cells expressing Pgp or BCRP proteins revealed an enhanced sensitivity 
towards 5 (48 hours ~1,2/0.08 µM). Indeed, an inhibition of P-gp drug transporters 
was confirmed only for conjugate 5. Enhanced Ca2+ concentrations were observed in 
HL-60 leukemia cells treated with compound 5. Together with the cell rounding and 
retraction of pseudopodes in KBv1+Vbl cervix carcinoma and in 518A2 melanoma cells 
visible via time-lapse microscopy, these are all hints at an induction of apoptotic cell 
death by conjugate 5 (Lotan and Lotan, 1980).  
 
 
 
 
 
7. Summary  
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Summary 
 This thesis presents a study on novel chemotherapeutics based on naturally 
designed scaffolds. The cytotoxicity of promising pharmaceutical compounds was 
tested on various cells of neural and/or cancerous origin, monitoring their specificity, 
re-growth retardation and mechanism of apoptosis induction. The proposed drug 
uptake was analysed using specific inhibitors to disable certain transporters/carriers. 
Changes in the shapes of cellular and sub-cellular components resulting from drug 
treatment were observed by light microscopy, immune-fluorescence microscopy, 
time-lapse recording microscopy and transmission electron microscopy. The apoptotic 
signals, increased cellular activity of caspase-3 or redundant calcium level, were 
monitored during drug incubation. Because DNA-degradation plays an important role 
in apoptosis, DNA-drug interactions affecting chromosomal or plasmid DNA were 
investigated from various perspectives. Since resistance is a constricting factor for 
drug efficiency, the interaction of the drugs with glutathione and various efflux 
transporters were analysed.  
 Many of the methods in this thesis were not previously in use in the 
department of organic chemistry. Therefore, the methods were optimised or 
performed in international collaboration during a short-time fellowship in the 
Laboratory of Cellular and Developmental Neurobiology, Institute of Experimental 
Medicine of the Hungarian Academy of Sciences, Budapest (2 months) and in the 
Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno (4 months). 
7.1 Chalcone (1) and its Pt-derivatives (2, 3) 
 The combretastatin A4 analogs chalcone 1 and chalcone-Pt 2 were found to be 
highly active against a variety of cancer cell lines while differing in their apoptosis 
induction and long-term regrowth retardation (Schobert et al., 2009).  
 Chalcone-Pt 2 was more tumour-specific than parent chalcone 1 in neural 
cells. This was apparent from the IC50 ratios (48 h) against primary astrocytes vs. 
human glioma cells U87 (>7000 for complex 2; 55 µM for compound 1). The cellular 
uptake of chalcone-Pt 2, like that of oxaliplatin, occurred mainly via organic cation 
transporters (OCT-1/2; ~32%) and copper transporter related proteins (Ctr1; ~24%), 
whereas that of chalcone 1 was dependent on endocytosis (~80%). In tubulin-rich 
neurons and 518A2 melanoma cells, complex 2 disrupted microtubules and actin 
filaments. Cancer cells treated with 2 could repair the cytoskeletal damage, but ceased 
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to proliferate and perished. Complex 2 was particularly cytotoxic against P-gp-rich 
cells. It acted as a substrate for ABC-transporters of types BCRP, MRP3, and MRP1 
and was therefore less active against the corresponding cancer cell lines. Complex 2 
arrested the cell cycle of the melanoma cells in G1 and G2/M phases. Massive 
fragmentation of the Golgi apparati of these cells was observed using TEM during 
incubation with complex 2 but not with 1. Unlike chalcone 1, the platinum complex 2 
is highly cell-line specific, and is taken up via cell-controlled transporters and induces 
apoptosis by triggering multiple targets. 
Chalcone-DAP-Pt 3 was tested for antitumour activity, DNA binding, and glutathione 
binding. In MTT-tests against cells of melanoma 518A2, complex 3 inhibited 
leukemia HL-60 and colon carcinoma HCT-116 more efficiently than 2 and 1. The 
morphology of tumor cells treated with the chalcones 1, 2, and 3 differed from that of 
cells exposed to colchicine. While complex 3 is only 70% water-soluble, it binds to 
the same DNA sites as cisplatin. In contrast to cisplatin, DNA binding of 3 caused a 
larger DNA unwinding angle and ten times more interstrand cross-links (~60%). 
These results were confirmed by a DNA-footprint experiment, where it was found 
that one chalcone-DAP-Pt molecule was coordinated to neighbouring guanine 
residues and formed a 1,2-d(GpG) intrastrand cross-link. In addition, DNA lesions 
due to binding of 3 were repaired by the melanoma cellular extract only half as 
efficiently as cisplatin-DNA adducts. Complex 3 also showed a much lower affinity 
towards the known platinum detoxifier glutathione. 
7.2 Illudin M (4) and its retinoate (5) 
 The fungal metabolite illudin M 4 is indiscriminately cytotoxic in cancer and 
non-malignant cells. Its retinoate 5 showed a greater selectivity for the malignant 
cells, especially in a cerebral cortex. Illudin M killed malignant glioma cells as well 
as primary neurons and astrocytes at similarly low concentrations by destroying their 
microtubule and glial fibrillary acidic protein (GFAP) networks. In contrast, the ester 
5 was distinctly more cytotoxic in highly dedifferentiated U87 glioma cells than in 
neurons, which were even stimulated to enhanced growth. This was also observed in 
co-cultures of normal neurons with U87 cells, where conjugate 5 singled out the latter 
and eventually killed them by induction of differentiation. Hence, illudin M retinoate 
5 appears to be a promising drug candidate to treat glioma stem cells. 
7. Zusammenfassung 
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Zusammenfassung 
 Diese Arbeit stellt eine Studie über neue Chemotherapeutika dar, welche 
ausgehend von Naturstoff-basierenden Strukturen dargestellt worden sind. Die 
cytotoxische Wirkung der vielversprechendsten Verbindungen wurde an 
verschiedenen Zellen neuralen und/oder malignen Ursprungs getestet, und ihre 
Spezifität, Wachstumshemmung sowie Mechanismen der Apoptoseinduktion wurden 
analysiert. Mutmaßliche Wege der Wirkstoffaufnahme wurden durch Einsatz 
spezifischer Hemmer bestimmter Transport- und Carrierproteine untersucht. 
Wirkstoff-induzierte morphologische Veränderungen zellulärer und sub-zellulärer 
Strukturen wurden Licht-mikroskopisch, Immunfluoreszenz-mikroskopisch, 
Zeitraffer-mikroskopisch und Transmissionselektronen-mikroskopisch beobachtet. 
Durch einzelne Wirkstoffe hervorgerufene apoptotische Signale wie verstärkte 
Caspase-3-Aktivität oder erhöhter Calciumspiegel wurden analysiert. Da die DNA-
Schädigung und der DNA-Abbau eine wichtige Rolle zur Apoptoseeinleitung und 
auch während der Apoptose spielt, wurden DNA-Wirkstoff-Wechselwirkungen 
bezüglich chromosomaler und Plasmid-DNA von verschiedenen Blickwinkeln aus 
untersucht. Schließlich stellt die Wirkstoffresistenz von Tumorzellen einen 
limitierenden Faktor dar, welche in entsprechenden Experimenten zur Interaktion der 
Wirkstoffe mit Glutathion oder mit verschiedenen Efflux-Transportern analysiert 
wurde.  
 Eine Vielzahl der in dieser Arbeit beschriebenen Methoden wurde vorher 
nicht am Lehrstuhl für Organische Chemie praktiziert. Deshalb wurde zum 
Methodenstudium und zur Methodenverfeinerung die Expertise anderer 
Forschungsinstitute im Rahmen kurzzeitiger Forschungsaufenthalte in Anspruch 
genommen, namentlich sind dies das Laboratory of Cellular and Developmental 
Neurobiology, Institute of Experimental Medicine of the Hungarian Academy of 
Sciences in Budapest (2 Monate) und das Institute of Biophysics, Academy of Sciences 
of the Czech Republic in Brünn (4 Monate). 
7.3 Chalkon (1) und seine Pt-Derivate (2, 3) 
Die Combretastatin-A4-Analoga Chalkon 1 und Chalkon-Pt 2 erwiesen sich 
als höchst wirksam gegen eine Vielzahl verschiedener Krebszell-Linien, während sie 
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sich in ihrer Fähigkeit, Apoptose zu induzieren und in ihrer Langzeitwirkung 
unterschieden (Schobert et al., 2009).  
 Chalkon-Pt 2 zeigte sich bei neuralen Zellen Tumor-spezifischer als die 
Vorläuferverbindung Chalkon 1. Dies wurde durch den Vergleich der IC50-Werte (48 
h) bei primären Astrocyten vs. humanen Gliomazellen U87 (>7000 µM für Komplex 
2;  55 µM für Verbindung 1) ersichtlich. Die Aufnahme von Chalkon-Pt 2 in die Zelle 
vollzog sich wie im Falle von Oxaliplatin hauptsächlich über organic cation 
transporters (OCT-1/2; ~32%) und copper transporter related proteins (Ctr1; ~24%), 
wogegen Chalkon 1 sich stark Endocytose-abhängig (~80%) zeigte. In Tubulin-
reichen Neuronen und in 518A2-Melanomzellen zerstörte der Komplex 2 effizient 
Mikrotubuli und Actinfilamente. Diese Krebszellen konnten zwar den cytoskeletalen 
Schaden wieder reparieren, hörten aber auf zu proliferieren und starben letztlich ab. 
Komplex 2 war besonders wirksam gegen P-gp-reiche Zellen. Es fungierte aber als 
Substrat für ABC-Transporter der Typen BCRP, MRP3 und MRP1 und war daher 
weniger aktiv gegen entsprechende Zelllinien. Komplex 2 stoppte den Zellzyklus von 
Melanomzellen in der G1- und G2/M-Phase. Eine massive Fragmentierung des Golgi-
Apparates dieser Zellen wurde mittels TEM nur nach Behandlung mit Komplex 2 und 
nicht bei Chalkon 1 beobachtet. Im Gegensatz zu Chalkon 1 zeigte sich der 
Platinkomplex 2 hoch Zelllinien-spezifisch, wurde kontrolliert über geeignete 
Transportproteine aufgenommen und induzierte Apoptose über vielfältige 
Mechanismen. 
Das Chalkon-Pt-Konjugat 3, welches im Gegensatz zu Komplex 2 einen 
Diamin-Liganden besitzt, wurde auf seine Antitumorwirkung, DNA-Bindung und 
Glutathion-Bindung untersucht. In MTT-Tests inhibierte Komplex 3 Leukämiezellen 
HL-60 und Darmkrebszellen HCT-116 effektiver als die Analoga 2 und 1. Die 
Morphologie der Tumorzellen, die mit den Chalkon-Derivaten 1, 2 und 3 behandelt 
wurden, unterschied sich von der von Zellen, die mit Colchicin behandelt wurden. 
Obwohl Komplex 3 weniger wasserlöslich ist als Cisplatin, bindet es an die gleichen 
DNA-Bindungsstellen wie Cisplatin. Im Gegensatz zu Cisplatin verursachte Komplex 
3 eine stärkere DNA-Entwindung und eine zehnmal größere Anzahl an Interstrang-
Quervernetzungen (~60%). Diese Ergebnisse wurden durch ein DNA-Footprint-
Experiment bestätigt, welches zeigte, dass nur ein einziges Molekül 3 die einzigen 
benachbarten Guaninreste koordinierte und die einzig mögliche 1,2-d(GpG)-
7. Zusammenfassung 
7.4-129 
 
Intrastrang-Quervernetzung bildete. Außerdem wurden durch Verbindung 3 
hervorgerufene DNA-Schäden durch 518A2-Melanomextrakte nur halb so effizient 
repariert als entsprechende Cisplatin-DNA-Addukte. Komplex 3 zeigte zudem eine 
weit geringere Affinität zum bekannten Platin-Entgifter Glutathion. 
7.4 Illudin M (4) und sein Retinoat (5) 
 Der Pilz-Metabolit Illudin M 4 ist eine hoch-cytotoxische Verbindung, tötet 
aber Krebszellen und non-maligne Zellen gleichermaßen ab und ist für einen 
klinischen Einsatz daher nicht geeignet. Sein Retinoat 5 dagegen zeigte eine höhere 
Selektivität gegenüber malignen Zellen, speziell im empfindlichen zerebralen 
Gewebe. Illudin M wirkte sowohl gegen Gliomazellen als auch primäre Neuronen 
und Astrocyten bei gleichermaßen geringen Dosen und zerstörte ihre Microtubuli- 
und GFAP(glial fibrillary acidic protein)-Netzwerke. Im Gegensatz dazu zeigte der 
Ester 5 eine deutlich höhere Cytotoxizität gegen U87 Gliomazellen als in Neuronen, 
bei letzteren wurde sogar das Wachstum stimuliert. Dieser Effekt wurde ebenfalls in 
Co-Kulturen normaler Neuronen mit U87-Zellen beobachtet, wo Konjugat 5 letztere 
selektiv abtötete. Das Retinoat 5 scheint folglich ein viel versprechender 
Wirkstoffkandidat gegen Hirntumore  und deren Stammzellen zu sein. 
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